



- (51) **International Patent Classification:**  
*C12N 15/82* (2006.01)    *C07K 14/415* (2006.01)  
*A01H 1/04* (2006.01)    *C12N 15/29* (2006.01)  
*A01H 5/00* (2006.01)    *C12Q 1/68* (2006.01)
- (21) **International Application Number:**  
PCT/CA2010/001853
- (22) **International Filing Date:**  
19 November 2010 (19.11.2010)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
12/592,195    20 November 2009 (20.11.2009)    US
- (63) **Related by continuation (CON) or continuation-in-part (CIP) to earlier application:**  
US    12/592,195 (CIP)  
Filed on    20 November 2009 (20.11.2009)
- (71) **Applicant (for all designated States except US):** ALBERTA INNOVATES - TECHNOLOGY FUTURES [CA/CA]; 250 Karl Clark Road, Edmonton, Alberta, T6N 1E4 (CA).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** VELCHEVA, Margarita [CA/CA]; 4620 - 106A Street, Edmonton, Alberta, T6H 5J3 (CA). VIDMAR, John [CA/CA]; 10715 - 123rd Street, Edmonton, Alberta, T5M 0C5 (CA). QUANDT, Jurgen [CA/CA]; 655 61 Street S.W., Edmonton, Alberta T6X 0G2 (CA).
- (74) **Agents:** SECHLEY, Konrad A. et al.; Gowling Lafleur Henderson LLP, 2300 - 550 Burrard Street, Vancouver, British Columbia V6C 2B5 (CA).
- (81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,

[Continued on next page]

(54) **Title:** VARIEGATION IN PLANTS

Figure 2



(57) **Abstract:** A variegated plant comprising a nucleic acid operatively linked to a regulatory region, the nucleic acid disrupts the expression of Cpn21. The nucleic acid is typically an antisense Cpn21 and the regulatory region may be an inducible regulatory region, a tissue specific regulatory region, or a developmental regulatory region.

ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

## VARIEGATION IN PLANTS

### FIELD OF INVENTION

[0001] The present invention relates to variegation in plants, and to methods of selecting plants based on this trait.

### 5 BACKGROUND OF THE INVENTION

[0002] Variegation in plants is defined as the normal green portion of the plant leaf being replaced by white, cream, yellow, or occasionally other colors, which may be in the form of blotches or stripes. The variegations can occur on the edge of the leaves (marginate variegation), or in the center of the leaf (medio variegation). Due to ornamental nature of  
10 variegated plants, these plants are desired by gardeners.

[0003] Variegations have been induced in plants by a variety of methods including the use of transposable elements (for example Itoh et al., 2002, *Plant Cell Physiol.* 43(5):578-8), plant transformation with variegated and distorted leaf (vdl) gene, located in the nucleus (Wang et al., 2000, *Plant Cell.* 12(11):2129-42), antisense glutamate 1-semialdehyde aminotransferase  
15 transformation, inhibiting chlorophyll synthesis with partial or complete suppression of the GSA-AT leading to severe plant damage (Hofgen et al., 1994, *Proc Natl Acad Sci U S A.*, 91:1726-1730), or spontaneous mutation in the nuclear genes that controlled organelle proteins or mutations in organelle genes (reviewed in Aluru et al., 2006, *J. ExpBot.* 57:1871-1881. Apuya et al., (2001, *Plant Physiol.* 126, 717-730) report that a T-DNA mutation in the  
20 chaperonin-60 $\alpha$  gene (*Cpn60*) of *Arabidopsis* results in a defect in embryo development, causing developmental arrest before the heart stage.

[0004] Leaf bleaching, along with other abnormal phenotypes such as stunted growth, delayed flowering, reduced root development and the like have been observed in transgenic tobacco plants that constitutively express *Arabidopsis* Cpn60 $\beta$  transcripts in sense and  
25 antisense orientation (Zabaleta, E, et al. 1994, *Plant Journal*, Vol. 6, pp. 425-432).

[0005] Chaperonins are multi-subunit double-ring oligomeric proteins found in bacteria, mitochondria, and plastids. Chaperonins are abundant constitutive proteins that increase in amount after stresses, such as heat shock, bacterial infection of macrophages, and an increase in the cellular content of unfolded proteins.

V81263WO

[0006] Higher plant chloroplasts contain a 21-kDa protein, chaperonin 21 (Cpn21) (Hirohashi T. et al, Biochem Biophys Acta. 1999 1429(2):512-5). The chloroplast Cpn21 polypeptide consists of two Cpn10-like domains fused together in tandem. The cDNA sequence of the Cpn21 (AtCpn21) precursor protein from *Arabidopsis thaliana* is known, and the deduced amino acid sequence of the AtCpn21 precursor protein, 253 amino acids long, shows 61% identity with the spinach Cpn21 protein. The AtCpn21 precursor protein contains a typical chloroplast transit peptide of 51 amino acids at its amino terminus and two Cpn10-like domains, with these two domains exhibiting 46% sequence identity. The predicted, mature polypeptide of AtCpn21 was expressed in *Escherichia coli* as a soluble 21-kDa protein. Gel-filtration and chemical cross-linking analyses showed that the recombinant mature AtCpn21 protein forms a stable homo-oligomer composed of three or four polypeptides.

[0007] Hanania et al., 2007 (Transgenic Res. 16 :515-525) disclosed that Cpn21 was differentially expressed in seeded and seedless grapes, and may have a role in seed abortion in some plants.

[0008] Sjogren et al., (2004, Plant Physiol, 136: 4114-4126), disclose *Arabidopsis clpC1* T-DNA insertion mutants that lack on average 65% content of a stromal molecular chaperone (ClpC). Mutants display a retarded-growth phenotype, leaves with a homogenous chlorotic appearance throughout all developmental stages. Photosynthetic performance was impaired in knockout lines, with relatively fewer photosystem I and photosystem II complexes, but no changes in ATPase and RuBisCO content.

## SUMMARY OF THE INVENTION

[0009] The present invention relates to variegation in plants, and to methods of selecting plants based on this trait.

[0010] It is an object of the invention to provide an improved variegated plant.

[0011] According to the present invention there is provided a variegated plant comprising a nucleic acid operatively linked to a regulatory region, wherein the nucleic acid disrupts the expression of a chaperonin. The chaperonin may be chaperonin 21 (Cpn21). The nucleic acid may be an antisense sequence of Cpn21, a nucleic acid that hybridizes under stringent

V81263WO

conditions with the complement of antisense Cpn21 *in vitro*, or an RNAi that disrupts the expression of Cpn21. Furthermore, the regulatory region may be an inducible regulatory region, a tissue specific regulatory region, a developmental regulatory region, or a constitutive regulatory region.

5 [0012] The present invention provides a chimeric construct comprising a first nucleic acid operatively linked to a first regulatory region, the first nucleic acid comprising a sequence that directly or indirectly disrupts the expression of Cpn21, or functional homologue of Cpn21, and a second nucleic acid encoding a protein of interest and operatively linked to a second regulatory region.

10 [0013] The present invention also provides a method (A) of producing a variegated plant comprising,

i) providing the plant comprising a nucleic acid operatively linked to a regulatory region, the nucleic acid disrupts the expression of Cpn21, and

15 ii) growing the plant under conditions that results in the expression of the nucleic acid, thereby producing the variegated plant.

[0014] Preferably, the nucleic acid in the step of providing is an antisense Cpn21, a nucleic acid that hybridizes under stringent conditions with the complement of antisense Cpn21 *in vitro*, or an RNAi that disrupts the expression of Cpn21. Furthermore, the regulatory region may be an inducible regulatory region, a tissue specific regulatory region, a developmental regulatory region, or a constitutive regulatory region. The tissue specific regulatory region may be a RuBisCO promoter, or may be a vein-specific promoter. The constitutive regulatory region may comprise a Cauliflower Mosaic Virus 35S (CaMV 35S, or 35S) promoter sequence. The inducible regulatory region may comprise an AlcR sequence and an AlcA promoter.

20 [0015] The present invention also pertains to a method (B) of selecting a plant comprising a nucleic acid of interest comprising,

i) providing the plant comprising a first nucleic acid operatively linked to a first regulatory region, the first nucleic acid disrupts the expression of Cpn21, and a second

V81263WO

nucleic acid encoding a protein of interest and operatively linked to a second regulatory region,

ii) growing the plant under conditions that result in the expression of the first and second nucleic acids, and

5           iii) selecting plants that display a variegated phenotype.

[0016] The nucleic acid in the step of providing may be an antisense Cpn21, a nucleic acid that hybridizes under stringent conditions with the complement of antisense Cpn21 *in vitro*, or an RNAi that disrupts the expression of Cpn21. Furthermore, the regulatory region may be an inducible regulatory region, a tissue specific regulatory region, a developmental regulatory region, or a constitutive regulatory region. The tissue specific regulatory region may be a RuBisCO promoter, or may be a vein-specific promoter. The constitutive regulatory region may comprise a Cauliflower Mosaic Virus 35S (CaMV 35S, or 35S) promoter sequence. The inducible regulatory region may comprise an AlcR sequence and an AlcA promoter.

[0017] The present invention also provides a method (C) of producing a variegated plant comprising,

i) transforming a plant with a nucleotide sequence comprising a nucleic acid operatively linked to a regulatory region, the nucleic acid disrupting the expression of Cpn21, and

ii) growing the plant under conditions that results in the expression of the nucleic acid, thereby producing the variegated plant.

[0018] The present invention also provides a method (D) of selecting a plant comprising a nucleic acid of interest comprising,

i) transforming a plant with a nucleotide sequence comprising a first nucleic acid operatively linked to a first regulatory region, the first nucleic acid disrupts the expression of Cpn21, or functional homologue of Cpn21, and a second nucleic acid encoding a protein of interest and operatively linked to a second regulatory region,

ii) growing the plant under conditions that result in the expression of the first and second nucleic acids, and

V81263WO

iii) selecting plants that display a variegated phenotype and expressing the nucleic acid of interest.

[0019] The first nucleic acid in the step of providing or transforming may be an antisense Cpn21, a nucleic acid that hybridizes under stringent conditions with the complement of antisense Cpn21 *in vitro*, or an RNAi that disrupts the expression of Cpn21. Furthermore, the regulatory region may be an inducible regulatory region, a tissue specific regulatory region, a developmental regulatory region, or a constitutive regulatory region.

[0020] The second nucleic acid sequence encoding a protein of interest, may include any nucleic acid, for example, but not limited to, a nucleic acid sequence that encodes a pharmaceutically active protein, for example growth factors, growth regulators, antibodies, antigens, their derivatives useful for immunization or vaccination and the like, interleukins, insulin, G-CSF, GM-CSF, hPG-CSF, M-CSF or combinations thereof, interferons, for example, interferon-alpha, interferon-beta, interferon-gamma, blood clotting factors, for example, Factor VIII, Factor IX, or tPA or combinations thereof. The second nucleic acid sequence may also encode an industrial enzyme, a protein supplement, a nutraceutical, or a value-added product for feed, food, or both feed and food use. Examples of such proteins include, but are not limited to proteases, oxidases, phytases, chitinases, invertases, lipases, cellulases, xylanases, enzymes involved in oil biosynthesis etc.

[0021] The plants produced using the methods defined above exhibited variegated leaves.

The methods as described herein may be used to produce plants with variegated leaves for ornamental purposes, or the occurrence of leaf variegation may be used to assist in plant selection, where leaf variegation is trait that is used as a selectable marker to indicate that transformation of a plant occurred. The methods of the present invention can be used within any plant including crop plants, ornamental plants, forage plants and the like, for example but not limited to *Nicotiana*, *Arabidopsis*, Canola, Flax, Hemp, *Brachypodium*, *Oryza*, *Brassica napus*, *Petunia spp.*, *Cyclamen spp.*, *Begonia spp.*, *Azalea spp.*, and *Spatifilium spp.*, *Artemisia spp.*, *Poplar*, *Rosa spp.*, Rose, *Musa spp.* (e.g. Banana), *Coffea Arabica*, Maize, *Glycine spp.* (e.g. Soybean), and the like.

[0022] The present invention further provides a nucleic acid construct comprising a nucleic acid operatively linked to a regulatory region, wherein the nucleic acid disrupts the expression

V81263WO

of Cpn21. The nucleic acid may be an antisense Cpn21, a nucleic acid that hybridizes under stringent conditions with the complement of antisense Cpn21 *in vitro*, or an RNAi that disrupts the expression of Cpn21. The regulatory region may be an inducible regulatory region, a tissue specific regulatory region, a developmental regulatory region, or a constitutive regulatory region.

[0023] The present invention also provides a nucleic acid construct comprising a first nucleic acid operatively linked to a first regulatory region, the first nucleic acid disrupts the expression of Cpn21, and a second nucleic acid encoding a protein of interest. The first nucleic acid may be an antisense Cpn21, a nucleic acid that hybridizes under stringent conditions with the complement of antisense Cpn21 *in vitro*, or an RNAi that disrupts the expression of Cpn21. The regulatory region may be an inducible regulatory region, a tissue specific regulatory region, a developmental regulatory region, or a constitutive regulatory region. The first regulatory region may comprise an AlcR sequence, and the second regulatory region may comprise an AlcA promoter.

[0024] The present invention also includes a vector comprising the nucleic acid construct of the present invention.

[0025] Genetically transformed plants expressing antisense chaperonin 21 exhibit a strong tendency to variegation of the leaves and flowers. An advantage of such a system is that the transformed plants and their progeny are free of heterologous nucleic acid sequences. The plants and methods described herein may be used to produce variegated plants for commercial use, including crop plants of for use within the ornamental market. Furthermore, the variegated phenotype obtained in plants using the methods described herein, may be used as a selectable marker. For example, variegated leaves may provide a visual criteria for selecting a plant encoding a protein of interest.

[0026] Linking the visual marker to a nucleic acid of interest may also be useful for identifying and segregating, or for the identity preservation of industrial or other genetically modified crops that express this trait. Tissue specific variegation (vein, leaf tip, stem etc), may be used so that the marker is expressed in desired parts of the plant to create different patterns in the same plant species and thus identifying and distinguish different genetically modified traits in the plant.

V81263WO

[0027] This summary of the invention does not necessarily describe all features of the invention. Other aspects and features of the present invention will become apparent to those of ordinary skill in the art upon review of the following description of specific embodiments of the invention.

## 5 BRIEF DESCRIPTION OF THE DRAWINGS

[0028] These and other features of the invention will become more apparent from the following description in which reference is made to the appended drawings wherein:

[0029] **FIGURE 1** shows patterns of variegated leaves from tobacco plants, transformed with Cpn21RNAi 35S. WP – wild type plant (non transformed) – top row, middle.

10 [0030] **FIGURE 2A-E** shows T1 tobacco plants expressing Cpn21RNAi - 35S constructs. A range of variegation pattern and color intensity is shown in plants. A control plant is shown in the right hand side of Figure 2B.

[0031] **FIGURE 3** shows variegation in the leaves of AlcR Cpn21RNAi transformed tobacco. The AlcA promoter was induced by spraying with a 2% ethanol solution.

15 [0032] **FIGURE 4** shows a Canola (*Brassica napus*) regenerant on selection media after transformation with Cpn21RNAi - 35S.

[0033] **FIGURE 5** shows patterns of variegation in canola transformed with Cpn21RNAi 35S (WP – untransformed control bottom left leaf).

20 [0034] **FIGURE 6** shows transgenic rice, transformed with Cpn21RNAi – 35S (right-side pot); left pot is control (untransformed plant).

[0035] **FIGURE 7** shows transgenic *Brachypodium*, transformed with Cpn21RNAi 35S (left-side pot); right pot is control (untransformed plant).

[0036] **FIGURE 8A:** SEQ ID NO: 1 – sequence encoding *A. thaliana* cpn21; **Figure 8B:** SEQ ID NO: 4 – Cpn21 antisense 35S; **Figure 8C:** SEQ ID NO: 5 – Cpn21 RNAi fragment with intron; **Figure 8D:** SEQ ID NO: 6 – Cpn21RNAi RBC; **Figure 8E:** SEQ ID NO: 7 – Cpn21 RNAiRBC; **Figure 8F:** SEQ ID NO: 8 – AlcR Cpn21 RNAi Sequence; **Figure 8G:** SEQ ID NO: 9 35S promoter; **Figure 8H:** SEQ ID NO: 10 – AlcA promoter (nucleotides 1-

V81263WO

232) with minimal ; **Figure 8I**: SEQ ID NO: 11 – *N. tabacum* RuBisCO (RBC) promoter sequence; **Figure 8J**: SEQ ID NO: 12 – AlcR fragment with minimal 35S promoter sequence; **Figure 8K**: SEQ ID NO: 23 Cpn21 Antisense; **Figure 8L**: PCR – amplified fragment of *A. thaliana* Cpn21 (SEQ ID NO: 2); **Figure 8M**: SEQ ID NO: 28 – pGreen0029-RBC construct; **Figure 8N**: SEQ ID NO: 29 pUC57-RBC construct. SEQ ID NO: 4 – nucleotides 103-866 comprise an Acpn21 antisense sequence; nucleotides 904-1156 comprise a NOS terminator sequence; nucleotides 10232-10648 comprise a 35S promoter sequence. SEQ ID NO: 5 – nucleotides 1-427 comprise ACpn RNAi fragment 1; nucleotides 938-2017 comprise an intron of the ACpn RNAi construct; nucleotides 2156-2627 comprise ACpn RNAi fragment 2. SEQ ID NO: 6 – nucleotides 8140-9175 comprise a 35 S promoter sequence; nucleotides 9324-9795 comprise ACpn RNAi fragment 1; nucleotides 9934-11013 comprise an intron of the ACpn RNAi construct; nucleotides 11479-11948 comprise ACpn RNAi fragment 2. SEQ ID NO: 7 – nucleotides 2-1026, RBC promoter; nucleotides 1280-1747 comprise ACpnRNAi fragment 1; nucleotides 1839-3193 comprise an intron of the ACpnRNAi construct; nucleotides 3349-3816 comprise ACpnRNAi fragment 2. SEQ ID NO: 8 – nucleotides 717-1502 comprise a 35 S promoter sequence; nucleotides 1529-4123 comprise an AlcR sequence; nucleotides 4130-4388 comprise a NOS terminator sequence; nucleotides 4389-4406 comprise an AlcA promoter sequence; nucleotides 5058-5525 comprise ACpnRNAi fragment 1; nucleotides 5617-6971 comprise an intron of the ACpnRNAi construct; nucleotides 7127-7594 comprise ACpnRNAi fragment 2.

## DETAILED DESCRIPTION

[0037] The present invention relates to variegation in plants, and to methods of selecting plants based on this trait.

[0038] The present invention provides a variegated plant comprising a nucleic acid operatively linked to a regulatory region, wherein the nucleic acid disrupts the expression of chaperonin 21 (Cpn21), or a functional homologue of Cpn21, for example Cpn10. The nucleic acid that disrupts the expression of Cpn21 or a functional homologue of Cpn21, may include but is not limited to, an antisense sequence of Cpn21 or a functional homologue of Cpn21, a nucleic acid that hybridizes under stringent conditions with the complement of antisense Cpn21 or a functional homologue of Cpn21, *in vitro*, or an RNAi that disrupts the expression of Cpn21 or a functional homologue of Cpn21. The regulatory region may be an

V81263WO

inducible regulatory region, a tissue specific regulatory region, a developmental regulatory region, or a constitutive regulatory region.

[0039] The Cpn21 sequence may comprise SEQ ID NO: 1, or a fragment of SEQ ID NO: 1 that exhibits Cpn21 activity. SEQ ID NO: 1 corresponds to an *Arabidopsis* chaperonin 21 (cpn21, Acpn21) sequence (NCBI GenBank Accession No. AF428366.1 gi:16226910 *Arabidopsis thaliana* AT5g20720/T1M15\_120 mRNA). A fragment of SEQ ID NO: 1 may comprise nucleotides 77-842 of SEQ ID NO: 1. However, the chaperonin sequence may also comprise, for example, *Vitis vinifera* cpn21 (NCBI GenBank Accession No. AY680699), spinach Cpn21 (Baneyz et al. 1995, JBC 270:10695-10702). Furthermore, Cpn21 polypeptide consists of two Cpn10-like domains fused together in tandem, and Cpn21 is considered a functional homologue of Cpn10 (accession number:AF059037; Bertsch U., et al., 1992, PNAS 89:8696-8700; Hirohashi T., et al., 1999, Biochem Biophys Acta 1429:512-515), therefore, the chaperonin sequence of the present invention may also include spinach chaperonin cpn10 (NCBI GenBank Accession No. M87646), *Helicosporidium sp. ex* *Simulium jonesii* cpn10 (NCBI GenBank Accession No. AY596494), or RbcX (Emlyn-Jones et al., 2006 Plant & Cell Physiology 47:1630-1640), or other functional homologue of Cpn21. Other examples of chaperonins, from both prokaryotes and eukaryotes (including plants) may also be found in cpndb- A chaperonin database (for example at URL: [cpndb.cbr.nrc.ca/](http://cpndb.cbr.nrc.ca/); Hill et al 2004. Genome Research 14:1669-1657, herein incorporated by reference). Chaperonin 21 may be indicated by the abbreviation “cpn21” or “Cpn21”.

[0040] The method as described herein involves the use of a nucleic acid sequence to disrupt or reduce or eliminates the expression of Cpn21, or a functional homologue of Cpn21, for example Cpn10. This may be achieved, for example but not limited to, by using a silencing nucleic acid as described below. An example of a silencing nucleic acid includes, but is not limited to, an antisense Cpn21, or a functional homologue of Cpn21, sequence, a nucleic acid that hybridizes under stringent conditions with the complement of an antisense Cpn21, or a functional homologue of Cpn21, sequence *in vitro*, or an RNAi that disrupts expression of Cpn21, or a functional homologue of Cpn21.

[0041] Examples of silencing nucleic acids include those comprising a sequence according to: a reverse-complement of SEQ ID NO: 1, 2, or a fragment thereof, SEQ ID NO: 4 or a fragment thereof, SEQ ID NO: 5 or a fragment thereof, SEQ ID NO: 23 or a fragment thereof,

V81263WO

nucleotides 2078-2518 of SEQ ID NO: 5, or the reverse complement of nucleotides 223-663 of SEQ ID NO: 2. Sequences encoding Cpn10 may also be used as Cpn10 may be considered a fragment of cpn21 (Bertsch U., et al., 1992, PNAS 89:8696-8700; Hirohashi T., et. al., 1999, Biochem Biophys Acta 1429:512-515).

5 [0042] The regulatory region used in the method and construct described above may be a constitutive regulatory region, an inducible regulatory region, a tissue specific regulatory region, or a developmental regulatory region.

[0043] The present invention therefore provides a method for reducing the level of Cpn21 in a plant or a tissue within the plant comprising,

10 i) introducing a nucleic acid sequence into a plant, the nucleic acid sequence comprising a regulatory region operatively associated with a silencing nucleotide sequence, wherein expression of the silencing nucleotide sequence reduces or eliminates the expression of Cpn21, and

15 ii) expressing the silencing nucleotide sequence within the plant or the tissue within the plant. The amount of the Cpn21 may be determined by comparing the level of Cpn21 expression in the plant, or a tissue of the plant, with a level of Cpn21 expression in a second plant, or the tissue from the second plant, that does not express the silencing nucleic acid sequence. The amount of Cpn21 may be determined using standard techniques including northern analysis, western analysis, SDS-PAGE and the like.

20 [0044] The present invention further provides a method for producing a variegated plant, comprising,

i) introducing a silencing nucleic acid sequence into the plant, the silencing nucleic acid sequence comprising a regulatory region operatively associated with the silencing nucleic acid sequence. The silencing nucleic acid sequence may comprise a reverse  
25 compliment of SEQ ID NO's: 1 or 2, a fragment of a reverse compliment of SEQ ID NO: 1, a sequence that hybridizes to the complement of the antisense of SEQ ID NO's: 1 or 2 or a sequence that hybridizes to a fragment of the complement of the antisense of SEQ ID NO: 1, and

ii) growing the plant.

V81263WO

[0045] Other silencing nucleic acids may be used in the method above, including SEQ ID NO's: 4, 5 or 23, or fragment thereof, nucleotides 2078-2518 of SEQ ID NO: 5, or the reverse complement of nucleotides 223-663 of SEQ ID NO: 2. Sequences encoding Cpn10 may also be used .

5 [0046] The regulatory region may be a constitutive regulatory region, an inducible regulatory region, a tissue specific regulatory region, or a developmental regulatory region. If an inducible regulatory region is used, then the method further includes a step of subjecting the plant to a chemical agent or environmental condition that induces the regulatory region and results in expression of the silencing nucleic acid.

10 [0047] In embodiments where chaperonin expression is disrupted, the level of chaperonin expression may be reduced by about 10% to about 100%, or any amount therebetween, when compared to the level of chaperonin expression obtained from a second plant that does not express the silencing nucleotide sequence. For example, Cpn21 expression may be reduced by from about 10% to about 60% or any amount therebetween, about 10% to about 50% or  
15 any amount therebetween, about 10% to about 40% or any amount therebetween, or from about 10% to about 30%, or any amount therebetween, or about 10% to about 20% or any amount therebetween.

[0048] By the term "expression" it is meant the production of a functional RNA, protein or both, from a nucleic acid molecule.

20 [0049] A "silencing nucleotide sequence" or "silencing nucleic acid sequence" refers to a sequence that when transcribed results in disrupting, reducing or eliminating expression of a target sequence. A silencing nucleotide sequence may encode for example, but not limited to, an antisense nucleotide, an RNAi, or an siRNA.

[0050] By "reduction of gene expression" or "reduction of expression" "disruption of  
25 expression" or "elimination of expression", it is meant a decrease in the level of mRNA, protein, or both mRNA and protein, encoded by a nucleic acid sequence. Expression may be reduced by from 10 to about 100%, or any amount therebetween, for example, from about 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, and 100%, or any  
30 amount therebetween. Reduction of expression may arise as a result of the lack of production

V81263WO

of full length RNA, for example mRNA, or through the expression of a silencing nucleic acid sequence, and result in cleaving mRNA, for example with a ribozyme (e.g. see Methods in Molecular Biology, vol 74 *Ribozyme Protocols*, P.C. Turner, ed, 1997, Humana Press), siRNA, or RNAi (e.g. see *Gene Silencing by RNA Interference, Technology and Application*, M. Sohail ed, 2005, CRC Press), or otherwise reducing the half-life of RNA, using antisense (e.g. see *Antisense Technology, A Practical Approach*, C. Lichtenstien and W. Nellen eds., 1997, Oxford University Press), ribozyme, siRNA, or RNAi techniques, or other related methods known in the art.

[0051] Antisense nucleic acid molecules interact with complementary strands of nucleotide sequences and when present, may modify the expression of a target nucleic acid. An antisense nucleic acid may be DNA or RNA and may be delivered as a composition, or transcribed *in vivo* or *in situ* from a template nucleic acid, a vector or other construct such as an artificial chromosome, or a transgenic sequence introduced into the genome of the host cell or organism. Antisense nucleic acids may be of varying length from a few tens of nucleotides, to several hundred nucleotides and may comprise antisense sequences that may interact with one, or more than one mRNA.

[0052] An antisense nucleic acid may be transcribed from a template nucleic acid, a plasmid or other genetic construct as a single RNA strand that self-anneals to form a hairpin-loop structure. The transcribed RNA strand may comprise two palindromic sequences that are capable of annealing to form a double-strand, separated by a loop, or unpaired section of RNA. The double stranded region may be from about 15 base pairs to several hundred base pairs in length, or any length therebetween, and, for example, may result in the formation of short double-stranded fragments (siRNA) when processed by DICER or RISC-like enzymes or enzyme complexes present in the plant. The short double stranded fragments may include, for example, but not limited to, 21-mers, with a 19 base pair double stranded portion and a two base overhang at the 3' end, as is generally known in the art.

[0053] Examples of an antisense sequence of SEQ ID NO: 1 include SEQ ID NO: 23, or a fragment thereof, nucleotides 2078-2518 of SEQ ID NO: 5 or a fragment thereof, or the reverse complement of nucleotides 223-663 of SEQ ID NO: 2, or a fragment thereof, the reverse complement of SEQ ID NO: 1, or a fragment thereof.

V81263WO

[0054] By "operatively linked" it is meant that the particular sequences interact either directly or indirectly to carry out an intended function, such as mediation or modulation of gene expression. The interaction of operatively linked sequences may, for example, be mediated by proteins that interact with the operatively linked sequences. A coding region of interest may also be introduced within a vector along with other sequences, typically heterologous, to produce a chimeric construct. A transcriptional regulatory region and a sequence of interest are "operably linked" when the sequences are functionally connected so as to permit transcription of the sequence of interest to be mediated or modulated by the transcriptional regulatory region.

[0055] As described below, variegated plants were produced using the methods as described herein with *Nicotiana tabacum* L. cv. SR1, *Arabidopsis thaliana* cv Landsberg, *Brassica napus* cv. DH12075 *Oryza sativa* and *Brachypodium distachyon* cv. Doublon Blue Sky plants as model systems. However, other plants may also be modified using the methods described herein, including a crop plant, an ornamental plant, a forage plant, and the like, for example but not limited to *Nicotiana*, *Arabidopsis*, Canola, Flax, Hemp, *Brachypodium*, *Oryza*, *Brassica napus*, *Petunia spp.*, *Cyclamen spp.*, *Begonia spp.*, *Azalea spp.*, *Spatifilium spp.* alfalfa, corn, barley, rice, tobacco, *Arabidopsis*, canola, flax, hemp, for example but not limited to *Cannabis sativa*, potato. Other examples of plants include species from the genera *Anacardium*, *Arachis*, *Asparagus*, *Atropa*, *Avena*, *Brassica*, *Brachypodium*, *Citrus*, *Citrullus*, *Capsicum*, *Carthamus*, *Cocos*, *Coffea*, *Cucumis*, *Cucurbita*, *Daucus*, *Elaeis*, *Fragaria*, *Glycine*, *Gossypium*, *Helianthus*, *Heterocallis*, *Hordeum*, *Hyoscyamus*, *Lactuca*, *Linum*, *Lolium*, *Lupinus*, *Lycopersicon*, *Malus*, *Manihot*, *Majorana*, *Medicago*, *Nicotiana*, *Olea*, *Oryza*, *Panicum*, *Pannasetum*, *Persea*, *Phaseolus*, *Pistachia*, *Pisum*, *Pyrus*, *Prunus*, *Raphanus*, *Ricinus*, *Secale*, *Senecio*, *Sinapis*, *Solanum*, *Sorghum*, *Theobromus*, *Trigonella*, *Triticum*, *Vicia*, *Vitis*, *Vigna*, and *Zea*.

[0056] Constructs used for plant transformation are set out in Table 4 and include:

Cpn21AS (a nucleic acid sequence encoding Cpn21 in antisense orientation under transcriptional control of a constitutive, CaMV 35S promoter),

Cpn21RNAi - 35S (Cpn21 RNAi hairpin-loop under transcriptional control of the 35S promoter),

V81263WO

Cpn21 RNAi RBC (Cpn21 RNAi hairpin-loop under transcriptional control of a tissue specific, RuBisCO (RBC) promoter),

Cpn21AS RBC a nucleic acid sequence encoding Cpn21 in antisense orientation under transcriptional control of the RBC promoter)

5 AlcRCpn21RNAi (Cpn21 RNAi hairpin-loop under transcriptional control of an alcohol inducible promoter).

[0057] Tobacco plants with varying levels of leaf variegation were produced using antisense expression of Cpn21 under the control of 35S promoter. Variegated tobacco plants were generated using on kanamycin selection medium or hygromycin selection medium, as well as  
10 on selection-free medium. Variegated *Arabidopsis*, canola (*B. napus*), *O. sativa* and *B. distachyon* plants were identified on kanamycin-free selection medium following transformation with Cpn21 gene in antisense orientation or RNAi.

[0058] The methods as described herein may be used to produce plants with variegated leaves for ornamental purposes, or the occurrence of leaf variegation may be used to assist in plant  
15 selection, where leaf variegation is trait that is used as a selectable marker to indicate that transformation of a plant occurred.

[0059] Therefore, the present invention provides a chimeric construct comprising a nucleic acid operatively linked to a regulatory region, the nucleic acid comprising a sequence that directly or indirectly disrupts the expression of Cpn21, or functional homologue of Cpn21, in  
20 a plant. The present invention also provides a method of producing a variegated plant comprising, transforming a plant with the construct just described, and growing the plant under conditions that results in the expression of the nucleic acid, thereby producing the variegated plant.

[0060] The nucleic acid may be an antisense Cpn21 or an antisense functional homologue of  
25 Cpn21, a nucleic acid that hybridizes under stringent conditions with the complement of an antisense Cpn21, or the complement of an antisense functional homologue of Cpn21 *in vitro*, or an RNAi that disrupts the expression of Cpn21, or functional homologue of Cpn21. Furthermore, the regulatory region may be an inducible regulatory region, a tissue specific regulatory region, a developmental regulatory region, or a constitutive regulatory region.

V81263WO

[0061] The present invention further provides a chimeric construct comprising a first nucleic acid operatively linked to a first regulatory region, the first nucleic acid comprising a sequence that directly or indirectly disrupts the expression of Cpn21, or functional homologue of Cpn21, and a second nucleic acid encoding a protein of interest and operatively linked to a second regulatory region.

[0062] The present invention also provides a method of selecting a plant comprising a nucleic acid of interest comprising,

i) transforming a plant with a nucleotide sequence comprising a first nucleic acid operatively linked to a first regulatory region, the first nucleic acid disrupts the expression of Cpn21, or functional homologue of Cpn21, and a second nucleic acid encoding a protein of interest and operatively linked to a second regulatory region,

ii) growing the plant under conditions that result in the expression of the first and second nucleic acids, and

iii) selecting plants that display a variegated phenotype and express the nucleic acid of interest.

[0063] The present invention also provides a method of selecting a plant comprising a nucleic acid of interest comprising,

i) providing the plant comprising a first nucleic acid operatively linked to a first regulatory region, the first nucleic acid disrupts the expression of Cpn21, or functional homologue of Cpn21, and a second nucleic acid encoding a protein of interest and operatively linked to a second regulatory region,

ii) growing the plant under conditions that result in the expression of the first and second nucleic acids, and

iii) selecting plants that display a variegated phenotype and express the nucleic acid of interest.

[0064] The first nucleic acid (in the step of providing or transforming) may be an antisense Cpn21 or an antisense functional homologue of Cpn21, a nucleic acid that hybridizes under stringent conditions with the complement of an antisense Cpn21, or the complement of an

V81263WO

antisense functional homologue of Cpn21 *in vitro*, or an RNAi that disrupts the expression of Cpn21, or functional homologue of Cpn21. Furthermore, the regulatory region may be an inducible regulatory region, a tissue specific regulatory region, a developmental regulatory region, or a constitutive regulatory region.

5 [0065] The second nucleic acid sequence encoding a protein of interest, may include any nucleic acid, for example, but not limited to, a nucleic acid sequence that encodes a pharmaceutically active protein, for example growth factors, growth regulators, antibodies, antigens, their derivatives useful for immunization or vaccination and the like, interleukins, insulin, G-CSF, GM-CSF, hPG-CSF, M-CSF or combinations thereof, interferons, for  
10 example, interferon-alpha, interferon-beta, interferon-gamma, blood clotting factors, for example, Factor VIII, Factor IX, or tPA or combinations thereof. The second nucleic acid sequence may also encode an industrial enzyme, a protein supplement, a nutraceutical, or a value-added product for feed, food, or both feed and food use. Examples of such proteins include, but are not limited to proteases, oxidases, phytases, chitinases, invertases, lipases,  
15 cellulases, xylanases, enzymes involved in oil biosynthesis etc.

[0066] The present invention includes nucleotide sequences having antisense *cpn21* activity and that hybridize to SEQ ID NO: 1, or that hybridized to the complement of antisense Cpn21 under stringent hybridization conditions (see Maniatis et al., in *Molecular Cloning (A Laboratory Manual)*, Cold Spring Harbor Laboratory (1982) p. 387 to 389; Ausubel, *et al.*  
20 (eds), 1989, *Current Protocols in Molecular Biology*, Vol. 1, Green Publishing Associates, Inc., and John Wiley & Sons, Inc., New York, at p. 2.10.3; both of which are herein incorporated herein by reference). Non-limiting examples of stringent hybridization conditions include hybridization in 4XSSC at 65°C for 8-16 hours, followed by washing in 0.1XSSC at 65°C for an hour or hybridization in 5XSSC and 50% formamide at 42°C for 8 to  
25 16 hours, followed by washing in about 0.5XSSC to about 0.2XSSC at 65°C for one hour. However, hybridization conditions may be modified in accordance with known methods depending on the sequence of interest (see Tijssen, 1993, *Laboratory Techniques in Biochemistry and Molecular Biology -- Hybridization with Nucleic Acid Probes*, Part I, Chapter 2 "Overview of principles of hybridization and the strategy of nucleic acid probe  
30 assays", Elsevier, New York; which is incorporated herein by reference). Generally, but not wishing to be limiting, stringent conditions are selected to be about 5°C lower than the thermal melting point for the specific sequence at a defined ionic strength and pH.

V81263WO

[0067] As would be understood to one of skill in the art, nucleotide sequences of varying length that hybridize to SEQ ID NO: 1 or the complement of SEQ ID NO: 1, when transcribed *in vivo*, may exhibit the property of reducing *cpn21* expression. Such nucleotide sequences may be from about 15 to about 900 nucleotides in length, or any length  
5 therebetween. Non-limiting examples of such sequences (including fragments of such sequences) include: GenBank Accession No. AF059037 (*cpn10*), GenBank Accession No. NM\_180714 (*cpn20*), GenBank Accession No. AF510565.1 (*hda2*), and SEQ ID NO: 4.

[0068] The present invention also includes nucleotide sequences having RNAi activity for *Cpn21*. For example, SEQ ID NO: 5 comprises a 440 nucleotide sequence (nucleotides 223-  
10 663 of SEQ ID NO: 2), and a reverse, complement nucleotide sequence of nucleotides 223-663 of SEQ ID NO: 2) separated by an intron. When a nucleic acid having the sequence of SEQ ID NO: 5 is transcribed, the RNA forms a hairpin-loop structure (the intron is the loop, the nucleotides corresponding to SEQ ID NO: 2 form a paired region). As would be understood by one of skill in the art, the double-stranded region is cleaved into shorter  
15 double-stranded RNAi molecules specific for *Cpn21*.

[0069] Also included are sequences having from about 75 to about 100% sequence identity, or from about 80% to about 100% sequence identity, with the antisense *Cpn21* sequence defined herein, provided that the sequences have antisense *cpn21* activity. The identity determinations may be made using oligonucleotide alignment algorithms for example, but not  
20 limited to, BLAST (Altschul et al 1990. *J. Mol Biol* 215:403-410; which is incorporated herein by reference). Software for performing BLAST analyses is available through the National Center for Biotechnology Information (GenBank URL: [ncbi.nlm.nih.gov/cgi-bin/BLAST/](http://ncbi.nlm.nih.gov/cgi-bin/BLAST/)). Default parameters include: Program: *blastn*; Database: *nr*; Expect 10; filter: default; Alignment: pairwise; Query genetic Codes: Standard(1)).  
25 Another example of an algorithm suitable for determining percent sequence identity and sequence similarity is FASTA (Pearson et al 1988. *Proc Natl Acad Sci USA* 85:2444-8).

[0070] A fragment or portion of a nucleic acid may comprise from about 60% to about 100%, of the length of the nucleic acid or nucleotide sequence, or any amount therebetween. For example, from about 60% to about 100%, from about 70% to about 100%, from about 80%  
30 to about 100%, from about 90% to about 100%, from about 95% to about 100%, of the length of the nucleic acid or nucleotide sequence, or any amount therebetween. Alternately, a

V81263WO

fragment or portion may be from about 150 to about 500 nucleotides, or any amount therebetween. For example, a fragment may be from 150 to about 500 nucleotides, or any amount therebetween, from about 200 to about 500 nucleotides, or any amount therebetween, from about 250 to about 500 nucleotides, or any amount therebetween, from about 300 to about 500 or any amount therebetween, from about 350 to about 500 nucleotides, or any amount therebetween, from about 400 to about 500 or any amount therebetween, from about 450 to about 500 or any amount therebetween. For example, about 5, 10, 20, 30, 40 or 50 nucleotides, or any amount therebetween may be removed from the 5' end, the 3' end or both the 5' and 3' end of the nucleic acid or nucleotide sequence.

10 [0071] By "regulatory region" (or regulatory element) it is meant a nucleic acid sequence that has the property of controlling the expression of a sequence that is operatively linked with the regulatory region. Such regulatory regions may include promoter or enhancer regions, and other regulatory elements recognized by one of skill in the art. By "promoter" it is meant the nucleotide sequences at the 5' end of a coding region, or fragment thereof, that contain all the  
15 signals essential for the initiation of transcription and for the regulation of the rate of transcription.

[0072] There are several types of regulatory elements, including those that are developmentally regulated, inducible, tissue-specific, constitutive or the like. A regulatory element that is developmentally regulated, is activated within certain organs or tissues of an  
20 organ at specific times during the development of that organ or tissue, and regulates the differential expression of a gene. However, some regulatory elements that are developmentally regulated may preferentially be active within certain organs or tissues at specific developmental stages, or may also be active in a developmentally regulated manner, or at a basal level in other organs or tissues within the plant as well. Such regulatory  
25 elements may be found in any organ, for example but not limited to, leaves, root, stem, buds, fruit, seeds, flowers, tubers, ovules, embryos or the like.

[0073] A regulatory element may be derived from any suitable source provided that the regulatory element is active in the host plant. A regulatory element may be derived from the same species or type of plant or plant cell in which it is used, or it may be obtained from a  
30 different plant source. A regulatory element may also be an animal nucleic acid sequence, a bacterial nucleic acid sequence, a viral nucleic acid sequence, a protozoan nucleic acid

V81263WO

sequence, or a cyanobacterial nucleic acid sequence, provided that the regulatory element functions within the host plant in which it is used. A regulatory element may comprise, in whole or in part, synthetic nucleic acid sequences not found in nature (a synthetic regulatory element).

5 [0074] A tissue-specific regulatory element is one that is capable of directly or indirectly activating transcription of one or more nucleotide sequences or genes in a tissue-specific manner. Such regulatory elements may be leaf-specific, guard cell specific, stem-specific, root specific, green tissue specific, organelle-specific or the like. Non limiting examples of guard-cell specific regulatory elements include promoter sequences of the *Arabidopsis* TGG1  
10 gene (Husebye et al 2002. *Plant Physiol* 128:1180-1188; Plesch et al 2000 *Gene* 249:83-9; PCT Patent Application No. WO 93/018169; which are incorporated herein by reference). Non-limiting examples of organelle-specific regulatory elements include promoter sequences of the pea chlorophyll a/b binding protein gene AB80 (Zabaleta et al 1994. *Plant J.* 6:425-432; which is incorporated herein by reference). Non-limiting examples of leaf-specific  
15 regulatory elements are described in PCT Patent Publications WO 02/077248; WO02/036786; WO 98/00533 (which are incorporated herein by reference). Non-limiting examples of root-specific or root-active regulatory elements are described in PCT Patent Publications. WO 06/066193; WO 05/085449 (which are incorporated herein by reference).

[0075] An inducible regulatory element is one that is capable of directly or indirectly  
20 activating transcription of one or more DNA sequences or genes in response to an inducer. In the absence of an inducer the DNA sequences or genes will not be transcribed. Typically the protein factor, that binds specifically to an inducible regulatory element to activate transcription, may be present in an inactive form which is then directly or indirectly converted to the active form by the inducer. However, the protein factor may also be absent. The  
25 inducer can be a chemical agent such as a protein, metabolite, growth regulator, herbicide or phenolic compound or a physiological stress imposed directly by heat, cold, salt, or toxic elements or indirectly through the action of a pathogen or disease agent such as a virus. A plant cell containing an inducible regulatory element may be exposed to an inducer by externally applying the inducer to the cell or plant such as by spraying, watering, heating or  
30 similar methods. Inducible elements may be derived from either plant or non-plant genes (e.g. Gatz, C. and Lenk, I.R.P., 1998, *Trends Plant Sci.* 3, 352-358; which is incorporated by reference). Examples, of potential inducible promoters include, but not limited to, steroid

V81263WO

inducible promoter, for example the estradiol promoter, tetracycline-inducible promoter (Gatz, C.,1997, *Ann. Rev. Plant Physiol. Plant Mol. Biol.* 48, 89-108; which is incorporated by reference), steroid inducible promoter (Aoyama, T. and Chua, N.H.,1997, *Plant J.* 2, 397-404; which is incorporated by reference), alcohol or ethanol-inducible promoter (Salter, M.G., et al, 1998, *Plant Journal* 16, 127-132; Caddick, M.X., et al,1998, *Nature Biotech.* 16, 177-180, which are incorporated by reference) cytokinin inducible *IB6* and *CKII* genes (Brandstatter, I. and Kieber, J.J.,1998, *Plant Cell* 10, 1009-1019; Kakimoto, T., 1996, *Science* 274, 982-985; which are incorporated by reference), auxin inducible element, DR5 (Ulmasov, T., et al., 1997, *Plant Cell* 9, 1963-1971; which is incorporated by reference), and a dexamethasone inducible promoter (Sablowski et al., 1998. *Cell* 92:93-103).

[0076] A constitutive regulatory element directs the expression of a gene throughout the various parts of a plant and continuously throughout plant development. Examples of known constitutive regulatory elements include promoters associated with the CaMV 35S transcript (Odell et al., 1985, *Nature*, 313: 810-812), octopine synthase promoter (Fromm et al 1989. *Plant Cell* 1:977-984), the nopaline synthase (NOS) promoter (Lam et al 1990. *J. Biol Chem.* 265:9909-9913), the rice actin 1 (Zhang et al, 1991, *Plant Cell*, 3: 1155-1165) and triosephosphate isomerase 1 (Xu et al, 1994, *Plant Physiol.* 106: 459-467) genes, the maize ubiquitin 1 gene (Cornejo et al, 1993, *Plant Mol. Biol.* 29: 637-646), the *Arabidopsis* ubiquitin 1 and 6 genes (Holtorf et al, 1995, *Plant Mol. Biol.* 29: 637-646), tobacco t-CUP promoter (WO/99/67389; US 5,824,872), the HPL promoter (WO 02/50291), and the tobacco translational initiation factor 4A gene (Mandel et al, 1995 *Plant Mol. Biol.* 29: 995-1004), all of which are herein incorporated by reference. The term "constitutive" as used herein does not necessarily indicate that a gene under control of the constitutive regulatory element is expressed at the same level in all cell types, but that the gene is expressed in a wide range of cell types even though variation in abundance is often observed.

[0077] Other non-limiting examples of developmentally regulated, inducible, tissue-specific, or constitutive regulatory elements are found in Table 1, and references therein, all of which are herein incorporated by reference.

[0078] Table 1: Regulatory elements

Regulatory Element	Associated gene or marker	Reference
--------------------	---------------------------	-----------

V81263WO

<b>Regulatory Element</b>	<b>Associated gene or marker</b>	<b>Reference</b>
Green tissue specific promoter	RbsS3A	Panguluri et al 2005. Indian J. Exp Biol 43(4):369-372
Green leaf specific promoter	AtSTP3	Buttner et al 2000. Plant Cell Env 23(2):175-184
Leaf primordial promoter	CAB	US 5,639,952
Light repressible promoter	Pra2 (pea)	AU 765413, CA2328139
	Pra2 (maize)	US 5639952, US 5656496
Vein promoter	AtSUC2	Imlau et al 1999. The Plant Cell 11:309-322
Heat shock promoter	sigma32 heat shock regulator	GenPept gi91070642 Chen et al 2005. PNAS 103(15):5977-5982
Alcohol-inducible promoter (Alc sequence)	alcR	Caddick et al., 1998
Stem-specific promoter	Stem-specific protein	WO 01/18211
Estradiol-inducible promoter	Per-8	US 6,784,340
Heatshock promoter	Gmshp17.3	Holtorf et al 1995. Plant Mol Biol 29(4):637-646
Pathogen-related promoter	PR1	Beilmann et al 1992. Plant Mol Biol 18(1):65-78
Cotyledon-specific promoter	At2S1/ast2S2	Guerche et al 1990. Plant Cell 2(5):469-478
Vascular tissue-specific promoter	RoIC	Matsuki et al 1989. Molecular Genetics and Genomics 220:12-16
Flower-specific promoter	ChsA	Koch et al 2001. Mol Biol and Evol. 18:1882-1891
Light-inducible promoter	ST-LS1 (L700)	Stockhaus et al 1987. PNAS 84(22):7943-7947
RuBisCO	CbbL, cbbM	Giri et al 2004. Appl Environ Microbiol 70(6):3443-3448
Cold-inducible promoter	cspA	US 6,479,260
Light-specific promoter	ssu	US5750385
Estrogen-inducible promoter	xve	Zua et al 2000. Plant J. 24(2):265-273
ABA-responsive promoter	CdeT27-45	Michel et al., 1993 Plant J. 4:29-40
Epidermis-specific	NtItp1	Canevascini et al., 1996. Plant Physiol 112:513-24

V81263WO

[0079] Other non-limiting examples of regulatory elements may comprise particular sequences or response elements. For example, a regulatory element may comprise one or more cis-acting motifs, such as an abscisic acid response element, an Sph/Ry element, a Myb recognition element or an Myc recognition element. These and/or other regulatory elements may be combined to provide a non-naturally occurring promoter, and inserted in –cis, 5' to the desired nucleic acid that is to be expressed (for example, the antisense cpn21, or the RNAi cpn21 as described herein).

[0080] The nucleic acid constructs of the present invention may be introduced into any desired plant, including forage plants, food crops, ornamental plants, or other plants depending upon the need. Thus, embodiments of the invention have use over a broad range of plants. Examples of such plants include, but not limited to, alfalfa, corn, barley, rice, tobacco, *Arabidopsis*, canola, wheat, oat, *Brassica*, *Oryza*, hemp, soybean, pea, ginseng, flax, hemp, maize, for example but not limited to *Cannabis sativa*, potato and ornamental plants, for example, but not limited to, *Petunia spp.*, *Cyclamen ssp*, *Begonia ssp*, *Azalea spp.*, *Spatifilium spp.* Other examples include species from the genera *Anacardium*, *Arachis*, *Artemisia*, *Asparagus*, *Atropa*, *Avena*, *Brassica*, *Brachypodium*, *Citrus*, *Citrullus*, *Capsicum*, *Carthamus*, *Cocos*, *Coffea* (e.g. *C. arabica*, *C. robusta*), *Cucumis*, *Cucurbita*, *Daucus*, *Elaeis*, *Fragaria*, *Glycine*, *Gossypium*, *Helianthus*, *Heterocallis*, *Hordeum*, *Hyoscyamus*, *Lactuca*, *Linum*, *Lolium*, *Lupinus*, *Lycopersicon*, *Malus*, *Manihot*, *Majorana*, *Medicago*, *Musa* (e.g. Banana), *Nicotiana*, *Olea*, *Oryza*, *Panicum*, *Pannisetum*, *Persea*, *Phaseolus*, *Pistachia*, *Pisum*, *Pyrus*, *Prunus*, *Raphanus*, *Ricinus*, *Rosa*, *Secale*, *Senecio*, *Sinapis*, *Solanum*, *Sorghum*, *Theobromus*, *Trigonella*, *Triticum*, *Vicia*, *Vitis*, *Vigna*, *Zea* and the like.

[0081] In the experiments outlined below, tobacco, *Arabidopsis*, Canola, rice or *Brachypodium* were used as the test organism for the expression of the constructs as defined herein, however it is to be understood that the constructs of the present invention may be introduced and expressed in any plant.

[0082] Also considered part of this invention are transgenic plants comprising a construct, vector or nucleic acid as described herein.

[0083] Methods of regenerating whole plants from plant cells are known in the art. In general, transformed plant cells are cultured in an appropriate medium, which may contain

V81263WO

selective agents such as antibiotics, where selectable markers are used to facilitate identification of transformed plant cells. Once callus forms, shoot formation can be encouraged by employing the appropriate plant hormones in accordance with known methods and the shoots transferred to rooting medium for regeneration of plants. The plants may then  
5 be used to establish repetitive generations, either from seeds or using vegetative propagation techniques.

[0084] To aid in identification of transformed plant cells, the constructs of this invention may be further manipulated to include plant selectable markers. Selectable markers may include but are not limited to enzymes which provide for resistance to an antibiotic such as  
10 gentamycin, hygromycin, kanamycin, and the like. Similarly, enzymes providing for production of a compound identifiable by colour change such as GUS (beta-glucuronidase), luminescence, such as luciferase, metabolism of a particular carbon source (preventing growth of nontransformants) such as phosphomannose isomerase, are useful.

[0085] Nucleic acids, antisense molecules, silencing nucleotide sequences, vectors or other  
15 genetic constructs (collectively referred to as "constructs" or "nucleic acid constructs") may be introduced into plant cells using Ti plasmids, Ri plasmids, plant virus vectors, direct DNA transformation, micro-injection, electroporation, floral dip, biolistic particle gun, or the like. For reviews of such techniques see, for example, Weissbach and Weissbach, *Methods for Plant Molecular Biology*, Academy Press, New York VIII, pp. 421-463 (1988); Geierman and  
20 Corey, *Plant Molecular Biology*, 2d Ed. (1988); and Miki and Iyer, Fundamentals of Gene Transfer in Plants. In *Plant Metabolism*, 2<sup>nd</sup> edition DT. Dennis, et al., (editors), Addison Wesley, Langmans Ltd. London, pp. 561-579 (1997); Clough and Bent, 1998 (*Plant J.* 16, 735-743). Hemp, for example but not limited to *Cannabis sativa* L. may be transformed using  
25 *Agrobacterium tumifaciens*, as described by Feeny and Punja, 2006. (*Methods Mol Biol* 344: 373-382; which is incorporated herein by reference)

[0086] The present invention further includes a suitable vector comprising the nucleic acid construct.

[0087] Also considered part of this invention are transgenic plants and their progeny that contain a nucleic acid construct of the present invention. Methods of regenerating whole  
30 plants from plant cells are known in the art, and the method of obtaining transformed and

V81263WO

- regenerated plants is not critical to this invention. In general, transformed plant cells are cultured in an appropriate medium, which may contain selective agents such as antibiotics, where selectable markers are used to facilitate identification of transformed plant cells. Once callus forms, shoot formation can be encouraged by employing the appropriate plant hormones in accordance with known methods and the shoots transferred to rooting medium for regeneration of plants. The plants may then be used to establish repetitive generations, either from seeds or using vegetative propagation techniques. Plant regeneration from cultured protoplasts is described in Evans et al. (Protoplasts Isolation and Culture, Handbook of Plant Cell Culture, pp. 124-176, MacMillian Publishing Company, New York, 1983; and Binding, Regeneration of Plants, Plant Protoplasts, pp. 21-73, CRC Press, Boca Raton, 1985; which are incorporated herein by reference). Regeneration can also be obtained from plant callus, explants, organs, or parts thereof. Such regeneration techniques are described generally in Klee et al. 1987 (Ann. Rev. Plant Phys. 38:467-486; which is incorporated herein by reference).
- 15 [0088] The silencing nucleic acid sequence or construct as described herein may also be introduced into a plant by crossing a first plant with a second plant that comprises the silencing nucleic acid sequence or construct, and selecting for expression of the nucleic acid.

[0089] Table 2. List of Sequences and primers according to some embodiments of the invention.

SEQ ID NO:	Description	Table/Figure/Sequence
1	Arabidopsis Cpn21	Figure 8A
2	Cpn21 fragment	Figure 8L
4	Cpn21 antisense 35S	Figure 8B
5	Cpn21 RNAi fragment with intron	Figure 8C
6	Cpn21 RNAi 35S	Figure 8D
7	Cpn21RNAi RBC	Figure 8E
8	AlcR Cpn21 RNAi Sequence	Figure 8F

V81263WO

SEQ ID NO:	Description	Table/Figure/Sequence
9	35S Promoter	Figure 8G
10	AlcA promoter	Figure 8H
11	RBC Promoter	Figure 8I
12	AlcR fragment with required 35S Promoter	Figure 8J
13	35SSF	AAAGGAAGGTGGCTCCTAC
14	35SSSR	CCATCTTTGCCCTTGAAGTC
15	CpnR2	GGAGTTCCTCCACTTCAGCAACGGC
16	35SF3	CTACGAGGAGCACCCACCCCC
17	35S-ASF	AAGGAAAGGCCATCGTTG
18	35S-ASR	CAAATACGCAGGAACTGAGG
19	RBCRnaiR	GAGCAGTGGATGGAAGTAAG
20	RBCRnaiF	ACTTTAGGGCACGATGTC
21	35S RNAIF	CTATCACCGTGCCAATAG
22	AlcR	GAGCCGTATAGAGCAGAGAC
23	Cpn 21 Antisense	Figure 8K
24	ACpn 21 RNAiF*	<u>GGGGACCACTTTGTACAAGAAAGCTGGG</u> <u>TGGGAGGCAGAGGAGAAGACTTTAG</u>
25	ACpn 21 RNAi R*	<u>GGGGACAAGTTTGTACAAAAAAGCAGGCT</u> <u>GGCTTCCGGTTGATACTGGTAGAGG</u>
26	ACpn 21 Antisense F	GGCACGTGAAATGGCGGCGACTCAACTTAC
27	ACpn 21 Antisense R	GGACTAGTCCAGATTATGCTCAGGCCGTTTAC
28	pGreen0029-RBC	Figure 8M
29	pUC57-RBC	Figure 8N

\* Underlined sequences correspond to Gateway™ (Invitrogen) extensions

V81263WO

[0090] The present invention will be further illustrated in the following examples. However it is to be understood that these examples are for illustrative purposes only, and should not be used to limit the scope of the present invention in any manner.

## Examples

### 5 Methods

#### Vector construction

[0091] *Arabidopsis* Chaperonin 21 sequence (GenBank Accession No. AF428366.1 gi:16226910 *Arabidopsis thaliana* AT5g20720/T1M15\_120 mRNA; SEQ ID NO: 1) was used to design PCR primers incorporating PmlI and SpeI sites for cloning purposes.

- 10 [0092] **Cpn21 Antisense under 35S promoter (cpn21AS) (SEQ ID NO: 4)** A sequence encoding cpn21 was amplified from *A. thaliana* cDNA using primers ACpn 21 Antisense F and ACpn 21 Antisense R (SEQ ID NO: 26 and 27) , incorporating SpeI (at the 5' end) and PmlI (at the 3' end) restriction enzyme recognition sequences for cloning purposes. The resulting PCR product was ligated into pGEM-T and verified by sequencing (resulting
- 15 construct Acpn21 antisense pGEM-T). ACpn21 antisense pGEM-T was digested with PmlI/ SpeI and the resulting 800bp fragment containing Cpn21 was ligated into a pCambia 1302 vector cut with PmlI/ SpeI, and verified by sequencing.

[0093] The pCambia vector (available from CAMBIA) was derived from a pPZP backbone (Hajdukiewicz et al 1994. Plant Mol Biol 25:989-994; GenBank Accession No: AF234301).

- 20 [0094] The "Cpn21 RNAi-35S" (SEQ ID NO: 6) construct places expression of the RNAi sequence of Cpn21 under control of the 35S promoter (SEQ ID NO: 9). To make the Cpn21 RNAi constructs a 500bp fragment from the middle of the Cpn21 gene was amplified by PCR using primers containing the Gateway® (Invitrogen) attB1 (forward) and attB2 (reverse) 5' extensions (ACpn 21 RNAi F and ACpn 21 RNAi R, SEQ ID NO: 24 and 25), following
- 25 manufacturers' instructions. The Gateway® BP recombination reaction was used to insert the Cpn21 PCR product into a pDONR™221 vector, and the resulting Cpn21 pDONR construct verified by sequencing. The Gateway® LR recombination reaction was again used to insert the Cpn21 sequence from Cpn21 pDONR into pKGW1WG2II (Karimi et al., 2002 Trends Plant Sci 7(5):193-195)in an RNAi format (sense and antisense sequences flanking an intron; when

V81263WO

transcribed, the nucleic acid forms a hairpin-loop structure) ( SEQ ID NO: 5) and verified by sequencing.

[0095] The “cpn21 RNAi-RBC” construct places expression of the RNAi sequence of Cpn21 under control of the RuBisCO (RBC) promoter (SEQ ID NO: 11). To make cpn21 RNAi-RBC (SEQ ID NO: 7), the cpn21 insert in RNAi orientation from pKGW1WG2II was excised with XmnI, and ligated into pGreen0029-RBC (SEQ ID NO: 28), linearized with XmnI/SmaI. pGreen0029-RBC comprises an *N. tabacum* RBC promoter (nucleotides 699-1744 of SEQ ID NO: 28) a multiple cloning site (nucleotides 1745-1841 of SEQ ID NO: 28), a sequence encoding a NOS terminator (nucleotides 1842-2122 of SEQ ID NO: 28), and was made by excising a KpnI/ApaI fragment of pUC57-RBC (SEQ ID NO: 29) comprising an RBC promoter, and ligating this fragment into a pGreen0029 vector that had been linearized with KpnI/ApaI. pGreen plasmids are known in the art and are described in, for example, references by Hellens et al., 2000 Plant Mol Biol 42:819-832; Hellens et al., 2000 Trends in Plant Sci 5:10:446-451; GenBank Accession No; Y09374).

[0096] The pUC57 vector is known and available from Genscript (GenScript USA Inc. 120 Centennial Ave Piscataway, NJ. Catalog # SD1176-50ug). pUC57-RBC comprises a *N. tabacum* RBC promoter (nucleotides 21-1066 of SEQ ID NO: 29), a multiple cloning site (nucleotides 1067-1163 of SEQ ID NO: 29) and a sequence encoding a NOS terminator (nucleotides 1164-1444 of SEQ ID NO: 29).

[0097] The resulting cpn21 RNAi-RBC construct was digested with BamHI/ XmnI to check for the presence of the insert.

[0098] The “Cpn21AS-RBC” construct places expression of the sense orientation of Cpn21 under control of the RBC promoter. To make Cpn21AS-RBC, the RBC promoter (SEQ ID NO: 11) was removed from pUC57 RBC (SEQ ID NO: 29) by digestion with HindIII and SpeI and inserted into pCambia 1302 AAS6 (from CAMBIA; cut with HindIII/SpeI) comprising a Cpn21 sequence in an antisense orientation. The resulting construct was digested with HindIII/ SpeI to check for correct insert size.

[0099] Inducible constructs comprising the Alc were also made. The Alc regulon is describe in Caddick 1998 et al. Briefly, the minimal regulon includes an alcR sequence and an AlcA promoter. The AlcR polypeptide (transcription factor) responds to the inducer molecule

V81263WO

(ethanol) when the plant is exposed to ethanol; the AlcR polypeptide binds the AlcA promoter, stimulating expression of the open reading frame operably linked to the AlcA promoter sequence.

[00100] The “AlcR Cpn21 RNAi” construct (SEQ ID NO: 8) places expression of the RNA format of Cpn21 under control of an alcohol-inducible promoter (AlcA – SEQ ID NO: 10). To make AlcR Cpn21 RNAi, a nucleic acid sequence comprising Cpn21 in RNAi configuration (sense and antisense sequences flanking an intron; when transcribed, the nucleic acid forms a hairpin-loop structure) from pKGW1WG2II Cpn21 RNAi digested with PspOMI/ XmnI, was ligated into a backbone containing an AlcA promoter from AIR-AIA pGreen 0029 cut with SmaI/ NotI. The construct was digested with BglII to check for correct banding pattern. The AlcR-AlcA pGreen0029 construct was obtained from GenScript. A1R sequence (GenBank Accession No. XM\_677155) and A1A promoter sequences (GenBank Accession No. M16196) are known in the art.

#### Transformation of tobacco plants (*Nicotiana tabacum* L. cv. SR1)

[00101] Tobacco plants grown *in vitro* were utilised for *Agrobacterium* transformation with the above constructs (Cpn21AS, Cpn21 RNAi-RBC, Cpn21AS-RBC, AlcR Cpn21 RNAi). *A. tumefaciens* carrying the construct of interest were grown in suspension culture (400 ml ) overnight in LB medium with antibiotics and agitation (28°C, 200 rpm). The bacterial suspension was centrifuged and resuspended in 5% sucrose (OD<sub>600</sub> ~ 1.0), supplemented with Silwet L-77 to a concentration of 0.02% (200 microliter (µL)/L). Leaf discs from *in vitro* growing plants were immersed for 30 minutes in the resuspended *A. tumefaciens*, followed by two days co-cultivation on solidified CT medium (Sigma-Aldrich). Co-cultivation was carried out in the dark 22°C and 70% humidity. Transformants were selected using selection medium (Murashige & Skoog – “MS”) in the presence or absence of selection agents (kanamycin or hygromycin) or induction agents (alcohol), according to the construct used in transformation (see Tables 3, 4 for media, selection agents, inducing agents). Plants demonstrating variegation were rooted and transferred to soil.

V81263WO

**Table 3** Composition of tissue culture media utilised for plant variegation *in vitro*

Media composition	CT plant cocultivation medium	½ strain MS seeds germination medium	MS tobacco shoots medium	MMO shoot initiation medium	N6 callus Induction medium	N6 Rice Regeneration medium	LS-Brachypodium Embryo Induction medium	LSR-Brachypodium Regeneration medium	MS basal medium
MS salts with vitamins	-	2.2 g/l	4.4 g/l	-	-	-	-	-	4.4 g/l
MS minimal organics	-	-	-	4.4 g/l	-	-	-	-	-
N6 salts	-	-	-	-	3.98 g/l	3.98 g/l	3.98 g/l	3.98 g/l	-
N6 Vitamins	-	-	-	-	1 ml/l	1 ml/l	1 ml/l	1 ml/l	-
Sucrose	-	10 g/l	30 g/l	30 g/l	30 g/l	30 g/l	30 g/l	-	30 g/l
Glucose	30 g/l	-	-	-	-	-	-	-	-
Maltose	-	-	-	-	-	-	-	30 g/l	-
KH <sub>2</sub> PO <sub>4</sub>	0.2 g/l	-	-	-	-	-	-	-	-
2,4 D	1 mg/l*	-	-	-	2 mg/l	-	5 mg/l	-	-
NAA	-	-	-	-	-	1 mg/l	-	-	-
IAA	0.8 mg/l**	-	0.8 mg/l	-	-	-	-	-	-
BA	-	-	-	4.5 mg/l****	-	1 mg/l	-	-	-
kinetin	2.0 mg/l**	-	2.0 mg/l	-	-	-	-	0.2 mg/l	-
DTT	75 mg/l	-	75 mg/l	75 mg/l	75 mg/l	75 mg/l	75 mg/l	75 mg/l	-
Vitamin C	150 mg/l	-	-	-	-	-	-	-	-
acetosyringone	150 um	-	-	-	-	-	-	-	-
agar	6.5 g/l***	6.5 g/l	6.5 g/l	6.5 g/l	6.5 g/l	6.5 g/l	6.5 g/l	6.5 g/l	6.5 g/l
pH	5.5	5.7	5.7	5.7	5.7	5.7	5.7	5.7	5.7

\* Only for canola transformation

\*\* Only for tobacco transformation

\*\*\* The same media without agar (liquid one) was used to dissolve Agrobacterium after overnight grow and cocultivation with explants prior CT agar.

V81263WO

**Table 4.** Constructs, inducing and selection agents, promoters and plants tested.

Construct	Inducing Agent	Selection Agent	Promoter	plants tested
Acpn21 antisense pGEMT	-	-	-	-
Cpn21 AS	none	hyg	35S	T, C, A
AlcR Cpn21RNAi	ethanol	kan	AlcA	T
pDONR221	-	-	-	-
Cpn21 RNAi 35S	none	kan	35S	T, C, R, B, A
Cpn21 RNAi RBC	none	kan	RBC	T
Cpn21 AS-RBC	none	kan	RBC	T
pKGW1WG211	-	-	-	-
pGreen0029 RBC NARNRT	-	-	-	-
pUC57 RBC	-	-	-	-
pCambia 1302 AS6	-	-	-	-
pCambia 1302 AAS6	-	-	-	-
AIR-AIA pGreen 0029	-	-	-	-

T= *Nicotiana tabacum*C= *Brassica napus* (Canola)A= *Arabidopsis thaliana*R= *Oryza sativa*B= *Brachypodium distachyon*

[00102] Hygromycin B (Invitrogen) and kanamycin (Sigma/Aldrich) were used as selection agents. Selection media was also supplemented with Timentin (GlaxoSmithKline). 2-4-D (Sigma), BA (Sigma), indole-3-acetic acid (IAA) (Invitrogen) and kinetin (Sigma) were used for induction of callus and/or shoot regeneration.

#### 5 Transformation of Arabidopsis

[00103] Transformation of Arabidopsis was according to the method of Clough and Bent, 1998. Briefly, *Arabidopsis* plants were grown until the flowering stage under long days light condition (16/8 hours photoperiod, 70% humidity, and 22°C), in potsoil. *A. tumifasciens* carrying the construct of interest (Cpn21AS or Cpn21 RNAi RBC) was grown in suspension culture (400 ml) overnight in LB medium with antibiotics, with agitation. The bacterial suspension was centrifuged and resuspended in 5% sucrose (OD<sub>600</sub> ~ 0.8), supplemented with Silwet L-77 to a concentration of 0.02% (200 µL/L). Flowering plants were immersed for 2-3 sec in the *A. tumifasciens* suspension and placed under plastic wrap for 24 hours. Dry matured seeds were collected, sterilized and germinated *in vitro* on selection medium (50 mg/l hygromycin) or selection-free medium (lacking hygromycin).

#### Transformation of Canola (*Brassica napus*)

[00104] *B. napus* cultivar DH 12075 characterised by high regeneration efficiency was used for chaperonin-transformation experiments. Seeds were germinated on 1/2 MS media for 6 days under long day light conditions (22°C, 16/8 hours photoperiod, 70% humidity). Cotyledons along with petioles from six day old explants were used for transformation experiments.

[00105] *A. tumifasciens* carrying the construct of interest (cpn21AS or Cpn21RNAi - 35S) was grown in suspension culture (400 ml) overnight in LB medium with antibiotics, with agitation (22°C, 200 rpm). Bacteria were collected by centrifugation and resuspended in CT medium at an OD<sub>600</sub>=0.4. Cotyledons along with a portion of petioles were detached from the plantlets and the cut side of the tissue dipped in the Agrobacterium suspension.

[00106] Explants were co-cultivated for 48 hours on CT agar medium supplemented with 100 µM acetosyringone, 1 mg/l 2,4-D and 75 mg/l DTT. Explants were then transferred

to MMO selection media enriched with either with 4.5 mg/l BA, 200 mg/l timentin and with or without 5 mg/l hygromycin and with or without 50 mg/l kanamycin.

[00107] Well developed shoots were detached from the explants and transferred to fresh medium. Rooting was carried out on MS medium lacking growth regulators, supplemented with 200 mg/l timentin, with or without hygromycin. Well rooted plants were hardened in soil. Plants were grown to flowering stage in an isolator at 23°C with 16/8 hour photoperiod. Mature seeds were harvested, sterilized, and germinated *in vitro* on selection media supplemented with 10 mg/l hygromycin or 100 mg/ml kanamycin. Young leaves were harvested for PCR analysis.

#### 10 **Example 1: Transformation of *N.tabacum* with Cpn21AS**

[00108] *Nicotiana tabacum* L. cv. SR1 plants were transformed with cpn21AS as described. The Cpn21 antisense sequence was expressed constitutively under control of the 35S promoter, as described.

[00109] Over 200 plants demonstrating various variegation patterns were selected following transformation in antisense orientation or RNAi. T0 plants at flowering stage were grown under isolators in growth cabinet (23°C day/19°C night; 16/8 hour photoperiod). Seeds from 15 randomly chosen variegated plants were harvested and sterilised and germinated *in vitro* on ½ MS media with hygromycin (50 mg/l) or hygromycin free MS media (Tables 3& 4). Three weeks after germination the number of Hyg<sup>R</sup> and Hyg<sup>S</sup> seedlings was determined. T0 and T1 plants were tested using PCR with primers 35S-ASR and 35S-ASF, to confirm the presence of the Cpn21 antisense sequence.

[00110] Shoots grown on hygromycin selection media were subcultured for further shoot elongation onto MS medium supplemented with hygromycin. At the shoot elongation stage, some leaves were lighter green, with small portions of dark green tissue at the edges while others exhibited variegation over the entire leaf. Variegated plants demonstrated rooting in hygromycin selection media, while those with bleached leaves demonstrated less viability, and reduced growth. Seeds from bleached plants either were not produced, or if they were, did not germinate upon cultivation *in vitro*. Partially variegated plants were grown under reduced light intensity (800 Lux) and produced viable seeds. 67.4% of regenerated

shoots were rooted on hygromycin media. 12.2% of all hygromycin-resistant rooted plants were visibly variegated.

[00111] Variegated *N. tabacum* plants were also identified on hygromycin-free medium (MS-hyg). A plant was considered variegated if one or more regions of one or more leaves displayed differential coloration. The efficiency of transformation was slightly decreased when plants were regenerated without selection pressure - 11.3% of regenerated plants were variegated and 4.4% were rooted after 3 weeks. These results demonstrate the variegation effect may be used as a marker of a transformed plant in the absence of artificial selection pressure.

10 [00112] T1 plants (produced by self fertilization of T0 plants) demonstrated variegation in ~25% of plants that germinated on hygromycin medium.

[00113] Nontransformed plants do not degrade hygromycin, and the surviving shoots on the selection medium (hygromycin-containing) were albino. Transformed plants grown on selection medium were green, or had some green tissue.

15 **Example 2: Transformation of Tobacco with cpnRNAi-35S**

[00114] Three weeks following transformation of leaf tissue with cpnRNAi-35S as described, shoots were assessed for variegation, coloration and rooting.

[00115] During the stage of shoot regeneration (initiation and elongation) bleaching was observed in some shoots under both selection and non-selection conditions (+/- kanamycin regeneration media). Well-growing shoots were subcultured for further elongation and rooting to MS selection medium. At this stage of shoot elongation, leaf coloration patterns included light green colouration over the entire leaf, variegated patterns, or yellow edges (Figure 1). 67.4% of regenerated shoots were rooted on kanamycin media, including variegated plants. Plants with bleached leaves were less robust, and demonstrated reduced growth. Overall, 43.7% of kanamycin rooted plants demonstrated variegation.

[00116] Variegated plants were also grown on media lacking kanamycin selection. Transformation efficiency was decreased when plants were regenerated without selection pressure, with 23.3% of the explants having regenerated at least one variegated plant.

[00117] T0 plants at flowering stage were grown and the seeds harvested. Bleached plants either failed to produce seed, or produced seed that did not germinate. Partially variegated plants were grown under reduced light intensity (800 Lux) and produced viable seeds.

5 [00118] Seeds harvested from variegated plants were sterilised and germinated *in vitro* on ½ MS media with appropriate antibiotics (e.g. kanamycin at 500 mg/l) or antibiotic free MS media to produce T1 progeny, and the number of kanamycin resistant (Kan<sup>R</sup>) and kanamycin sensitive (Kan<sup>S</sup>) seedlings were tallied at 3 weeks' growth. Self-fertilisation of T0 regenerants yielded either near to 3:1 or 2:1 segregation ratio of kanamycin positive/negative  
10 plants, and a 3:1 ratio of variegation positive/variegation negative plants. Variegated T1 plants were easily identified on kanamycin negative media, and a variety of variegation patterns were observed, including bleached or light green leaf edges, with darker leaf tissue, light veination with darker leaf tissue, or speckled/spotted variegation over the entire leaf (Figure 2A-E).

15 [00119] PCR was used on tissues from visibly variegated T1 progeny to confirm the transgenic status of the regenerants transformed with cpnRNAi-35S, however a significant rate of sterility in T1 seeds was observed. Seeds were germinated on MS basal cultivation media without selection, with 42 % of the seeds were germinated and produced viable plants.

### **Example 3: Transformation of tobacco with Cpn21RNAi-RBC**

20 [00120] Transformation efficiency of tobacco plants transformed with Cpn21RNAi-RBC under tissue specific promoter was similar to those transformed with Cpn21RNAi - 35S. Leaves were generally brighter comparing to the control (wild type), with variegation in transformed plants observed at later growth stages. Stem colour, viability and morphology during vegetative development and flowering stage of the transformed plants was similar to  
25 untransformed plants, and seeds were produced. PCR was used on tissues from visibly variegated T1 progeny plants to confirm the transgenic status of the regenerants.

**Example 4: Transformation of Tobacco with Cpn21RNAi-AlcR**

[00121] Transformation efficiency of tobacco plants transformed with Cpn21RNAi-AlcR was similar to those transformed with Cpn21RNAi - 35S or Cpn21RNAi-RBC..

5 Regenerated plants demonstrated normal morphology and seed viability. (78% germination for T0 generation; 81% for wild type control).

[00122] During the stage of shoot elongation ethanol in concentration of 2% was added to the selection media if the plants were transformed with Cpn21 under ethanol inducible promoter. The new developed leaves demonstrated variegated morphology (Figure 3). Some  
10 older leaves demonstrated variegation in the new growth meristematic areas.

[00123] Expression from the AlcR promoter may be induced by any of several methods: supplement of the cultivation media with 2% ethanol; exposure of regenerants to ethanol vapour (placement of a small test tube containing 99% ethanol inside the magenta jar with growing shoots); spraying leaves (*in vitro* or *in vivo*) with 2% ethanol. All three  
15 methods induced variegation in developing tissues, including leaves and stems.

[00124] About 2 % of the plants growing in ethanol free media also developed variegated pattern.

[00125] 34.2% of rooted plants regenerated on antibiotic free media (supplemented with ethanol during shoot elongation) were visibly variegated. Regenerated plants were  
20 transferred to the soil and seeds were produced, harvested, sterilised and germinated *in vitro*. A germination ratio of about 3:1 (germinated :non-germinated) was observed on antibiotic selection (kanamycin) media. When ethanol was added to the regeneration media, 12.8% of the plants demonstrated variegation.

**Example 5: Transformation of *Arabidopsis* with Cpn21S, Cpn21AS, Cpn21RNAi - 35S**

25 [00126] *Arabidopsis* was transformed with Cpn21AS and transgenic progeny grown as described.

[00127] Less than 1% (0.4%) efficiency was observed in *Arabidopsis* transformed with cpn21AS or Cpn21RNAi - 35S constructs, and only 0.2% demonstrated variegation. The

seedling transformants demonstrated bleaching, and lacked any significant amount of green colouration.

[00128] Transformants comprising Cpn21RNAi - 35S were rooted on kanamycin selection media and viable seeds were produced by some variegated plants. T1 segregation of  
5 kanamycin resistant:sensitive was about 1:1; about 63.2% of regenerants were variegated. PCR was used on tissues from visibly variegated T1 progeny to confirm the transgenic status of the regenerants transformed with Cpn21RNAi - 35S.

**Example 6: Transformation of Canola (*Brassica napus*) with Cpn21RNAi - 35S, cpn21AS**

10 [00129] The transformation efficiency with Cpn21RNAi - 35S was low and few variegated plants were identified in the media without kanamycin selection. Approximately 32 variegated shoots (1.2% of total amount of the regenerants) were regenerated on kanamycin free media. T0 Plants developed roots but the growth was inhibited. Seed development was delayed relative to untransformed plants however viable seed was  
15 produced, and germinated seeds demonstrated variegation in early leaves and were distinguishable from untransformed plants (Figure 4 and 5).

[00130] PCR was used on tissues from visibly variegated T1 progeny plants to confirm the transgenic status of the regenerants.

**Example 7: Constructs and transgenic plants comprising vein-specific promoter.**

20 [00131] A promoter for vein-specific expression of a chaperonin construct may be used to transform plants. The Cpn21AS construct may be digested with restriction enzymes to remove the 35S promoter, according to standard methods. An AtSUC2 promoter, amplified as described in Imlau et al 1999 (Cell 11:309-322) may be ligated into the cut vector, and the construct verified by sequencing. Briefly, PCR amplification may be performed using the  
25 primers HP-SUC2P, comprising HindIII and PmlI sites (SEQ ID NO: 19) and SNN-SUC2P SacI, NotI, and NcoI sites (SEQ ID NO: 20). The resulting plasmid comprising the vein-specific promoter may be transformed into plant tissue of interest using known methods, such as those exemplified herein.

**Example 8: Transformation of *Oryza sativa* (indica) with Cpn21RNAi -35S**

[00132] An embryogenic culture was initiated from mature indica rice seeds (cv. Nipponbare) on 2xN6 medium supplemented with 2 mg/l 2-4D. The embryogenic culture was maintained by subculturing on the fresh medium every 3 weeks. For *Agrobacterium* mediated transformation, the protocol of Kumar et al., 2005 (Plant. Mol. Biol. Rep. 232: 67-73) was used. Regenerated shoots were obtained four to six weeks after the transfer of embryonic callus to regeneration media (supplemented with kanamycin 100 mg/l and 200 mg/l timentin). Elongated shoots were rooted on selection media. Well rooted plants were subsequently transferred to pots (Figure 6) for growth, maturation and production of seed. Self-pollinated and T1 seeds were germinated in kanamycin (500 mg/l) selection medium. PCR was used on tissues from visibly variegated T1 progeny plants to confirm the transgenic status of the regenerants.

**Example 9: Transformation of *Brachypodium distachyon* with Cpn21RNAi - 35S**

[00133] Immature embryos were utilized as a source of primary explants for embryogenic culture, using the protocol of Draper et al., (2001). (Plant Physiol. 127: 1539-1555). Embryo initiation was on media (LS) supplemented with 5 mg/l 2-4D (callus-inducing medium, CIM). The embryogenic culture was maintained by subculturing on CIM fresh medium every 3 weeks. For *Agrobacterium* mediated transformation, the protocol of Vogel et al., 2006 (Cell, Tissue and Organ Culture 84: 199-211) was used. Regenerated shoots were obtained four to six weeks after the transfer of embryonic callus to regeneration media, supplemented with 0.2 mg/l kinetin, 50 mg/l kanamycin and 150 mg/l timentin. Elongated shoots were rooted on selection media. Well rooted plants were transferred to pots (Figure 7) for growth, maturation and production of seed. Self-pollinated and T1 seeds germinated in kanamycin (500 mg/l) selection medium. PCR was used on tissues from visibly variegated T1 progeny plants to confirm the transgenic status of the regenerants.

[00134] All citations are herein incorporated by reference, as if each individual publication was specifically and individually indicated to be incorporated by reference herein and as though it were fully set forth herein. Citation of references herein is not to be construed nor considered as an admission that such references are prior art to the present invention.

[00135] One or more currently preferred embodiments of the invention have been described by way of example. The invention includes all embodiments, modifications and variations substantially as hereinbefore described and with reference to the examples and figures. It will be apparent to persons skilled in the art that a number of variations and  
5 modifications can be made without departing from the scope of the invention as defined in the claims. Examples of such modifications include the substitution of known equivalents for any aspect of the invention in order to achieve the same result in substantially the same way.

**WHAT IS CLAIMED IS:**

1. A variegated plant comprising a nucleic acid operatively linked to a regulatory region, wherein the nucleic acid disrupts the expression of Cpn21.
2. The variegated plant of claim 1, wherein the nucleic acid is an antisense Cpn21, or a  
5 nucleic acid that hybridizes under stringent conditions with the complement of antisense Cpn21.
3. The variegated plant of claim 1, wherein the regulatory region is an inducible regulatory region, a tissue specific regulatory region, a developmental regulatory region or a constitutive regulatory region.
- 10 4. The variegated plant of claim 3, wherein the inducible regulatory region is an alcohol-inducible promoter.
5. The variegated plant of claim 3, wherein the tissue specific regulatory region is a RuBisCO promoter.
6. The variegated plant of claim 1, wherein the nucleic acid is an RNAi.
- 15 7. The variegated plant of claim 6, wherein the RNAi comprises a fragment of SEQ ID NO: 1.
8. The variegated plant of claim 6 wherein the RNAi comprises SEQ ID NO: 5, or a fragment or portion thereof.
9. A method of producing a variegated plant comprising,  
20 i) providing the plant a nucleic acid operatively linked to a regulatory region, the nucleic acid disrupting the expression of Cpn21, and  
ii) growing the plant under conditions that results in the expression of the nucleic acid, thereby producing the variegated plant.
- 25 10. The method of claim 9, wherein the nucleic acid is an antisense Cpn21 or a nucleic acid that hybridizes under stringent conditions with the complement of antisense Cpn21.

11. The method of claim 9, wherein the regulatory region is an inducible regulatory region, a tissue specific regulatory region, a developmental regulatory region or a constitutive regulatory region.
12. A method of selecting a plant comprising a gene of interest comprising,
- 5 i) providing the plant comprising a first nucleic acid operatively linked to a first regulatory region, wherein the first nucleic acid disrupts the expression of Cpn21, and a second nucleic acid encoding the gene of interest and operatively linked to a second regulatory region,
- ii) growing the plant under conditions that result in the expression of the first and  
10 second nucleic acids, and
- iii) selecting plants that display a variegated phenotype and express the nucleic acid of interest.
13. The method of claim 12, wherein the nucleic acid is an antisense Cpn21 or a nucleic acid that hybridizes under stringent conditions with the complement of antisense Cpn21.
- 15 14. The method of claim 12, wherein the regulatory region is an inducible regulatory region, a tissue specific regulatory region, a developmental regulatory region or a constitutive regulatory region.
15. The method of claim 14 wherein the inducible regulatory region is alcohol-inducible.
16. The method of claim 12, wherein the first regulatory region comprises an AlcR  
20 sequence and the second regulatory region comprises an AlcA promoter.
17. The method of claim 9 wherein the regulatory region comprises a RuBisCO promoter.
18. The method of claim 9 wherein the regulatory region comprises an AlcR sequence and an AlcA promoter.
19. The method of claim 9 wherein the regulatory region comprises a vein-specific  
25 promoter.

20. A chimeric construct comprising a nucleic acid operatively linked to a regulatory region, the nucleic acid comprising a sequence that directly or indirectly disrupts the expression of Cpn21, or functional homologue of Cpn21.
21. The chimeric construct of claim 20, wherein the construct further comprises a second  
5 nucleic acid encoding a protein of interest and operatively linked to a second regulatory region.
22. A method of selecting a plant comprising a gene of interest comprising, transforming the plant with a nucleotide sequence comprising the chimeric construct of claim 21, growing the plant under conditions that result in the expression of the first and second nucleic acids,  
10 and selecting plants that display a variegated phenotype and express the nucleic acid of interest.

V81263WO

Figure 1




Figure 2



V81263WO

Figure 3



V81263WO

Figure 4



V81263WO

Figure 5




V81263WO

Figure 6



V81263WO

**Figure 7**



V81263WO

**Figure 8A****SEQ ID NO: 1****gi|16226910|gb|AF428366.1|AF428366 Arabidopsis thaliana AT5g20720/T1M15\_120 mRNA, complete cds**

AACTCTCTCTACTGCAATTTTTAGGGTTTTATCCTCCGAAAGTCTCAACCTTTTTCTTATCCT  
CAACAAGGAGAAATGGCGGCGACTCAACTTACAGCGTCACCAGTGACTATGTCAGCAAGGAG  
CTTAGCCTCGCTGGATGGTCTCAGAGCTTCGAGTGTCAAGTTTTTCATCTTTGAAACCAGGGAC  
CCTTAGACAGAGCCAGTCCGTCGTTTGGTTGTCAAAGCTGCTTCTGTTGTTGCCCTAAGTAT  
ACTTCAATTAAGCCATTGGGAGATCGAGTTTTGGTGAAGATCAAGGAGGCAGAGGAGAAGAC  
TTTAGGTGGTATCTTACTTCCATCCACTGCTCAATCAAAACCTCAAGGAGGTGAAGTCGTTGC  
CGTGGGTGAAGGAAGAAGACTATTGGGAAGAACAAAATTGATATCACTGTCCCTACTGGAGCAC  
AAATTATCTACTCAAATACGCAGGAACTGAGGTGGAGTTCAATGATGTGAAGCATCTTATCC  
TCAAGGAAGATGATATTGTTGGCATTCTTGAGACAGAGGACATCAAAGATCTCAAACCTTTGA  
ATGACCGAGTCTTTATTAAGGTTGCTGAGGCGGAGGAGAAAACAGCTGGAGGGTTGTTGTTA  
ACCGAGACTACCAAAGAGAAGCCTTCTATTGGCACGGTGATAGCAGTTGGACCGGGTTCCCTA  
GACGAGGAAGGTAAAATTACGCCTCTACCAGTATCAACCGGAAGCACAGTACTTTACTCCAA  
GTATGCTGGTAACGACTTCAAGGGCAAAGATGGTTCCAACACTACATTGCCCTCAGAGCTTCAGA  
TGTGATGGCTATACTTTCTTAGTTATGTTATATCTTTGTAATCTGCAACTTGTATCCCAATTGTG  
GAAATTTTTTCCGTAAACGGCCTGAGCATAATCTGGAATAAAGACTTGAGTTTGAAAATGTGA  
TTTTATTGCC

V81263WO

**Figure 8B**

**SEQ DI NO: 4**

**Cpn21 Antisense 35S**

TGACCATGGTAGATCTGACTAGTCCAGATTATGCTCAGGCCGTTTACGGAAAAAATTTCCACA  
 ATTGGGATACAAGTTGCAGATTACAAAGATATAACATAACTAAGAAAGTATAGCCATCACAT  
 CTGAAGCTCTGAGGGCAATGTAGTTGGAACCATCTTTGCCCTTGAAGTCGTTACCAGCATACT  
 TGGAGTAAAGTACTGTGCTTCCGGTTGATACTGGTAGAGGGCGTAATTTTACCTTCCTCGTCTAG  
 GGAACCCCGTCCAACCTGCTATCACCGTGCCAATAGAAGGCTTCTCTTTGGTAGTCTCGGTAA  
 CAACAACCCCTCAGCTGTTTTCTCCTCCGCTCAGCAACCTTAATAAAGACTCGGTCATTCAA  
 GGTTTGAGATCTTTGATGTCCTCTGTCTCAAGAATGCCAACAATATCATCTTCCTTGAGGATAA  
 GATGCTTCACATCATTGAACCTCACCTCAGTTCCTGCGTATTTGGAGTAGATAATTTGTGCTCC  
 AGTAGGGACAGTGATATCAATTTTGTTCCTCCCAATAGTTCCTTCACCCACGGCAACGACT  
 TCACCTCCTTGAGTTTTGATTGAGCAGTGGATGGAAGTAAGATACCACCTAAAGTCTTCTCC  
 TCTGCCTCCTTGATCTTCACCAAACTCGATCTCCCAATGGCTTAATTGAAGTATACTTAGGGG  
 CAACAACAGAAGCAGCTTTGACAACCAACGACGGAACCTGGCTCTGTCTAAGGGTCCCTGGT  
 TTCAAAGATGAAAACCTTGACACTCGAAGCTCTGAGACCATCCAGCGAGGCTAAGCTCCTTGGT  
 GACATAGTCACTGGTGACGCTGTAAGTTGAGTCGCCGCCATTTACGTCGTGAATTGGTGACCA  
 GCTCGAATTTCCCGATCGTTCAAACATTTGGCAATAAAGTTTCTTAAGATTGAATCCTGTTGC  
 CGGTCTTGCGATGATTATCATATAATTTCTGTTGAATTACGTTAAGCATGTAATAATTAACATG  
 TAATCGATGACGTTATTTATGAGATGGGTTTTATGATTAGAGTCCCGCAATTATACATTTAAT  
 ACGCGATAGAAAACAAAATATAGCGCGCAAACCTAGGATAAATTATCGCGCGGGTGTACATCT  
 ATGTTACTAGATCGGGAATTAACACTACAGTGTGTTGACAGGATATATTGGCGGGTAAACCTAA  
 GAGAAAAGAGCGTTTATTAGAATAACGATATTTAAAAGGGCGTGAAAAGGTTTATCCGTTT  
 GTCCATTTGTATGTGCATGCCAACACAGGGTTCCCCTCGGGATCAAAGTACTTTGATCCAAC  
 CCCTCCGCTGCTATAGTGCAGTCGGCTTCTGACGTTCAGTGCAGCCGCTTCTGAAAACGACA  
 TGTCGCACAAGTCCTAAGTTACGCGACAGGCTGCCGCCCTGCCCTTTTCTGGCGTTTTCTTGT  
 CGCGTGTTTTAGTCGCATAAAGTAGAATACTTGCGACTAGAACCGGAGACATTACGCCATGAA  
 CAAGAGCGCCGCCGCTGGCCTGCTGGGCTATGCCCGCGTCAGCACCGACGACCAGGACTTGA  
 CCAACCAACGGGCCGAACCTGCACGCGGCCGGCTGCACCAAGCTGTTTTCCGAGAAGATCACC  
 GGCACCAGGCGCGACCGCCCGGAGCTGGCCAGGATGCTTGACCACCTACGCCCTGGCGACGT  
 TGTGACAGTGACCAGGCTAGACCGCCTGGCCCGCAGCACCCGCGACCTACTGGACATTGCCG  
 AGCGCATCCAGGAGGCCGGCGCGGGCCTGCGTAGCCTGGCAGAGCCGTGGGGCCGACACCACC  
 ACGCCGCGCCGCGCATGGTGTGACCGTGTTCGCCGGCATTGCCGAGTTCGAGCGTTCCTTA  
 ATCATCGACCGCACCCCGAGCGGGCGGAGGCCGCCAAGGCCCGAGGCGTGAAGTTTGGCCC  
 CCGCCCTACCCACCCCGGCACAGATCGCGCACGCCCGCGAGCTGATCGACCAGGAAGGCC  
 GCACCGTGAAGAGGGCGGCTGCACTGCTTGGCGTGCATCGCTCGACCCTGTACCGCGCACTTG  
 AGCGCAGCGAGGAAGTGACGCCCACCGAGGCCAGGCGGGCGGGTGCCTTCCGTGAGGACGCA  
 TTGACCGAGGCCGACGCCCTGGCGGCCCGGAGAATGAACGCCAAGAGGAACAAGCATGAA  
 ACCGCACCAGGACGGCCAGGACGAACCGTTTTTATTACCGAAGAGATCGAGGCGGAGATGA  
 TCGCGGCCGGGTACGTGTTTCGAGCCCGCCGCGCAGTCTCAACCGTGCCGGCTGCATGAAATCC  
 TGGCCGGTTTTGTCTGATGCCAAGCTGGCGGCTGGCCGGCCAGCTTGGCCGCTGAAGAAACCG  
 AGCGCCGCGTCTAAAAAGGTGATGTGATTTGAGTAAAACAGCTTGGCGTATGCGGTGCGTG  
 CGTATATGATGCGATGAGTAAATAAACAATAACGCAAGGGGAACGCATGAAGTTATCGCTG  
 TACTTAACCAGAAAGGCGGGTCAAGCAAGACGACCATCGCAACCCATCTAGCCCGCGCCCTG  
 CAACTCGCCGGGGCCGATGTTCTGTTAGTCGATTCCGATCCCCAGGGCAGTGCCCGGATTGG  
 GCGGCCGTGCGGGAAGATCAACCGCTAACCGTTGTCGGCATCGACCGCCCGACGATTGACCG  
 CGACGTGAAGGCCATCGGCCGGCGGACTTCGTAGTGATCGACGGAGCGCCCCAGGCGGGG  
 ACTTGGCTGTGCCGATCAAGGCAGCCGACTTCGTGCTGATTCCGGTGCAGCCAAGCCCTT  
 ACGACATATGGGCCACCGCCGACCTGGTGGAGCTGGTTAAGCAGCGCATTGAGGTCACGGAT  
 GGAAGGCTACAAGCGGCCTTTGTCGTGTCGCGGGCGATCAAAGGCACGCGCATCGGCGGTGA  
 GGTTGCCGAGGCGCTGGCCGGGTACGAGCTGCCATTCTTGAGTCCCGTATCACGCAGCGCGT  
 GAGTACCCAGGCACTGCCGCCGCCGACACAACCGTCTTGAATCAGAACCCGAGGGCGACG  
 CTGCCCGGAGGTCCAGGCGCTGGCCGCTGAAATTAATCAAACTCATTTGAGTTAATGAGG  
 TAAAGAGAAAATGAGCAAAAGCACAAACACGCTAAGTGCCGGCCGTCCGAGCGCACGCAGC  
 AGCAAGGCTGCAACGTTGGCCAGCCTGGCAGACACGCCAGCCATGAAGCGGGTCAACTTTCA

V81263WO

Figure 8B continued

GTTGCCGGCGGAGGATCACACCAAGCTGAAGATGTACGCGGTACGCCAAGGCAAGACCATTA  
 CCGAGCTGCTATCTGAATACATCGCGCAGCTACCAGAGTAAATGAGCAAATGAATAAATGAG  
 TAGATGAATTTTAGCGGCTAAAGGAGGCGGCATGGAAAATCAAGAACAACCAGGCACCGACG  
 CCGTGGAAATGCCCCATGTGTGGAGGAACGGGCGGTTGGCCAGGCGTAAGCGGCTGGGTTGTC  
 TGCCGGCCCTGCAATGGCACTGGAACCCCCAAGCCCAGGAATCGGCGTGACGGTTCGCAAAC  
 CATCCGGCCCCGTACAAATCGGCGCGGCGCTGGGTGATGACCTGGTGGAGAAGTTGAAGGCC  
 GCGCAGGCCCGCCAGCGGCAACGCATCGAGGCAGAAGCACGCCCCGGTGAATCGTGGCAAGC  
 GGCCGCTGATCGAATCCGCAAAGAATCCCGGCAACCGCCGGCAGCCGGTGCGCCGTCGATTA  
 GGAAGCCGCCAAGGGCGACGAGCAACCAGATTTTTTCGTTCCGATGCTCTATGACGTGGGCA  
 CCCGCGATAGTTCGACATCATGGACGTGGCCGTTTTCCGTTGTCGAAGCGTGACCGACGAG  
 CTGCGCAGGTGATCCGCTACGAGCTTCCAGACGGGCACGTAGAGGTTCCGCAGGGCCGGCC  
 GGCATGGCCAGTGTGTGGGATTACGACCTGGTACTGATGGCGGTTTCCCATCTAACCGAATCC  
 ATGAACCGATACCGGGAAGGGAAGGGAGACAAGCCCAGCCGCGTGTCCGTTCCACACGTTGC  
 GGACGTAACAAGTTCTGCCGGCGAGCCGATGGCGGAAAGCAGAAAGACGACCTGGTAGAAA  
 CCTGCATTCCGTTAAACACCACGCACGTTGCCATGCAGCGTACGAAGAAGGCCAAGAACGGC  
 CGCCTGGTGACGGTATCCGAGGGTGAAGCCTTGATTAGCCGCTACAAGATCGTAAAGAGCGA  
 AACCAGGGCGGCCGGAGTACATCGAGATCGAGCTAGCTGATTGGATGTACCGCGAGATCACAG  
 AAGGCAAGAACCAGGACGTGCTGACGGTTCACCCCGATTACTTTTTGATCGATCCCGGCATCG  
 GCCGTTTTCTTACCGCCTGGCACGCCGCGCCGAGGCAAGGCAGAAGCCAGATGGTTGTTCA  
 AGACGATCTACGAACGCAGTGGCAGCGCCGGAGAGTTCAAGAAGTTCTGTTTACCCTGCGC  
 AAGCTGATCGGGTCAAATGACCTGCCGGAGTACGATTTGAAGGAGGAGGCGGGCAGGCTGG  
 CCCGATCCTAGTCATGCGCTACCGCAACCTGATCGAGGGGCAAGCATCCGCCGTTTCCCTAATG  
 TACGGAGCAGATGCTAGGGCAAATTGCCCTAGCAGGGGAAAAAGGTGCAAAAAGGTCTCTTTC  
 CTGTGGATAGCACGTACATTGGGAACCCAAAGCCGTACATTGGGAACCCGGAACCCGTACATT  
 GGGAACCCAAAGCCGTACATTGGGAACCCGTCACACATGTAAGTGAAGTACTGATATAAAAGAGAA  
 AAAAGGCGATTTTTCCGCCTAAAACCTTTAAAACCTTATTAATAACTCTTAAAACCCGCTGGC  
 CTGTGCATAACTGTCTGGCCAGCGCACAGCCGAAGAGCTGCAAAAAGCGCCTACCCTTCGGTC  
 GCTGCGCTCCCTACGCCCCGCGCTTCGCGTCGGCCTATCGCGGCGCGCTGGCCGCTCAAAAAT  
 GGCTGGCCTACGGCCAGGCAATCTACCAGGGCGCGGACAAGCCGCGCCGTCGCCACTCGACC  
 GCCGGCGCCACATCAAGGCACCCTGCCTCGCGCGTTTTCCGGTATGACGGTGAAAACCTCTGA  
 CACATCGAGCTCCCGGAGACGGTACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGC  
 CCGTACAGGGCGCGTACAGCGGGTGTGGCGGGTGTGCGGGCGCAGCCATGACCCAGTCACGTA  
 GCGATAGCGGAGTATACTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGC  
 ACCATATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAATACCCGCATCAGGCGCTCT  
 TCCGCTTCCCTCGCTCACTGACTCGCTGCGCTCGGTCTGCTCGGCTGCGGCGAGCGGTATCAGCTC  
 ACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGA  
 GCAAAAAGGCCAGCAAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAG  
 GCTCCGCCCCCTGACGAGCATCAAAAATCGACGCTCAAGTCAGAGGTGGCGAAAACCCGA  
 CAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGA  
 CCCTGCCGCTTACCGGATACCTGTCCGCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAG  
 CTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTGCTTCCGCTCCAAGCTGGGCTGTGTGCACGA  
 ACCCCCCGTTACGCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGT  
 AAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATG  
 TAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTAT  
 TTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCG  
 GCAAAACAACCACCGCTGGTAGCGGTGGTTTTTTTTGTTTGAAGCAGCAGATTACGCGCAGAA  
 AAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAAACGAAA  
 ACTCACGTTAAGGGATTTTGGTTCATGCATTCTAGGTAATAAAAACAATTCATCCAGTAAAATAT  
 AATATTTTATTTTCTCCAATCAGGCTTGATCCCCAGTAAAGTCAAAAAATAGCTCGACATACTG  
 TTCTTCCCAGATATCCTCCCTGATCGACCGGACGCAGAAGGCAATGTCATACCACTTGCCGC  
 CCTGCCGCTTCTCCCAAGATCAATAAAGCCACTTACTTTGCCATCTTTCACAAAGATGTTGCTG  
 TCTCCCAGGTCGCGGTGGGAAAAGACAAGTTTCTTCCGGGCTTTTCCGCTTTAAAAAATCAT  
 ACAGCTCGCGCGGATCTTTAAATGGAGTGTCTTCTTCCCAGTTTTCCGCAATCCACATCGGCCAG  
 ATCGTTATTCAGTAAGTAATCCAATTCGGCTAAGCGGCTGTCTAAGCTATTCGTATAGGGACA

V81263WO

ATCCGATATGTCGATGGAGTGAAAGAGCCTGATGCACTCCGCATACAGCTCGATAATCTTTTC  
 AGGGCTTTGTTTCATCTTCATACTCTTCCGAGCAAAGGACGCCATCGGCCTCACTCATGAGCAG  
 ATTGCTCCAGCCATCATGCCGTTCAAAGTGCAGGACCTTTGGAACAGGCAGCTTTCTTCCAG  
 CCATAGCATCATGTCCTTTTCCCGTTCACATCATAGGTGGTCCCTTTATACCGGCTGTCCGTC  
 ATTTTTAAATATAGGTTTTTCATTTTCTCCCACCAGCTTATATACCTTAGCAGGAGACATTCCTT  
 CCGTATCTTTTACGCAGCGGTATTTTCGATCAGTTTTTTCAATTCCGGTGATATTCTCATTTTA  
 GCCATTTATTATTTCTTCTCTTTTCTACAGTATTTAAAGATACCCCAAGAAGCTAATTATAA  
 CAAGACGAACTCCAATTCCTGTTTCTTGCATTCTAAAACCTTAAATACCAGAAAACAGCTTT  
 TTCAAAGTTGTTTTCAAAGTTGGCGTATAACATAGTATCGACGGAGCCGATTTTGAAACCGCG  
 GTGATCACAGGCAGCAACGCTCTGTCAATCAACATGCTACCCTCCGCGAGATCAT  
 CCGTGTTCAAACCCGGCAGCTTAGTTGCCGTTCTTCCGAATAGCATCGGTAACATGAGCAA  
 GTCTGCCGCTTACAACGGCTCTCCCGCTGACGCCGTTCCGGACTGATGGGCTGCCTGTATCG  
 AGTGGTGATTTTGTGCCGAGCTGCCGGTCCGGGAGCTGTTGGCTGGCTGGTGGCAGGATATAT  
 TGTGGTGAAACAAATTGACGCTTAGACAACCTAATAACACATTGCGGACGTTTTTAATGTAC  
 TGAATTAACGCCGAATTAATTCGGGGGATCTGGATTTTAGTACTGGATTTTGGTTTTAGGAATT  
 AGAAATTTTATTGATAGAAGTATTTTACAAATACAAATACATACTAAGGGTTTCTTATATGCTC  
 AACACATGAGCGAAACCCTATAGGAACCCTAATCCCTTATCTGGGAACTACTCACACATTAT  
 TATGGAGAACTCGAGCTTGTGATCGACAGATCCGGTCCGCATCTACTCTATTTCTTTGCCCT  
 CGGACGAGTGCTGGGGCGTCCGTTTCCACTATCGGGCAGTACTTCTACACAGCCATCGGTCCA  
 GACGGCCGCGCTTCTGCGGGCGATTTGTGTACGCCGACAGTCCCGGCTCCGGATCGGACGAT  
 TGCGTCGCATCGACCCTGCGCCCAAGCTGCATCATCGAAATTGCCGTCAACCAAGCTCTGATA  
 GAGTTGGTCAAGACCAATGCGGAGCATATACGCCCGGAGTCGTGGCGATCCTGCAAGCTCCG  
 GATGCCTCCGCTCGAAGTAGCGCGTCTGCTGCTCCATACAAGCCAACCACGGCTCCAGAAGA  
 AGATGTTGGCGACCTCGTATTGGGAATCCCCGAACATCGCCTCGCTCCAGTCAATGACCGCTG  
 TTATCGGGCCATTGTCCGTCAGGACATTGTTGGAGCCGAAATCCCGGTGCACGAGGTGCCGGA  
 CTTCCGGGCGAGTCCCTCGGCCAAAGCATCAGCTCATCGAGAGCCTGCCGCGAGGACGCACTG  
 ACGGTGTCGTCATCACAGTTTGCCAGTGATACACATGGGGATCAGCAATCGCGCATATGAAA  
 TCACGCCATGTAGTGTATTGACCGATTCTTCCGGTCCGAATGGGCCGAACCCGCTCGTCTGG  
 CTAAGATCGGCCGACGGATCGCATCCATAGCCTCCGCGACCGGTTGTAGAACAGCGGGCAG  
 TTCGGTTTTAGGCAGGTCTTGCAACGTGACACCCTGTGCACGGCGGGAGATGCAATAGGTCAG  
 GCTCTCGCTAAACTCCCCAATGTCAAGCACTTCCGGAATCGGGAGCGCGGCCGATGCAAAGTG  
 CCGATAAACATAACGATCTTTGTAGAAACCATCGGCGCAGCTATTTACCCGACAGGACATATCC  
 ACGCCCTCTACATCGAAGCTGAAAGCACGAGATTCTTCGCCCTCCGAGAGCTGCATCAGGTC  
 GGAGACGCTGTGCAACTTTTCGATCAGAACTTCTCGACAGACGTCCGGTGAGTTCAGGCTT  
 TTTCATATCTCATTGCCCCCCGGGATCTGCGAAAGCTCGAGAGAGATAGATTTGTAGAGAGAG  
 ACTGGTGATTTACGCGTGTCTCTCCAAATGAAATGAACTTCTTATATAGAGGAAGGTCTTG  
 CGAAGGATAGTGGGATTGTGCGTCATCCCTTACGTGAGTGGAGATATCACATCAATCCACTTG  
 CTTTGAAGACGTGGTTGGAACGTCTTCTTTTCCACGATGCTCCTCGTGGGTGGGGTCCATCT  
 TTGGGACCACTGTCCGCAGAGGCATCTTGAACGATAGCCTTTCTTTATCGCAATGATGGCAT  
 TTGTAGGTGCCACCTTCTTTTCTACTGTCTTTTGTGAAAGTGACAGATAGCTGGGCAATGGA  
 ATCCGAGGAGGTTTCCCGATATTACCCTTTGTTGAAAAGTCTCAATAGCCCTTTGGTCTTCTGA  
 GACTGTATCTTTGATATTCTTGGAGTAGACGAGAGTGTCTGTGCTCCACCATGTTATCACATCAA  
 TCCACTTGCTTTGAAGACGTGGTTGGAACGTCTTCTTTTCCACGATGCTCCTCGTGGGTGGGG  
 GTCCATCTTTGGGACCACTGTCCGCAGAGGCATCTTGAACGATAGCCTTTCTTTATCGCAATG  
 ATGGCATTGTAGGTGCCACCTTCTTTTCTACTGTCTTTTGTGAAAGTGACAGATAGCTGGG  
 CAATGGAATCCGAGGAGGTTTCCCGATATTACCCTTTGTTGAAAAGTCTCAATAGCCCTTTGG  
 TCTTCTGAGACTGTATCTTTGATATTCTTGGAGTAGACGAGAGTGTCTGTGCTCCACCATGTTGG  
 CAAGCTGCTCTAGCCAATACGCAAACCCGCTCTCCCGCGCGTTGGCCGATTCAATTAATGCGA  
 CTGGCACGACAGGTTTCCCGACTGGAACGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTT  
 AGCTCACTCATTAGGCACCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGGAAT  
 TGTGAGCGGATAACAATTTACACAGGAAACAGCTATGACCATGATTACGAATTGTGAGCTCG  
 GTACCCGGGGATCCTCTAGAGTGCACCTGCAGGCATGCAAGCTTGGCACTGGCCGTCGTTTTA  
 CAACGTGCTGACTGGGAAAACCCTGGCGTTACCCAATTAATCGCCTTGCAGCACATCCCCCT  
 TTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTCCCAACAGTTGCGCAGC  
 CTGAATGGCGAATGCTAGAGCAGCTTGGATCAGATTGTGCTTTCCCGCCTTCAAGTT  
 AGCTTCATGGAGTCAAAGATTCAAATAGAGGACCTAACAGAACTCGCCGTAAAGACTGGCGA

V81263WO

ACAGTTCATACAGAGTCTCTTACGACTCAATGACAAGAAGAAAATCTTCGTCAACATGGTGGA  
GCACGACACACTTGTCTACTCCAAAAATATCAAAGATACAGTCTCAGAAGACCAAAGGGCAA  
TTGAGACTTTTCAACAAAGGGTAATATCCGGAAACCTCCTCGGATTCCATTGCCAGCTATCT  
GTCACTTTATTGTGAAGATAGTGGAAAAGGAAGGTGGCTCCTACAAATGCCATCATTGCGATA  
AAGGAAAGGCCATCGTTGAAGATGCCTCTGCCGACAGTGGTCCCAAAGATGGACCCCCACCC  
ACGAGGAGCATCGTGGAAAAGAAGACGTTCCAACCACGTCTTCAAAGCAAGTGGATTGATG  
TGATATCTCCACTGACGTAAGGGATGACGCACAATCCCACACTATCCTTCGCAAGACCCTTCCTC  
TATATAAGGAAGTTCATTTCAATTTGGAGAGAACACGGGGGACTCT

V81263WO

**Figure 8 C**  
**SEQ ID NO: 5**  
**Cpn21 RNAi fragment with intron**

CTAGTACAAAAAGCAGGCTGGGGAGGCAGAGGAGAAGACTTTAGGTGGTATCTTACTTCCA  
TCCACTGCTCAATCAAAACCTCAAGGAGGTGAAGTCGTTGCCGTGGGTGAAGGAAGAACTAT  
TGGGAAGAACAAAATTGATATCACTGTCCCTACTGGAGCACAAATTATCTACTCCAAATACGC  
AGGAACTGAGGTGGAGTTCAATGATGTGAAGCATCTTATCCTCAAGGAAGATGATATTGTTGG  
CATTCTTGAGACAGAGGACATCAAAGATCTCAAACCTTTGAATGACCGAGTCTTTATTAAGGT  
TGCTGAGGCGGAGGAGAAAACAGCTGGAGGGTGTGTTAACCAGACTACCAAAGAGAAGC  
CTTCTATTGGCACGGTGATAGCAGTTGGACCGGGTCCCTAGACGAGGAAGGTAATAATTACGC  
CTCTACCAGTATCAACCGGAAGCACCCAGCTTTCATAGTGACTGGATATGTTGTGTTTTACAGT  
ATTATGTAGTCTGTTTTTATGCAAAATCTAATTTAATATATTGATATTTATATCATTTTACGTT  
TCTCGTTCAGCTTTCTTGTACAAAGTGGTGATATCACTAGTGCGGCCGCCTGCAGGTGACCAT  
ATGGTCGACCTGCAGGCGGCCGACTAGTGATGCTGTTATGTTCAAGTGTCAAGCTGACCTGCA  
AACACGTTAAATGCTAAGAAGTTAGAATATATGAGACACGTTAACTGGTATATGAATAAGCT  
GTAAATAACCGAGTATAAACTCATTAACTAATATCACCTCTAGAGTATAATATAATCAAATTC  
GACAATTTGACTTTCAAGAGTAGGCTAATGTAAAATCTTTATATATTTCTACAATGTTCAAAG  
AAACAGTTGCATCTAAACCCCTATGGCCATCAAATTCATGAACGCTAAGCTGATCCGGCGAG  
ATTTTCAGGAGCTAAGGAAGCTAAAATGGAGAAAAAATCACTGGATATACCACCGTTGATA  
TATCCCAATGGCATCGTAAAGAACATTTTGAGGCCATTCAGTCAGTTGCTCAATGTTCTATA  
ACCAGACCGTTCAGCTGGATATTACGGCCTTTTTAAAGACCGTAAAGAAAAATAAGCACAAAG  
TTTTATCCGGCCTTTATTCACATTCTTGCCCGCCTGATGAATGCTCATCCGGAATTCCGTATGG  
CAATGAAAGACGGTGAGCTGGTGATATGGGATAGTGTTACCCCTTGTTACACCGTTTTCCATG  
AGCAAACCTGAAACGTTTTTCATCGCTCTGGAGTGAATACCACGACGATTTCCGGCAGTTTCTAC  
ACATATATTCGCAAGATGTGGCGTGTTACGGTGAAAACCTGGCCTATTTCCCTAAAGGGTTTA  
TTGAGAATATGTTTTTCGTCTCAGCCAATCCCTGGGTGAGTTTACCAGTTTTGATTTAAACGT  
GGCCAATATGGACAACCTTCTTCGCCCCCGTTTTCCACATGGGCAAATATTATACGCAAGGCGA  
CAAGGTGCTGATGCCGCTGGCGATTGAGGTTTCATCATGCCGTCTGTGATGGCTTCCATGTCGG  
CAGAATGCTTAATGAATTACAACAGTACTGCGATGAGTGGCAGGGCGGGGCGTAAACGCGTG  
GATCAGCTTAATATGACTCTCAATAAAGTCTCATACCAACAAGTGCCACCTTATTCAACCATC  
AAGAAAAAAGCCAAAATTTATGCTACTCTAAGGAAAACCTTCACTAAAGAAGACGATTTAGAG  
TGTTTTACCAAGAATTTCTGTATCTTACTAAACAACCTAAAGATCGGTGTGATACAAAACCTA  
ATCTCATTAAAGTTTATGCTAAAATAAGCATAATTTTACCCACTAAGCGTGACCAGATAAACA  
TAACTCAGCACACCAGAGCATATATATTGGTGGCTCAAATCATAGAACTTACAGTGAAGAC  
ACAGAAAGCCGTAAGAAGAGGCAAGAGTATGAAACCTTACCTCATATTTCCATGAGGTTGC  
TTCTGATCCCGCGGGATATCACCCTTTGTACAAGAAAGCTGAACGAGAAACGTAATAATGAT  
ATAAATATCAATATATTAATTAAGATTTTGCATAAAAAACAGACTACATAACTGTAAAACA  
CAACATATCCAGTCACTATGAAAGCTGGGTGCTTCCGGTTGATACTGGTAGAGGCGTAATTTT  
ACCTTCCTCGTCTAGGGAACCCGGTCCAACCTGCTATCACCGTGCCAATAGAAGGCTTCTCTTTG  
GTAGTCTCGGTTAACAACAACCCTCCAGTGTCTTCTCCTCCGCTCAGCAACCTTAATAAAGA  
CTCGGTCAATCAAAGGTTTGAGATCTTTGATGTCTCTGTCTCAAGAATGCCAACAATATCATC  
TTCCTTGAGGATAAGATGCTTCACATCATTGAACTCCACCTCAGTTCCTGCGTATTGGAGTAG  
ATAATTTGTGCTCCAGTAGGGACAGTGATATCAATTTTGTCTTCCCAATAGTTCTTCCCTCAC  
CCACGGCAACGACTTCACCTCCTTGAGGTTTTGATTGAGCAGTGGATGGAAGTAAGATACCAC  
CTAAAGTCTTCTCCTCTGCCTCCCCAGCCTGCTTTTTTTGTAAGTAGT

V81263WO

**Figure 8 D**

**SEQ ID NO: 6**

**Cpn21 RNAi 35S**

AGGATCCCCGGGTACCCTCGAATTATCATAATGAGAATTAAGGGAGTCACGTTATGACCCCC  
 GCCGATGACGCGGGACAAGCCGTTTTACGTTTTGGAAGTACAGAACCGCAACGTTGAAGGAG  
 CCACTCAGCCGCGGGTTTTCTGGAGTTTAATGAGCTAAGCACATACGTCAGAAACCATTATTGC  
 GCGTTCAAAAGTCGCCTAAGGTCATATCAGCTAGCAAATATTTCTTGTCAAAAATGCTCCAC  
 TGACGTTCCATAAATCCCCTCGGTATCCAATTAGAGTCTCATATTCCTCAACTCGATCGA  
 GGCATGATTGAACAAGATGGATTGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGCTATTC  
 GGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGCG  
 CAGGGGCGCCCGGTTCTTTTTGTCAAGACCGACCTGTCCGGTGCCTGAATGAACTCCAAGAC  
 GAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTGTGCTCGACGTT  
 GTCCTGAAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTC  
 ATCTCACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATGCGGCGGCTGCATAC  
 GCTTGATCCGGCTACCTGCCATTGACCACCAAGCGAAACATCGCATCGAGCGAGCACGTAC  
 TCGGATGGAAGCCGGTCTTGTGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCGCGC  
 CAGCCGAACTGTTCCGCAGGCTCAAGGCGCGGATGCCCCACGGCGAGGATCTCGTCTGACCC  
 CACGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCCGTTTTCTGGATTCATCGAC  
 TGTGGCCGGTGGGTGGCGGACCGCTATCAGGACATAGCGTTGGTACCCGCTGATATTGCT  
 GAAGAGCTTGGCGGGAATGGGCTGACCGCTTCTCGTGTCTTACGGTATCCGCCGCTCCCGAT  
 TCGCAGCGCATCGCCTTCTATCGCCTTCTGACGAGTCTTCTGAGCGGGACTCTGGGGTTCGG  
 ACTTAGCTAGAGTCAAGCAGATCGTTCAAACATTTGGCAATAAAGTTTCTTAAGATTGAATC  
 CTGTTGCCGGTCTTGCGATGATTATCATATAATTTCTGTTGAATTACGTTAAGCATGTAATAAT  
 TAACATGTAATGCATGACGTTATTTATGAGATGGGTTTTTATGATTAGAGTCCCGCAATTATAC  
 ATTTAATACGCGATAGAAAACAAAATATAGCGCGCAAAGTAAATATCGCGCGCGGT  
 GTCATCTATGTTACTAGATCGACCGCATGCAAGCTGATAATTCAATTCGGCGTTAATTCAGT  
 ACATTAATAAACGTCGCAATGTGTTATTAAGTTGTCTAAGCGTCAATTTGTTTACACCACAAT  
 ATATCCTGCCACCAGCCAGCCAACAGCTCCCCGACCGGCAGCTCGGCACAAAATCACCCTCG  
 ATACAGGCAGCCATCAGTCCGGGACGGCGTCAGCGGGAGAGCCGTTGTAAGGCGGCAGACT  
 TTGCTCATGTTACCGATGCTATTTCGGAAGAACGGCAACTAAGCTGCCGGGTTTGAAACACGGA  
 TGATCTCGCGGAGGGTAGCATGTTGATTGTAACGATGACAGAGCGTTGCTGCCTGTGATCAAT  
 TCGGGCACGAACCCAGTGGACATAAGCCTCGTTCCGGTTCGTAAGCTGTAATGCAAGTAGCGTA  
 ACTGCCGTCACGCAACTGGTCCGAAACCTTGACCGAACGCAGCGGTGGTAACGGCGCAGTGG  
 CGGTTTTCATGGCTTCTTGTTATGACATGTTTTTTGGGGTACAGTCTATGCCTCGGGCATCCA  
 AGCAGCAAGCGCGTTACGCCGTGGGTCGATGTTTGTGTTATGGAGCAGCAACGATGTTACGC  
 AGCAGGGCAGTCCCTAAAACAAAAGTTAAACATCATGGGGGAAGCGGTGATCGCCGAAGTA  
 TCGACTCAACTATCAGAGGTAGTTGGCGTCATCGAGCGCCATCTCGAACCGACGTTGCTGGCC  
 GTACATTTGTACGGCTCCGCAGTGGATGGCGGCTGAAGCCACACAGTGAATTGATTTGCTG  
 GTTACGGTGACCGTAAGGCTTGATGAAACAACGCGGCGAGCTTTGATCAACGACCTTTTGAA  
 ACTTCGGCTTCCCCTGGAGAGAGCGGAGATTCTCCGCGCTGTAGAAGTACCATTGTTGTGCAC  
 GACGACATCATTCCGTGGCGTTATCCAGCTAAGCGCGAACTGCAATTTGGAGAATGGCAGCGC  
 AATGACATTCCTTGACGGTATCTTCGAGCCAGCCACGATCGACATTGATCTGGCTATCTTGCTG  
 ACAAAGCAAGAGAACATAGCGTTGCCTTGGTAGGTCCAGCGGCGGAGGAACCTTTTGATCC  
 GGTTCTTGAACAGGATCTATTTGAGGCGCTAAATGAAACCTTAACGCTATGGAACCTCGCCGCC  
 CGACTGGGCTGGCGATGAGCGAAATGTAGTGCTTACGTTGTCCCGCATTTGGTACAGCGCAGT  
 AACCGGCAAAATCGCGCCGAAGGATGTCGCTGCCGACTGGGCAATGGAGCGCCTGCCGGCCC  
 AGTATCAGCCCGTCATACTTGAAGCTAGACAGGCTTATCTTGGACAAGAAGAAGATCGCTTGG  
 CCTCGCGCGCAGATCAGTTGGAAGAATTTGTCCACTACGTGAAAGGCGAGATACCAAGGTA  
 GTCGGCAATAATGTCTAGCTAGAAATTCGTTCAAGCCGACCGGCTTCGCCGGCGTTAACTC  
 AAGCGATTAGATGACTAAGCACATAATTGCTCACAGCCAAACTATCAGGTCAAGTCTGCTTT  
 TATTATTTTTAAGCGTGCATAATAAGCCCTACACAAATTGGGAGATATATCATGCATGACCAA  
 AATCCCTTAACGTGAGTTTTCTGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATC  
 TTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTCAAACAAAAAACCACCGCTACCA  
 GCGGTGGTTTTGTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAAGTGGCTTCAGC  
 AGAGCGCAGATACCAAATACTGTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAAC

V81263WO

TCTGTAGCACCGCCTACATAACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCG  
ATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGGCGCAGCGGTGCG  
GGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAG  
ATACCTACAGCGTGAGCTATGAGAAAAGCGCCACGCTTCCCGAAGGGAGAAAGGGCGGACAGGT  
ATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGC  
CTGGTATCTTTATAGTCCTGTCCGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGC  
TCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCC  
TTTTGCTGGCCTTTTTGCTCACATGTTCTTCTCGCTTATCCCCTGATTCTGTGGATAACCGTAT  
TACCGCTTTGAGTGAGCTGATACCGCTCGCCGACGCCGAACGACCGAGCGCAGCGAGTACG  
TGAGCGAGGAAGCGGAAGAGCGCCTGATGCGGATTTTTCTCCTTACGCATCTGTGCGGATTTT  
CACACCGCATATGGTGCACCTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGTATA  
CACTCCGCTATCGCTACGTGACTGGGTCAATGGCTGCGCCCCGACACCCGCCAACACCCGCTGA  
CGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGG  
GAGCTGCATGTGTGAGAGGTTTTACCGTCAACACCGAAACGCGCAGGCGAGGGTGCCTTGAT  
GTGGGCGCCGGCGGTGAGTGGCGACGGCGGGCTTGTCCGCGCCCTGGTAGATTGCCTGGCC  
GTAGGCCAGCCATTTTTGAGCGGCCAGCGGCCGCGATAGGCCGACGCGAAGCGGCGGGGCGT  
AGGGAGCGCAGCGACCGAAGGGTAGGCGCTTTTTGCAGCTCTTCGGCTGTGCGCTGGCCAGA  
CAGTTATGCACAGGCCAGGCGGGTTTTAAGAGTTTTAATAAGTTTTAAAGAGTTTTAGGCGGA  
AAAATCGCCTTTTTCTCTTTTATATCAGTCACTTACATGTGTGACCGGTTCCCAATGTACGGC  
TTTGGGTTCCCAATGTACGGGTTCCGGTTCCTCAATGTACGGCTTTGGGTTCCCAATGTACGTGC  
TATCCACAGGAAAGAGACCTTTTTCGACCTTTTTCCCCTGCTAGGGCAATTTGCCCTAGCATCTG  
CTCCGTACATTAGGAACCGGCGGATGCTTCGCCCTCGATCAGGTTGCGGTAGCGCATGACTAG  
GATCGGGCCAGCCTGCCCGCCTCCTCCTCAAATCGTACTCCGGCAGGTCATTTGACCCGAT  
CAGCTTGCACACGGTGAAACAGAACTTCTTGAACCTCCGGCGCTGCCACTGCGTTCGTAGAT  
CGTCTTGAACAACCATCTGGCTTCTGCCTTGCTGCGGCGCGGCGTGCCAGGCGGTAGAGAAA  
ACGGCCGATGCCGGGATCGATCAAAAAGTAATCGGGGTGAACCGTCAGCACGTCCGGGTTCT  
TGCCTTCTGTGATCTCGCGGTACATCCAATCAGCTAGCTCGATCTCGATGACTCCGGCCGCCC  
GGTTTCGCTCTTTACGATCTTGTAGCGGCTAATCAAGGCTTACCCTCGGATACCGTACACCAG  
CGGCCGTTCTTGGCCTTCTTCGTACGCTGCATGGCAACGTGCGTGGTGTAAACCGAATGCAG  
GTTTTACCAGTTCGTCTTCTGCTTCCGCCATCGGCTCGCCGGCAGAACTTGAGTACGTCCG  
CAACGTGTGGACGGAACACGCGCCGGCTTGTCTCCCTTCCCTTCCCGGTATCGGTTATCG  
ATTCGGTTAGATGGGAAACCGCCATCAGTACCAGTTCGTAATCCCACACACTGGCCTAGCCGG  
CCGGCCCTGCGGAAACCTCTACGTGCCCGTCTGGAAGCTCGTAGCGGATCACCTCGCCAGCTC  
GTCGGTACGCTTCGACAGACGGAACGAAACGCCACGTCCATGATGCTGCGACTATCGCGGGTG  
CCCACGTATAGAGCATCGGAACGAAAAATCTGGTTGCTCGTCGCCCTTGGGCGGCTTCTTA  
ATCGACGGCGCACCGGCTGCCGGCGGTTGCCGGGATTCTTTGCGGATTCGATCAGCGGCCGCT  
TGCCACGATTCACCGGGGCGTGTCTTCTGCCTCGATGCGTTGCCGCTGGGCGGCTGCGCGGCC  
TTCAACTTCTCCACCAGGTCATACCCAGCGCCGCGCCGATTTGTACCGGGCCGGATGGTTTG  
CGACCGTACGCCGATTCCTCGGGCTTGGGGGTTCCAGTGCCATTGCAGGGCCGGCAGACAAC  
CCAGCCGCTTACGCCTGGCCAACCGCCGTTTCTCCACACATGGGGCATTCCACGGCGTCCGGT  
GCCTGGTTGTTCTTGATTTTCCATGCCGCCTCCTTTAGCCGCTAAAATTCATCTACTCATTTATT  
CATTTGCTCATTTACTCTGGTAGCTGCGCGATGATTTACAGATAGCAGCTCGGTAATGGTCTTGC  
CTTGGCGTACCGCGTACATCTTACGCTTGGTGTGATCTCCGCCGGAACCTGAAAGTTGACCC  
GCTTCATGGCTGGCGTGTCTGCCAGGCTGGCCAACGTTGCAGCCTTGCTGCTGCGTGCCTCG  
GACGGCCGGCACTTAGCGTGTGTTGTCTTTGTCTATTTTTCTTTTACCTCATTAACCTCAAATG  
AGTTTTGATTTAATTTACGCGGCCAGCGCCTGGACCTCGCGGGCAGCGTGCCTCGGCTGATACG  
GGACTAAGAATGGGCAGCTCGTACCCGGCCAGCGCCTCGGCAACCTCACCGCCGATGCGCG  
TGCCTTGATCGCCCGGACACGACAAAGGCCGCTTGTAGCCTTCCATCCGTGACCTCAATGC  
GCTGCTTAACCACTCCACCAGGTCGGCGGTTGGCCCATATGTCGTAAGGGCTTGGCTGCACCG  
GAATCAGCACGAAGTCGGCTGCCTTGATCGCGGACACAGCCAAGTCCGCCGCTGGGGCGCT  
CCGTGATCACTACGAAGTCGCGCCGCGGATGACCTTACGTCGCGGTAATCGTCCGGGCGG  
TCGATGCCGACAACGGTTAGCGGTTGATCTTCCCGCACGGCCGCCAAATCGCGGCTAGCCC  
TGGGGATCGGAATCGACTAACAGAACATCGGCCCGCGGAGTTGCAGGGCGGGGCTAGATG  
GGTTGCGATGGTCTGCTTGCCTGACCCGCTTTCTGGTTAAGTACAGCGATAACCTTCATGCGT  
TCCCCTTGCATTTTGTATTTACTCATCGCATCATATACGCAGCGACCGCATGACGCAAGCT

V81263WO

GTTTTACTCAAATACACATCACCTTTTTAGACGGCGGCGCTCGGTTTTCTCAGCGGCCAAGCTG  
GCCGGCCAGGCCGCCAGCTTGGCATCAGACAAACCGGCCAGGATTTTCATGCAGCCGCACGGT  
TGAGACGTGCGCGGGCGGCTCGAACACGTACCCGGCCGCGATCATCTCCGCTCGATCTCTTC  
GGTAATGAAAAACGGTTTCGTCCTGGCCGTCCTGGTGCGGTTTCATGCTTGTTCCTCTTGGCGTT  
CATTCTCGGCGGCCGCCAGGGCGTCGGCCTCGGTCAATGCGTCCTCACGGAAGGCACCGCGCC  
GCCTGGCCTCGGTGGGCGTCACTTCTCGCTGCGCTCAAGTGCGCGGTACAGGGTCGAGCGAT  
GCACGCCAAGCAGTGCAGCCGCCTTTACGGTGCGGCCTTCTGGTCGATCAGCTCGCGGG  
CGTGCGCGATCTGTGCCGGGTGAGGGTAGGGCGGGGCCAAACTTCACGCCTCGGGCCTTG  
GCGGCCTCGCGCCCGCTCCGGGTGCGGTGATGATTAGGGAACGCTCGAACTCGGCAATGCC  
GGCGAACACGGTCAACACCATGCGGCCGGCCGGCGTGGTGGTGTGCGCCACGGCTCTGCCA  
GGCTACGCAGGCCCGCGCCGGCTCCTGGATGCGCTCGGCAATGTCCAGTAGGTGCGGGTGC  
TGCGGGCCAGGCGGTCTAGCCTGGTCACTGTCAACGTCGCCAGGGCGTAGGTGGTCAAGC  
ATCCTGGCCAGCTCCGGGCGGTGCGCCTGGTGGCGGTGATCTTCTCGGAAAACAGCTTGGTG  
CAGCCGGCCGCGTGCAGTTCGGCCCGTGGTGGTCAAGTCCTGGTCGTCGGTGCTGACCGG  
GCATAGCCAGCAGGCCAGCGGCGGCGCTTGTTCATGGCGTAATGTCTCCGGTTCTAGTCG  
CAAGTATTCTACTTTATGCGACTAAAACACGCGACAAGAAAACGCCAGGAAAAGGGCAGGGC  
GGCAGCCTGTGCGTAACCTTAGGACTTGTGCGACATGTCGTTTTTCAGAAGACGGCTGCACTGA  
ACGTCAGAAGCCGACTGCACTATAGCAGCGGAGGGTTGGATCAAAGTACTTTGATCCCGAG  
GGGAACCCTGTGGTTGGCATGCACATACAAATGGACGAACGGATAAACCTTTTTACGCCCTTT  
TAAATATCCGTTATTCTAATAAACGCTCTTTTCTTTAGGTTTACCCGCCAATATATCTGTCA  
AACACTGATAGTTTAAACTGAAGCGGGAAACGACAATCTGATCCAAGCTCAAGCTAAGCTT  
GAGCTCTCCCATATGGTCGACTAGAGCCAAGCTGATCTCCTTTGCCCGGAGATCACCATGGA  
CGACTTTCTCTATCTCTACGATCTAGGAAGAAAGTTCGACGGAGAAGGTGACGATACCATGTT  
CACCACCGATAATGAGAAGATTAGCCTCTTCAATTTAGAAAAGATGCTGACCCACAGATGGT  
TAGAGAGGCCTACGCGGCAGGTCTCATCAAGACGATCTACCCGAGTAATAATCTCCAGGAGA  
TCAAATACCTTCCCAAGAAGGTTAAAGATGCAGTCAAAGATTGAGGACTAACTGCATCAAG  
AACACAGAGAAAGATATATTTCTCAAGATCAGAAGTACTATTCCAGTATGGACGATTCAAGG  
CTTGCTTCATAAACAAGGCAAGTAATAGAGATTGGAGTCTCTAAGAAAAGTAGTTCCTACTGA  
ATCAAAGGCCATGGAGTCAAAAATTCAGATCGAGGATCTAACAGAACTCGCCGTGAAGACTG  
GCGAACAGTTCATACAGAGTCTTTTACGACTCAATGACAAGAAGAAAATCTTCGTCAACATGG  
TGGAGCACGACACTCTCGTCTACTCCAAGAATATCAAAGATACAGTCTCAGAAGACCAAAGG  
GCTATTGAGACTTTTCAACAAAGGGTAATATCGGGAAACCTCCTCGGATTCCATTGCCAGCT  
ATCTGTCACTTCATCAAAGGACAGTAGAAAAGGAAGGTGGCACCTACAAATGCCATCATTG  
CGATAAAGGAAAGGCTATCGTTCAAGATGCCTCTGCCGACAGTGGTCCCAAAGATGGACCCC  
CACCCACGAGGAGCATCGTGGAAAAAGAAGACGTTCCAACCACGTCTTCAAAGCAAGTGGAT  
TGATGTGATATCTCCACTGACGTAAGGGATGACGCACAATCCCACTATCCTTCGCAAGACCCT  
TCCTCTATATAAGGAAGTTCATTTTCAATTTGGAGAGGACTGCAGGACGATCCGTATTTTTACAA  
CAATTACCACAACAAAACAACAACAACATTACAATTTACTATTCTAGTCGACCTGCAG  
GCGGCCGCACTAGTGATATCACAAGTTTGTACAAAAAAGCTGAACGAGAAACGTAATAATGAT  
ATAAATATCAATATATTAATTAGATTTTGCATAAAAAACAGACTACATAATACTGTAAAACA  
CAACATATCCAGTCACTAGTACAAAAAAGCAGGCTGGGGAGGCAGAGGAGAAGACTTTAGGT  
GGTATCTTACTTCCATCCACTGCTCAATCAAACCTCAAGGAGGTGAAGTCGTTGCCGTGGGT  
GAAGGAAGAACTATTGGGAAGAACAAAATTGATATCACTGTCCCTACTGGAGCACAAATTAT  
CTACTCAAATACGCAGGAACTGAGGTGGAGTTCAATGATGTGAAGCATCTTATCCTCAAGGA  
AGATGATATTGTTGGCATTCTTGAGACAGAGGACATCAAAGATCTCAAACCTTTGAATGACCG  
AGTCTTTATTAAGGTTGCTGAGGCGGAGGAGAAAACAGCTGGAGGGTTGTTGTTAACCGAGA  
CTACCAAAGAGAAGCCTTCTATTGGCACGGTATAGCAGTTGGACCGGGTTCCCTAGACGAG  
GAAGGTAATAATTACGCCTTACCAGTATCAACCGGAAGCACCCAGCTTTCATAGTGACTGGAT  
ATGTTGTGTTTTACAGTATTATGTAGTCTGTTTTTATGCAAAAATCTAATTTAATATATTGATAT  
TTATATCATTTTACGTTTCTCGTTACGTTCTTGTACAAAAGTGGTGATATCCCGCGGGATCAG  
AAGCAACCTCATGAAATGATGAGGTAAGTTTCAATACTCTTGCCTCTTACGGCTTTCTGT  
GTCTTCACTGTAAGTTTCTATGATTTGAGCCACCAATATATATGCTCTGGTGTGAGTTATG  
TTTTATCTGGTCACGCTTAGTGGGTAATAATTATGCTTATTTTAGCATAAACTTTAATGAGATTAG  
GTTTTGTATCACACCGATCTTTAGTTGTTTAGTAAGATGACAGAAATCTTGGTAAAACACTCT  
AAATCGTCTTCTTAGTGAAGTTTTCTTAGAGTAGCATAAATTTGGCTTTTTTCTTGATGGTT  
GAATAAGGTGGCACTTGTGGTATGAGACTTTATTGAGAGTCATATTAAGCTGATCCACGCGT

V81263WO

TTACGCCCCGCCCTGCCACTCATCGCAGTACTGTTGTAATTCATTAAGCATTCTGCCGACATGG  
AAGCCATCACAGACGGCATGATGAACCTGAATCGCCAGCGGCATCAGCACCTTGTCGCCTTGC  
GTATAATATTTGCCCATGGTGAAAACGGGGGCGAAGAAGTTGTCCATATTGGCCACGTTTAAA  
TCAAAACTGGTGAAACTCACCCAGGGATTGGCTGAGACGAAAAACATATTCTCAATAAACCC  
TTTAGGGAAATAGGCCAGGTTTTACCGTAACACGCCACATCTTGCGAATATATGTGTAGAAA  
CTGCCGAAATCGTCTGGTATTCCTCCAGAGCGATGAAAACGTTTCAGTTTGCTCATGGAA  
AACGGTGAACAAGGGTGAACACTATCCCATATCACCAGCTCACCGTCTTTCATTGCCATACG  
GAATTCGGATGAGCATTATCAGGCGGGCAAGAATGTGAATAAAGGCCGGATAAAACTTGT  
GCTATTTTTTCTTACGGTCTTTAAAAAGGCCGTAATATCCAGCTGAACGGTCTGGTTATAGGT  
ACATTGAGCAACTGACTGAAATGCCTCAAATGTTCTTTACGATGCCATTGGGATATATCAAC  
GGTGGTATATCCAGTGATTTTTTCTCCATTTTAGCTTCTTAGCTCCTGAAAATCTCGCCGGA  
TCAGCTTAGCGTTCATTGAATTTGATGGCCATAGGGGTTTAGATGCAACTGTTTCTTTGAACAT  
TGTAGAAATATATAAAGATTTTACATTAGCCTACTCTTGAAAGTCAAATTGTCGAATTTGATTA  
TATTATACTCTAGAGGTGATATTAGTTAATGAGTTTATACTCGGTTATTTACAGCTTATTCATA  
TACCAGTTAACGTGTCTCATATATTCTAACTTCTTAGCATTTAACGTGTTTGCAGGTCAGCTTG  
ACACTGAACATAACAGCATCACTAGTGCGGCCGCTGCAGGTCGACCATATGGTTCGACCTGCA  
GGCGGCCGCACTAGTGATATCACCACTTTGTACAAGAAAGCTGAACGAGAAAACGTAAAATGA  
TATAAATATCAATATATTAATAATTAGATTTTGCATAAAAAACAGACTACATAACTGTAAAAC  
ACAACATATCCAGTCACTATGAAAGCTGGGTGCTTCCGGTTGATACTGGTAGAGGCGTAATTT  
TACCTTCTCGTCTAGGGAACCCGGTCCAACCTGCTATCACCGTGCCAATAGAAGGCTTCTCTTT  
GGTAGTCTCGGTTAACAACAACCCTCCAGCTGTTTTCTCCTCCGCCTCAGCAACCTTAATAAAG  
ACTCGGTCATTCAAAGGTTGAGATCTTTGATGTCCTCTGTCTCAAGAATGCCAACAATATCAT  
CTTCTTGAGGATAAGATGCTTACATCATTGAACTCCACCTCAGTTCCTGCGTATTTGGAGTA  
GATAATTTGTGCTCCAGTAGGGACAGTGATATCAATTTTGTCTTCCCAATAGTTCTTCTTCA  
CCCACGGCAACGACTTCACCTCCTTGAGGTTTTGATTGAGCAGTGGATGGAAGTAAGATACCA  
CCTAAAGTCTTCTCCTCTGCCTCCCAGCCTGCTTTTTTGTACATAGTACTGGATATGTTGTGT  
TTACAGTATTATGTAGTCTGTTTTTATGCAAAATCTAATTTAATATATTGATATTTATATCAT  
TTACGTTTCTCGTTCAGTTTTTTGTACAAACTGTGATATCCCGCGGCCATGCTAGAGTCCG  
CAAAAATCACAGTCTCTCTACAAATCTATCTCTCTATTTTTCTCCAGAATAATGTGTGA  
GTAGTTCCCAGATAAGGGAATTAGGGTCTTATAGGGTTTCGCTCATGTGTTGAGCATATAAG  
AAACCCTTAGTATGATTTGTATTTGTAAAATACTTCTATCAATAAAATTTCTAATTCCTAAAA  
CCAAAATCCAGTGACCTGCAGGCATGCGACGTCGGGCCCTCTAG

V81263WO

**Figure 8 E**  
**SEQ ID NO: 7**  
**RBC Cpn21 RNAi Sequence**

GATAAGCTTGTGGGAACGAGATAAGGGCGAAGTGCCTAGTAGCCTGCTATTTAAAATATAT  
CCACAATTTATAATGTATTTGAAGATTAGTCAATTCGTCCAAAATTCAGGACTAAGTATCTTG  
AATTTTTGTATCCTGAATTTTTGGGCTACTAATTTGGAACCTCAGGACTTAATGTCCTAAATTTT  
TGAGCCGCTAATTTGAAATTCAGGACTAAGTGTTTTGAATTTTTGAACTGCTTATTCGAAATGC  
AAGACTAAGTGACATGAATTTTTGAACTGCTAATTTAAAATTCAGGACATAAGATTTGAATTT  
TCAAACATAATTTTTAACTTTAGGGCACGATGTCCTGAAGTTTGAATCTTGAGATCTAACTT  
CAAGATGCAGCGTCTTGAAGTTTGAAGTGAAGTGGCTAATCTTTAAATACTTGTAACTGTGGA  
TACATTTTTAAATAATATATTTAAAAGCGGCTACCTGGTATCATCTTCACGAGAATTTCCAAG  
TTAATTGTAAAGGAAATAGTGGTGTGCATCAAGTTATGGACAATATAAGGAAGCAAACAGT  
ACTCTAGCTATCAAATTAGTTTCCACTTCTAAACCATGAATATTAGGAAAAACAAGAAACAAA  
ACAAATACATAAAACAATACGGCTAAAGCCAAGGAAAAGGGACTCTAAAAAATTAACCAA  
CCTCAATCACACATTCATATCCTCTTCCCTACCCCATCTAGGATGAGATAAGATTACTAGGTCTT  
ACACGTGGCACCTCCATTGTGGTACTAAATGAAGAGTGGCTTAGCTCAAAATATAATTTTCC  
AACCTTTCATGTGTGGATATTAAGTTTTGTGTAGTGAATCAAGAACCACATAATCCAATGGTT  
AGCTTTATTCCAAGATGAGGGGGTGTGATTTTTGTCCGTCAGATATAGGAAATATGTAAAA  
CCTTATCATTATATAGGGTGGTGGGCAACTATGCAATGACCATATTGGAAGTTAAAGGAAA  
AGAGAGAAAGAGAAATTCCTCGTCAACATGGTGGAGCACGACACTCTCGTCTACTCCAAGAA  
TATCAAAGATACAGTCTCAGAAGACCAAGGGCTATTGAGACTTTTCAACAAAGGGTAATAT  
CGGAAACCTCCTCGGATTCCATTGCCAGCTATCTGTCACTTCATCAAAGGACAGTAGAAA  
AAATAATGATTTTTATTTGACTGATAGTGACCTGTTGTTGCAACACATTGATGAGCAATGCTT  
TTTTATAATGCCAACTTTGTACAAAAAGCAGGCTGGGGAGGCAGAGGAGAAGACTTTAGTT  
GGTATCTTACTTCCATCCACTGCTCAATCAAACCTCAAGGAGGTGAAGTCGTTGCCGTGGGT  
GAAGGAAGAACTATTGGGAAGAACAAAATTGATATCACTGTCCCTACTGGAGCACAAATTAT  
CTACTCAAATACGCAGGAACTGAGGTGGAGTCAATGATGTGAAGCATCTTATCCTCAAGGA  
AGATGATATTGTTGGCATTCTTGAGACAGAGGACATCAAAGATCTCAAACCTTTGAATGACCG  
AGTCTTTATTAAGGTTGCTGAGGCGGAGGAGAAAACAGCTGGAGGGTGTGTTAACCAGAGA  
CTACCAAAGAGAAGCCTTCTATTGGCACGGTATAGCAGTTGGACCGGGTTCCTTAGACGAG  
GAAGGTAATAATTACGCCTTACCAGTATCAACCGGAAGCACCCAGCTTTCTGTACAAAGTTG  
GCATTATAAGAAAGCATTGCTTATCAATTTGTTGCAACGAACAGGTCATCATCAGTCAAATA  
AAATCATTATTTATCAGAAGCAACCTCATGGAAATGATGAGGTAAGGTTTCATACTCTTGCTT  
CTTCTTACGGCTTCTGTGTCTTCACTGTAAGTTTCTATGATTTGAGCCACCAATATATATGCTC  
TGGTGTGCTGAGTTATGTTTATCTGGTCACGCTTAGTGGGTAATAATTATGCTTATTTTAGCATA  
AACTTTAATGAGATTAGGTTTTGTATCACACCGATCTTTAGTTGTTTAGTAAGATGACAGAAAT  
TCTTGGTAAACACTCTAAATCGTCTTCTTTAGTGAAGTTTTCTTAGAGTAGCATAAATTTG  
GCTTTTTCTTGATGGTTGAATAAGGTGGCACTTGTGGTATGAGACTTTATTGAGAGTCATAT  
TAAGCTGATCCACGCGTTTACGCCCGCCCTGCCACTCATCGCAGTACTGTTGTAATTCATTA  
GCATTCTGCCGACATGGAAGCCATCACAGACGGCATGATGAACCTGAATCGCCAGCGGCATC  
AGCACCTTGTGCCTTGCATATAATTTGCCATGGTGAACCGGGGGCAAGAAGTTGTCC  
ATATTGCCACGTTTAAATCAAACCTGGTGAACACTCACCCAGGGATTGGCTGAGACGAAAAA  
CATATTCTCAATAAACCTTTAGGGAAATAGCCAGGTTTTACCGTAACAGCCACATCTTG  
CGAATATATGTGTAGAACTGCCGAAATCGTCTGGTATTCACTCCAGAGCGATGAAACAGT  
TTCAGTTTGCTCATGGAACCGGTGTAACAAGGGTGAACACTATCCCATATCACCAGCTCACC  
GTCTTTCATTGCCATACGGAATTCGGGATGAGCATTATCAGGCGGGCAAGAATGTGAATAAA  
GGCCGGATAAACTTGTGCTTATTTTTCTTACGGTCTTAAAAAGGCCGTAATATCCAGCTGA  
ACGGTCTGGTTATAGGTACATTGAGCAACTGACTGAAATGCCTCAAAATGTTCTTTACGATGC  
CATTGGGATATATCAACGGTGGTATATCCAGTGATTTTTTTCTCCATTTAGCTTCTTAGCTCC  
TGAAAATCTCGCCGGATCAGCTTAGCGTTCATTGAATTTGATGGCCATAGGGGTTTAGATGCA  
ACTGTTTCTTTGAACATTGTAGAAATATATAAAGATTTTACATTAGCCTACTCTTGAAGTCAA  
ATTGTCGAATTTGATTATATTACTCTAGAGGTGATATTAGTTAATGAGTTTATACTCGGTTA  
TTTACAGCTTATTCATATACCAGTTAACGTGTCTCATATATTCTAACTTCTTAGCATTAAACGT  
GTTTGCAGGTCAGCTTGACACTGAACATAACAGCATCACTAGTGCGGCCGCTGCAGGTGAC

V81263WO

CATATGGTCGACCTGCAGGCGGCCGCACTAGTGATATCAAATAATGATTTTATTTTACTGAT  
AGTGACCTGTTTCGTTGCAACAAATTGATAAGCAATGCTTTCTTATAATGCCAACTTTGTACAA  
GAAAGCTGGGTGCTTCCGGTTGATACTGGTAGAGGCGTAATTTTACCTTCCCTCGTCTAGGGAA  
CCCCTGCAACTGCTATCACCGTGCCAATAGAAGGCTTCTCTTTGGTAGTCTCGGTTAACAAAC  
AACCTCCAGCTGTTTTCTCCTCCGCCTCAGCAACCTTAATAAAGACTCGGTCATTCAAAGGTT  
TGAGATCTTTGATGTCCTCTGTCTCAAGAATGCCAACAAATCATCTTCTTGAGGATAAGATG  
CTTACATCATTGAACTCCACCTCAGTTCCTGCGTATTTGGAGTAGATAATTTGTGCTCCAGTA  
GGGACAGTGATATCAATTTTGTCTTCCCAATAGTTCCTTCCCTTACCCACGGCAACGACTTCAC  
CTCCTTGAGGTTTTGATTGAGCAGTGGATGGAAGTAAGATACCACCTAAAGTCTTCTCCTCTG  
CCTCCCCAGCTGCTTTTTTGTACAAAGTTGGCATTATAAAAAAGCATTGCTCATCAATGTGTT  
GCAACGAACAGGTCCTATCAGTCAAAATAAAATCATTATTTGATATCCCAGGCCATGCTAG  
AGTCCGCAAAAATCACCAGTCTCTCTACAAATCTATCTCTCTATTTTTCTCCAGAATAAT  
GTGTGAGTAGTTCAGATAAGGGAATTAGGGTCTTATAGGGTTTCGCTCATGTGTTGAGCA  
TATAAGAAACCCTTAGTATGATTTGTATTTGTAAAATACTTCTATCAATAAAATTTCTAATTC  
CTAAAACCAAAATCCAGTGACCTGCAGGCATGCGACGTGCGGCCCTCTAGAGGATCCCCGGG  
GGATCCACTAGTTCAGAGCGGCCGCCACCGCGGTGGAGCTCCAGCTTTTGTCCCTTTAGTG  
AGGGTTAATCCGAGCTTGGCGTAATCATGGTCATAGCTGTTTCTGTGTGAAATTGTTATCCG  
CTCACAATTCCACACAACATACGAGCCGGAAGHCATAAAGTGTAAGCCTGGGGTGCCTAAT  
GAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTCCAGTCGGGAAACCTGT  
CGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCCTATTGGGCGC  
TCTCCGCTTCCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCCGCTGCGGGCAGCGGTATCAG  
CTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATG  
AAGGCCTTGACAGGATATATTGGCGGGTAAACTAAGTCGCTGTATGTGTTTGTGAGATCTC  
ATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCG2AAAAAGGCCGCGTTGCTGGCGTTTTT  
CCATAGGCTCCGCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAA  
ACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCCTCTCCTG  
TTCCGACCCTGCCGCTTACCGGATACCTGTCCGCTTCTCCCTTCCGGAAGCGTGGCGCTTTC  
TCATAGCTCAGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCCGCTCAAGCTGGGCTGTGTG  
CACGAACCCCCGTTACGCCCCGACCGCTTCCGCTTACCGGTAACATCGTCTTGAGTCCAAC  
CCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAG  
GTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGTACACTAGAGAAG  
AGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAGAAGAGTTGGTAGCTCTTG  
ATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTTGTTTGAAGCAGCAGATTACGCG  
CAGAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGA  
CGAAAATCAGTAAAGGATTTTGGTCAAGAGATTATCAAAAAGGATCTTACCTAGATCCT  
TTTAAATTAATAAATGAAGTTTTAAATCAATCTAAAGTATATATGTGTAACATTGGTCTAGTGA  
TTAGAAAACTCATCGAGCATCAAATGAACTGCAATTTATTCATATCAGGATTATCAATACC  
ATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACCTCACCGAGGAGTTCCATAGGAT  
GGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTT  
CCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTG  
AGAATGGCAAAAGTTTATGCATTTCTTTCCAGACTTGTTC AACAGGCCAGCCATTACGCTCGT  
CATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGACGAA  
ATACGCGATCGCTGTTAAAGGACAATTACAAACAGGAATCGAATGCAACCGGCCAGGAAC  
ACTGCCAGCGCATCAACAATATTTTACCTGAATCAGGATATCTTCTAATACCTGGAATGCT  
GTTTTCCCTGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTG  
ATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACAACA  
TTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACCTCTGGCGCATCGGGCTTCCCATACAAT  
CGGTAGATTGTGCGACCTGATTGCCCCGACTTATCGCGAGCCCATTTATACCCATATAAATCA  
GCATCCATGTTGGAATTAATCGCGGCTTGTAGCAAGACGTTTCCCGTTGAATATGGCTCATA  
ACACCCCTTGATTAFACTGTTTATGTAAGCAGACAGTTTTTATTGTTTATGATATATTTTTATC  
TTGTGCAATGTAACATCAGAGATTTTGTAGACACAACGTGGCTTTGTTGAATAAATCGAATTT  
TGCTGAGTTGAAGGATCAGATCACGCATCTTCCCACAACGCAGACCGTTCCGTGGCAAAGCA  
AAAGTTCAAAATCACC AACTGGTCCACCTACAACAAAGCTCTCATCAACCGTGGCTCCCTCAC  
TTTCTGGCTGGATGATGGGGCGATT CAGGCGATCCCCATCCAACAGCCCGCGTGGAGCGGGC  
TTTTTTATCCCCGGAAGCCTGTGGATAGAGGGTAGTTATCCACGTGAAACCGCTAATGCCCG  
CAAAGCCTTGATTACGGGGCTTCCGGCCCCGCTCCAAAACTATCCACGTGAAATCGCTAAT

V81263WO

CAGGGTACGTGAAATCGCTAATCGGAGTACGTGAAATCGCTAATAAGGTCACGTGAAATCGC  
 TAATCAAAAAGGCACGTGAGAACGCTAATAGCCCTTTCAGATCAACAGCTTGCAAACACCCCT  
 CGTCCGGCAAGTAGTTACAGCAAGTAGTATGTTCAATTAGCTTTTCAATTATGAATATATAT  
 ATCAATTATTGGTCGCCCTTGGCTTGTGGACAATGCGCTACGCGCACCGGCTCCGCCCGTGG  
 CAACCGCAAGCGGTTGCCACCGTCGAGCGCCAGCGCCTTTGCCACAACCGGCGGGCCGGC  
 CGCAACAGATCGTTTTATAAATTTTTTTTTTTTGA AAAAAGAAAAAGCCCGAAAGGCGGCAACCT  
 CTCGGGCTTCTGGATTTCCGATCCCCGGAATTAGAGATCTTGGCAGGATATATTGTGGTGTA  
 CGTTATCAGCTTGCATGCCGGTTCGATCTAGTAACATAGATGACACCGCGCGCGATAATTTATC  
 CTAGTTTGGCGCTATATTTGTTTTCTATCGCGTATTAATGTATAATTGCGGGACTCTAATC  
 AAAAAACCCATCTCATAAATAACGTCATGCATTACATGTTAATTATTACATGCTTAACGTAAT  
 TCAACAGAAATTATATGATAATCATCGCAAGACCGGCAACAGGATTCAATCTTAAGAACTTT  
 ATTGCCAAATGTTTGAACGATCTGCTTACTCTAGCTAGAGTCCGAACCCAGAGTCCCGCTC  
 AGAAGAAGTTCGTAAGAAGGCGATAGAAGGCGATGCGCTGCGAATCGGGAGCGGCGATAACC  
 GTAAAGCACGAGGAAGCGGTCAGCCATTTCGCCGCAAGCTCTTCAGCAATATCACGGGTAG  
 CCAACGCTATGTCCTGATAGCGGTCCGCCACACCCAGCCGGCCACAGTCGATGAATCCAGAA  
 AAGCGGCCATTTCCACCATGATATTTCGGCAAGCAGGCATCGCCCTGGGTACGACGAGATCC  
 TCGCCGTCGGGCATCCGCGCCTTGAGCCTGGCGAACAGTTTCGGCTGGCGCGAGCCCTGATGC  
 TCTTCGTCCAGATCATCCTGATCGACAAGACCGGCTTCCATCCGAGTACGTCCTCGCTCGATGC  
 GATGTTTCGCTTGGTGGTTCGAATGGGCAGGTAGCCGGATCAAGCGTATGCAGCCGCCGATTG  
 CATCAGCCATGATGGATACTTTCTCGGCAGGAGCAAGGTGAGATGACAGGAGATCCTGCCCC  
 GGCATTCGCCCAATAGCAGCCAGTCCCTTCCCGCTTTCAGTGACAACGTCGAGCACAGCTGCG  
 CAAGGAACGCCCGTCGTGGCCAGCCACGATAGCCGCGCTGCCTCGTCTTGGAGTTCATTCAAG  
 GCACCGGACAGGTTCGGTCTTGACAAAAGAACCGGGCGCCCCTGCGCTGACAGCCGGAACAC  
 GGCGGCATCAGAGCAGCCGATTGTCTGTTGTGCCAGTCATAGCCGAATAGCCTCTCCACCCA  
 AGCGGCCGAGAACCTGCGTGCAATCCATCTTGTTCATCATGCCTCGATCGAGTTGAGAGTG  
 AATATGAGACTCTAATTGGATACCGAGGGGAATTTATGGAACGTCAGTGGAGCATTTTTGACA  
 AGAAATATTGCTAGCTGATAGTGACCTTAGCCGACTTTTGAACGCGCAATAATGGTTTCTGA  
 CGTATGTGCTTAGCTCATTAAACTCCAGAAACCCGCGGCTGAGTGGCTCCTTCAACGTTGCGG  
 TTCTGTGAGTTCCAAACGTAACCGGCTTGTCCC GCGTCATCGGCGGGGTCATAACGTTGACT  
 CCCTTAATTCTCATGTATCGATAACATTAACGTTTACAATTTTCGCGCCATTCCGCAATCAGGCT  
 GCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTTTCGCTATTACGCCAGCTGGCGAAAG  
 GGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCAGTCACGACGTTGTA  
 AAACGACGGCCAGTGAATTGTAATACGACTCACTATAGGGCGAATTGGGTACCGGGCCCCC  
 CTCGAGGTCGACGGTATCGATAAGCTTGATATCGAATTCCTGCA

**Figure 8 F**

**SEQ ID NO: 8**

**AlcR Cpn21 RNAi Sequence**

ATTCAGGGCACCGGACAGGTTCGGTCTTGACAAAAGAACCGGGCGCCCCTGCGCTGACAGCC  
 GGAACACGGCGGCATCAGAGCAGCCGATTGTCTGTTGTGCCAGTCATAGCCGAATAGCCTCT  
 CCACCCAAGCGGCCGAGAACCTGCGTGCAATCCATCTTGTTCATCATGCCTCGATCGAGTT  
 GAGAGTGAATATGAGACTCTAATTGGATACCGAGGGGAATTTATGGAACGTCAGTGGAGCAT  
 TTTTGACAAGAAATATTTGCTAGCTGATAGTGACCTTAGGCGACTTTTGAACGCGCAATAATG  
 GTTCTGACGTATGTGCTTAGCTCATTAAACTCCAGAAACCCGCGGCTGAGTGGCTCCTTCAA  
 CGTTGCGGTTCTGTCAGTTCCAAACGTAACCGGCTTGTCCC GCGTCATCGGCGGGGTCATA  
 ACGTACTCCCTTAATTCTCATGTATCGATAACATTAACGTTTACAATTTTCGCGCCATTCCCA  
 TTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTTTCGCTATTACGCCAGCTG  
 GCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCAGTCACG  
 ACGTTGTAACGACGGCCAGTGAATTGTAATACGACTCACTATAGGGCGAATTGGGTACCG  
 GGCCCCCTCGAGGTCGACTGCCAACATGGTGGAGCACGACACTCTCGTCTACTCCAAGAAT  
 ATCAAAGATACAGTCTCAGAAGACCAAAGGGCTATTGAGACTTTTCAACAAAGGGTAATATC  
 GGGAAACCTCCTCGGATTCCATGCCCAGCTATCTGTCACTTCATCAAAGGACAGTAGAAAA  
 GGAAGGTGGCACCTACAAATGCCATCATTGCGATAAAGGAAAGGCTATCGTTCAAGATGCCT

V81263WO

CTGCCGACAGTGGTCCCAAAGATGGACCCCCACCCACGAGGAGCATCGTGGAAAAAGAAGAC  
 GTTCCAACCACGTCTTCAAAGCAAGTGGATTGATGTGATAACATGGTGGAGCACGACTCTC  
 GTCTACTCCAAGAATATCAAAGATACAGTCTCAGAAGACCAAAGGGCTATTGAGACTTTTCAA  
 CAAAGGGTAATATCGGGAAACCTCCTCGGATTCCATTGCCAGCTATCTGTCACTTCATCAA  
 AGGACAGTAGAAAAGGAAGGTGGCACCTACAAATGCCATCATTGCGATAAAGGAAAGGCTAT  
 CGTTCAAGATGCCTCTGCCGACAGTGGTCCCAAAGATGGACCCCCACCCACGAGGAGCATCGT  
 GGAAAAAGAAGACGTTCCAACCACGTCTTCAAAGCAAGTGGATTGATGTGATATCTCCACTG  
 ACGTAAGGGATGACGCACAATCCCCTACTCCTTCGCAAGACCTTCTCTATAAAGGAAAGTTC  
 ATTTCAATTTGGAGAGGACACGCTGAAATCACCAGTCTCTCTCTACAAATCTATCTCTCGAGC  
 TTTCGACAGATCCCGGGGAGTACTATGTGCTGGAACCCCGCATGCTCCAGGCCTCATTCCCAG  
 ATTTGACTCCATGGCTGACAGCATCCAGACCGCACGTTTTTTGGACTTCTGATACCATCTATAC  
 AGATATCACTGTGATATTCTCCTGCACACAGCATGGCAGATACGCGCCGACGCCAGAATCAT  
 AGCTGCGATCCCTGTGCAAGGGCAAGCGACGCTGTGATGCCCCGAAACGAGGCCAATGAAA  
 ACGGCTGGGTTTTCGTGTTCAAATTGCAAGCGTTGGAACAAGGATTGTACCTTCAATTGGCTCT  
 CATCCCAACGCTCCAAGGCAAAAGGGGCTGCACCTAGAGCGAGAACAAGAAAGCCAGGAC  
 CGCAACAACCACAGTGAACCATCAACTTCAGCTGCAACAATCCCTACACCGGAAAGTGACA  
 ATCAGGATGCGCCTCCAGTCATAAATCTCAGCAGCGCTCCCGAGCTGGACTCAGGGGCTAC  
 TCTCCACCCCGCGACCTTTTCGATTTACGCCACTCTGCTATTCCCGCAAATGCAGAAGATGC  
 GGCCAACGTGACGTCAGACGCACCTTTTCCGTGGGATCTAGCCATCCCGGTGATTTTCAGCAT  
 GGGCCAACAGCTCGAGAAACCTCTCAGTCCGCTCAGTTTTCAAGCAGTCTTCTTCCGCCCA  
 TAGCCCGAACACGGATGACCTCATTCCGAGCTGGAAGAGCAGACTACGGATCCGGACTCGG  
 TTACCGATACTAATAGTGTACAACAGGTCGCTCAAGATGGATCGCTATGGTCTGATCGGCAGT  
 CGCCGCTACTGCCTGAGAACAGTCTGTGCATGGCCTCAGACAGCACAGCACGGCGATATGCC  
 GTTCCACAATGACGAAGAATCTGATGCGAATCTACCACGATAGTATGGAGAATGCACTGTCT  
 GCTGGCTGACAGAGCACAATTGTCCATACTCCGACCAGATCAGCTACCTGCCGCCAAGCAGC  
 GGGCGGAATGGGGCCCGAAGTGGTCAAACAGGATGTGCATCCGGGTGTGCCGGCTAGATCGC  
 GTATCTACCTCATTACGCGGGCGCGCCCTGAGTGCAGGAGGACAAAGCCGACGCCCGAGC  
 CCTGCTATCGCGATCGTAGCTTTTTGCGTCGCAATGGACGCAGCATGCGCAGAGGGGGGCTGG  
 GCTAAATGTTCCCTGCAGACATAGCCCGGATGAGAGGTCCATCCGGAGGAACGCCTGGAATG  
 AAGCACGCCATGCCTTGCAGCACAGGAGGATTCCATCATTCCGGTTATATTTGCGAATA  
 TCATCTTTTCTCTCACGCAGAGTGTGCTGGATGATGATGAGCAGCACGGTATGGGTGCACGTC  
 TAGACAAGCTACTCGAAAATGACGGTGCGCCCGTGTTCCTGGAAACCGCGAACCGTCACTTT  
 ATACATTCCGACATAAGTTTTGCACGAATGCAACGCCGCGTAAGGCTTTCAACAGGCTCCCGG  
 GAGGATCTGTCGCATCGACATTCCCGGTATTTTCGAGACACCGACGCCGCTGCTGAAAGCC  
 CACAGCTTGACCCGTTGTGGCCAGTGAGGAGCATCGCAGTACATTAAGCCTTATGTTCTGGC  
 TAGGGATCATGTTTCGATACACTAAGCGCTGCAATGTACCAGCGACCACTCGTGGTGTGAGATG  
 AGGATAGCCAGATATCATCGGCATCTCCACCAAGGCGCGGCTGAAACGCCGATCAACCTA  
 GACTGCTGGGAGCCCCGAGACAGGTCCCGAGCAATCAAGAAAAGAGCGACGTATGGGGCG  
 ACCTCTCCTCCGCACCTCGGACTCTCTCCAGATCACGAATCCCACACACAAATCTCTCAGCC  
 AGCGGCTCGATGGCCCTGCACCTACGAACAGGCCCGCCGCTCTCTCCTCTGCAACGCCCGT  
 CAAAGTCTCCTCTACCGCCGCTCACGCAGTCCAAACCCTCCTCTATCGCGGCGCCAGCCC  
 TGCCCGCCTTGAAGCGGCCATCCAGAGAACGCTCTACGTTTATAATCACTGGACAGCGAAGTA  
 CCAACCATTTATGCAGGACTGCGTTGCTAACCACGAGCTCCTCCCTTCGCGCATCCAGTCTTG  
 TACGTCATTCTAGACGGTCACTGGCATCTAGCCGCGATGTTGCTAGCGGACGTTTTGGAGAGC  
 ATCGACCGGATTCGTAATCTGATATCAACCACATCGACCTTGTAAACAAAGCTAAGGCTCGAT  
 AATGCACTAGCAGTTAGTGGCCTTGGCGGCTCTTCACTCCGAGGCCAGGAGCTGGACCCGGG  
 AAAGCATCTCCGATGTATCGCCATTTCCATGATTCTCTGACCGAGGTGGCATTCTGGTAGAA  
 CCGTGGACCGCTGTTCTTATTCACTGTTTCCAAAGCTGCGTATATCTTGCTGGACTGTTTAG  
 ATCTGGACGGCCAAGGAAATGCACTAGCGGGGACTGCAGCTGCGGCAAAATTGCAACTAC  
 TGCATTCCGGCGCTGCAATTTCTGGGAGGAAAGTCCGATATGGCGGCGCTGGTTGCGAAGGAT  
 TTAGAGAGAGGTTTGAATGGGAAAGTTGACAGCTTTTTGTAGGGAGCGGGACTCTGGGGTTCG  
 GACTCTAGCTAGAGTCAAGCAGATCGTTCAAACATTTGGCAATAAAGTTTTCTTAAGATTGA  
 CCTGTTGCCGGTCTTGGGATGATTATCATATAATTTCTGTTGAATTACGTTAAGCATGTAATA  
 TTAACATGTAATGCATGACGTTATTTATGAGATGGGTTTTTTGATTAGAGTCCCGCAATTATAC  
 ATTTAATACGCGATAGAAAACAAAATATAGCGCGCAAACTAGGATAAAAAGCTTCCGGGATA  
 GTTCCGACCTAGGATTGGATGCATGCGGAACCGCACGAGGGCGGGGCGGAAATTGACACACC

V81263WO

ACTCCTCTCCACGCAGCCGTTCAAGAGGTACGCGTATAGAGCCGTATAGAGCAGAGACGGAG  
 CACTTTCTGGTACTGTCCGCACGGGATGTCCGCACGGAGAGCCACAAACGAGCGGGGCCCG  
 TACGTGCTCTCCTACCCAGGATCGCATCCTCGCATAGCTGAACATCTATATAAGGAAGTTCA  
 TTTCATTTGGAGAGGACACGCTGAAATCACCAGTCTCTCTCTACAAATCTATCTCTCTCGAGCT  
 TTCGCAGATCCCGGGGAGTACTCGAAGTACTTCAGATATCGAATTCCTGCAGCGGATCCACTA  
 GTTCTAGACACGTGATTTAAATGGTTTCTTCGTCAACATGGTGGAGCACGACACTCTCGTCTAC  
 TCCAAGAATATCAAAGATACAGTCTCAGAAGACCAAAGGGCTATTGAGACTTTTCAACAAAG  
 GGTAATATCGGGAAACCTCCTCGGATTCATTGCCAGCTATCTGTCACTTCATCAAAGGAC  
 AGTAGAAAAATAATGATTTTTATTTTGACTGATAGTGACCTGTTGCAACACATTGATGA  
 GCAATGCTTTTTTATAATGCCAACTTGTACAAAAAAGCAGGCTGGGGAGGCAGAGGAGAAG  
 ACTTTAGGTGGTATCTTACTTCCATCCACTGCTCAATCAAACCTCAAGGAGGTGAAGTCGTT  
 GCCGTGGGTGAAGGAAGAACTATTGGGAAGAACAAAATTGATATCACTGTCCCTACTGGAGC  
 ACAATTATCTACTCCAAATACGCAGGAACTGAGGTGGAGTTCAATGATGTGAAGCATCTTAT  
 CCTCAAGGAAGATGATATTGTTGGCATTCTTGAGACAGAGGACATCAAAGATCTCAAACCTTT  
 GAATGACCGAGTCTTTATTAAGGTTGCTGAGGCGGAGGAGAAAACAGCTGGAGGGTTGTTGT  
 TAACCGAGACTACCAAAGAGAAGCCTTCTATTGGCACGGTGATAGCAGTTGGACCGGGTTCCC  
 TAGACGAGGAAGGTAAAATTACGCCTCTACCAGTATCAACCGGAAGCACCCAGCTTTCTTGTA  
 CAAAGTTGGCATTATAAGAAAGCATTGCTTATCAATTTGTTGCAACGAACAGGTCATATCAG  
 TCAAATAAAATCATTATTTATCAGAAGCAACCTCATGGAAATGATGAGGTAAGGTTTCATAC  
 TCTGCTCTTCTTACGGCTTCTGTGTCTTCACTGTAAGTTTCTATGATTTGAGCCACCAATAT  
 ATATGCTCTGGTGTGCTGAGTTATGTTTATCTGGTCACGCTTAGTGGGTAATAATTATGCTTATT  
 TTAGCATAAACTTTAATGAGATTAGGTTTTGTATCACACCGATCTTAGTTGTTTAGTAAGATG  
 ACAGAAATCTTGGTAAAACACTCTAAATCGTCTTCTTAGTGAAGTTTTCTTAGAGTAGCAT  
 AAATTTTGGCTTTTTTCTTGATGGTTGAATAAGGTGGCACTTGTGGTATGAGACTTTATTGAG  
 AGTCATATTAAGCTGATCCACGCGTTTACGCCCGCCCTGCCACTCATCGCAGTACTGTTGTAA  
 TTCATTAAGCATTCTGCCGACATGGAAGCCATCACAGACGGCATGATGAACCTGAATCGCCAG  
 CGGCATCAGCACCTTGTGCCTTGCGTATAATATTTGCCATGGTGAAAACGGGGGCGAAGAA  
 GTTGTCCATATTGGCCACGTTTAAATCAAACCTGGTGAACCTCACCCAGGGATTGGCTGAGAC  
 GAAAAACATATTCTCAATAAACCTTTAGGGAAATAGGCCAGGTTTTACCGTAACACGCCAC  
 ATCTTGCGAATATATGTGTAGAAAACCTGCCGAAATCGTCGTGGTATTCACTCCAGAGCGATGA  
 AAACGTTTCAGTTTGTCTCATGGAAAACGGTGAACAAGGGTGAACACTATCCCATATCACCAG  
 CTCACCGTCTTTCATGCCATACGGAATCCGGATGAGCATTATCAGGCGGGCAAGAATGTG  
 AATAAAGGCCGATAAACTTGTGCTTATTTTTCTTACGGTCTTAAAAAGGCCGTAATATCC  
 AGCTGAACGGTCTGGTTATAGGTACATTGAGCAACTGACTGAAATGCCTCAAAATGTTCTTTA  
 CGATGCCATTGGGATATATCAACGGTGGTATATCCAGTGATTTTTTCTCCATTTAGCTTCCCT  
 TAGCTCCTGAAAATCTCGCCGATCAGCTTAGCGTTCATTGAATTTGATGGCCATAGGGGTTT  
 AGATGCAACTGTTTCTTTGAACATTGTAGAAATATATAAAGATTTTACATTAGCCTACTCTTGA  
 AAGTCAAATTGTGCAATTTGATTATATTACTCTAGAGGTGATATTAGTTAATGAGTTTATAC  
 TCGTTATTTACAGCTTATTCATATACCAGTTAACGTGTCTCATATATTCTAACTTCTTAGCATT  
 TAACGTGTTTGCAGGTGACCTGACACTGAACATAACAGCATCACTAGTGCAGGCCGCTGCAG  
 GTCGACCATATGGTTCGACCTGCAGGCGGCCGACTAGTGATATCAAATAATGATTTTATTTTG  
 ACTGATAGTGACCTGTTGTTGCAACAAATTGATAAGCAATGCTTTCTTATAATGCCAACTTTG  
 TACAAGAAAGCTGGGTGCTTCCGGTTGATACTGGTAGAGGCGTAATTTACCTTCTCGTCTA  
 GGGAACCCGGTCCAACCTGCTATCACCGTGCCAATAGAAGGCTTCTCTTTGGTAGTCTCGGTTA  
 ACAACAACCTCCAGCTGTTTTCTCCTCCGCCTCAGCAACCTTAATAAAGACTCGGTCAATCAA  
 AGGTTTGAGATCTTTGATGTCTCTGTCTCAAGAATGCCAACAATATCATCTTCTTGAGGATA  
 AGATGCTTACATCATTGAACTCCACCTCAGTTCCTGCGTATTTGGAGTAGATAATTTGTGCTC  
 CAGTAGGGACAGTGATATCAATTTTGTCTTCCAATAGTTCTTCTTACCCACGGCAACGAC  
 TTCACCTCCTGAGGTTTGTATTGAGCAGTGGATGGAAGTAAGATACCACCTAAAGTCTTCTC  
 CTCTGCCTCCCCAGCCTGCTTTTTGTACAAAAGTTGGCATTATAAAAAAGCATTGCTCATCAAT  
 GTGTTGCAACGAACAGGTCATCAGTCAAAAATAAAAATCATTATTTGATATCCCGCGGCCAT  
 GCTAGAGTCCGCAAAAATCACCAGTCTCTCTACAAAATCTATCTCTCTATTTTTCTCCAGA  
 ATAATGTGTGAGTAGTTCCCAGATAAGGGAATTAGGGTCTTATAGGGTTCGCTCATGTGTT  
 GAGCATATAAGAAACCCTTAGTATGTATTTGTATTTGTAAAATACTTCTATCAATAAAATTTCT  
 AATTCCTAAAACCAAAATCCAGTGACCTGCAGGCATGCGACGTCGGGCCCTAGAGGATCCC  
 CAACGACGCGTAGTTTAAACATTTATCCTAGTTTGCAGCCTATATTTGTTTTCTATCGCGTAT

V81263WO

TAAATGTATAATTGCGGGACTCTAATCAAAAAACCCATCTCATAAATAACGTCATGCATTACA  
TGTTAATTATTACATGCTTAACGTAATTCAACAGAAATTATATGATAATCATCGCAAGACCGG  
CAACAGGATTCAATCTTAAGAAACTTTATTGCCAAATGTTTGAACGATCTGCTTACTCTAGCT  
AGAGTCCGAACCCAGAGTCCCGCTCAGGCGCGCCACCGCGGTGGAGCTCCAGCTTTTGT  
CCCTTTAGTGAGGGTTAATTCCGAGCTTGGCGTAATCATGGTCATAGCTGTTTCCCTGTGTGAAA  
TTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAGCCTGGGG  
TGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTCCAGTCGGG  
AAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTTCGTA  
TTGGGCGCTCTCCGCTTCTCGCTCACTGACTCGCTGCGCTCGGTCGTTTCGGCTGCGGCGAGC  
GGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAA  
AGAACATGAAGGCCTTGACAGGATATATTGGCGGGTAAACTAAGTCGCTGTATGTGTTTGT  
GAGATCTCATGTGAGCAAAGGCCAGCAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTG  
GCGTTTTTCCATAGGCTCCGCCCCCTGACGAGCATCACAAAATCGACGCTCAAGTCAGAGG  
TGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGC  
TCTCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCTTTCTCCCTTCGGGAAGCGTGG  
CGTTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTGCTTCGCTCCAAGCTGGG  
CTGTGTGCACGAACCCCGGTTACGCCGACCGCTGCGCCTTATCCGGTAACATCGTCTTGA  
GTCCAACCCGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCA  
GAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTA  
GAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAGAAGAGTTGGTA  
GCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTTGTTTGCAAGCAGCAGA  
TTACGCGCAGAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTC  
AGTGGAACGAAAACCTCACGTTAAGGGATTTTGGTTCATGAGATTATCAAAAAGGATCTTACCT  
AGATCCTTTTAAATTAATAAATGAAGTTTTAAATCAATCTAAAGTATATATGTGTAACATTGGT  
CTAGTGATTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTAT  
CAATACCATATTTTTGAAAAAGCCGTTCTGTAAATGAAGGAGAAAACTCACCGAGGCAAGTCC  
ATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCGGACTCGTCCAACATCAATAACAACCTA  
TTAATTTCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAAT  
CCGGTGAGAATGGCAAAGTTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTAC  
GCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTTCGTGATTGCGCCTGAGCGA  
GACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCCGGCGC  
AGGAACACTGCCAGCGCATCAACAATTTTTACCTGAATCAGGATATTCTTCTAATACCTGG  
AATGCTGTTTTCCCTGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAA  
TGCTTGATGGTCGGAAGAGGCATAAATCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTA  
ACAACATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACCTCTGGCGCATCGGGCTTCCCA  
TACAATCGGTAGATTGTGCGACCTGATTGCCGACATTATCGCGAGCCCATTTATACCCATAT  
AAATCAGCATCCATGTTGGAATTTAATCGCGGCCTTGAGCAAGACGTTTCCCGTTGAATATGG  
CTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTTCATGATGATATAT  
TTTTATCTTGTGCAATGTAACATCAGAGATTTTGGAGACACAACGTTGGCTTTGTTGAATAAATCG  
AACTTTTGCTGAGTTGAAGGATCAGATCACGCATCTTCCCGACAACGCAGACCGTTCCGTGGC  
AAAGCAAAGTTCAAAAATCACCAACTGGTCCACCTACAACAAGCTCTCATCAACCGTGGCTC  
CTCACTTTCTGGCTGGATGATGGGGCGATTACGGCGATCCCATCCAACAGCCCGCCGTCGA  
GCGGGCTTTTTATCCCGGAAGCCTGTGGATAGAGGGTAGTTATCCACGTGAAACCGCTAAT  
GCCCCGAAAGCCTTGATTCACGGGGCTTTCCGGCCCCGCTCCAAAAACTATCCACGTGAAATC  
GCTAATCAGGGTACGTGAAATCGCTAATCGGAGTACGTGAAATCGCTAATAAGGTCACGTGA  
AATCGCTAATCAAAAAGGCACGTGAGAACGCTAATAGCCCTTCAGATCAACAGCTTGCAAA  
CACCCCTCGCTCCGGCAAGTAGTTACAGCAAGTAGTATGTTCAATTAGCTTTTCAATTATGAAT  
ATATATATCAATTATTGGTCGCCCTTGGCTTGTGGACAATGCGCTACGCGCACCGGCTCCGCC  
CGTGGACAACCGCAAGCGGTTGCCACCGTCGAGCGCCAGCGCCTTTGCCACAACCCGGCG  
GCCGGCCGCAACAGATCGTTTTATAAATTTTTTTTTTTTGA AAAAAGAAAAGCCCGAAAGGCGG  
CAACCTCTCGGGCTTCTGGATTTCCGATCCCCGGAATTAGAGATCTTGGCAGGATATATTGTG  
GTGTAACGTTATCAGCTTGCATGCCGGTGCATCTAGTAACATAGATGACACCGCGCGGATAA  
TTTATCCTAGTTTTCGCGCTATATTTGTTTTCTATCGCGTATFAAATGTATAATTGCGGGACTC  
TAATCAAAAAACCCATCTCATAAATAACGTCATGCATTACATGTTAATTATTACATGCTTAAC  
GTAATTCAACAGAAATTATATGATAATCATCGCAAGACCGGCAACAGGATTCAATCTTAAGA  
AACTTTATTGCCAAATGTTTGAACGATCTGCTTACTCTAGCTAGAGTCCGAACCCAGAGTC



V81263WO

AAGCTTGTGGGAACGAGATAAGGGCGAAGTGCCTAGTAGCCTGCTATTTAAAATATATCCA  
 CAATTTATAATGTATTTGAAGATTAGTCAATTCGTCCAAAATTCAGGACTAAGTATCTTGAATT  
 TTTGTATCCTGAATTTTTGGGCTACTAATTTGGAACCTCAGGACTTAATGTCCTAAATTTTTGAG  
 CCGCTAATTTGAAATTCAGGACTAAGTGTTTTGAATTTTTGAACTGCTTATTCGAAATGCAAGA  
 CTAAGTGACATGAATTTTTGAACTGCTAATTTAAAATTCAGGACATAAGATTTGAATTTTCAA  
 ACATAATTTTTAACTTTAGGGCACGATGTCCTGAAGTTTGAATCTTGAGATCTAAACTTCAAG  
 ATGCAGCGTCTTGAAGTTGAGTGAACCTGGCTAATCTTTAAATACTTGTAAACTGTGGATACA  
 TTTTAAATAATATATTTAAAAGCGGCTACCTGGTATCATCTTCACGAGAATTTTCCAAGTTAA  
 TTGTAAAGGAAATAGTGGTGTTCATCAAGTTATGGACAATATAAGGAAGCAAACAGTACTC  
 TAGCTATCAAATTAGTTTTCCAATTCTAAACCATGAATATTAGGAAAAACAAGAAACAAAACA  
 AATATACATAAAACAATACGGCTAAAGCCAAGGAAAAGGGACTCTAAAAAATTAACCAACCT  
 CAATCACACATTCATATCCTCTTCCCTACCCCATCTAGGATGAGATAAGATTACTAGGTCTTACA  
 CGTGGCACCTCCATTGTGGTACTAAATGAAGAGTGGCTTAGCTCAAAATATAATTTTCCAAC  
 CTTTCATGTGTGGATATTAAGTTTTGTGTAGTGAATCAAGAACCACATAATCCAATGGTTAGCT  
 TTATTTCCAAGATGAGGGGGTGTGATTTTTGTCCGTCAGATATAGGAAATATGTA AACCTT  
 ATCATTATATATAGGGTGGTGGGCAACTATGCAATGACCATATTGGAAGTTAAAGGAAAAGA  
 GAGAAAGAGAAAT

Figure 8 J

SEQ ID NO: 12

**AlcR fragment with required 35s Promotor**

CATGGTGGAGCACGACACTCTCGTCTACTCCAAGAATATCAAAGATACAGTCTCAGAAGACC  
 AAAGGGCTATTGAGACTTTTCAACAAAGGGTAATATCGGGAAACCTCCTCGGATTCCATTGCC  
 CAGCTATCTGTCACTTCATCAAAAGGACAGTAGAAAAGGAAGGTGGCACCTACAAATGCCAT  
 CATTGCGATAAAGGAAAGGCTATCGTTCAAGATGCCTCTGCCGACAGTGGTCCCAAAGATGG  
 ACCCCACCCACGAGGAGCATCGTGGAAAAAGAAGACGTTCCAACCACGTCTTCAAAGCAAG  
 TGGATTGATGTGATAACATGGTGGAGCACGACACTCTCGTCTACTCCAAGAATATCAAAGATA  
 CAGTCTCAGAAGACCAAAGGGCTATTGAGACTTTTCAACAAAGGGTAATATCGGGAAACCTC  
 CTCGGATTCCATTGCCAGCTATCTGTCACTTCATCAAAAGGACAGTAGAAAAGGAAGGTGGC  
 ACCTACAAATGCCATCATTGCGATAAAGGAAAGGCTATCGTTCAAGATGCCTCTGCCGACAGT  
 GGTCCCAAAGATGGACCCACCCACGAGGAGCATCGTGGAAAAAGAAGACGTTCCAACCAC  
 GTCTTCAAAGCAAGTGGATTGATGTGATATCTCCACTGACGTAAGGGATGACGCACAATCCCA  
 CTATCCTTCGCAAGACCTTCTCTATATAAGGAAGTTCAATTTCAATTTGGAGAGGACACGCTGA  
 AATCACCAGTCTCTCTACAAATCTATCTCTCTCGAGCTTTCGCAGATCCCGGGGAGTACTAT  
 GTGCTGGAACCCCGCATGCTCCAGGCCTCATTCCCCAGATTTGACTCCATGGCTGACAGCAT  
 CCAGACCCGACGTTTTTGGACTTCTGATACCATCTATACAGATATCACTGTGATATTCTCTG  
 CACACAGCATGGCAGATACGCGCCGACGCCAGAATCATAGCTGCGATCCCTGTGCAAGGGC  
 AAGCGACGCTGTGATGCCCGAAACGAGGCCAATGAAAACGGCTGGGTTTCGTGTTCAAATT  
 GCAAGCGTTGGAACAAGGATTGTACCTTCAATTGGCTCTCATCCCAACGCTCCAAGGCAAAAG  
 GGGCTGCACCTAGAGCGAGAACAAGAAAGCCAGGACCGCAACAACCACAGTGAACCATC  
 AACTTCAGCTGCAACAATCCCTACACCGGAAAGTGACAATCACGATGCGCCTCCAGTCATAAA  
 CTCTCACGACGCGCTCCCGAGCTGGACTCAGGGGCTACTCTCCACCCCGGCGACCTTTTCGA  
 TTTACGCCACTCTGCTATTCCCGCAAATGCAGAAGATGCGGCCAACGTGCAGTCAGACGCACC  
 TTTCCGTGGGATCTAGCCATCCCCGGTGATTTTCAGCATGGGCCAACAGCTCGAGAAACCTCT  
 CAGTCCGCTCAGTTTTCAAGCAGTCTTCTTCCGCCCATAGCCGAACACGGATGACCTCATT  
 CGCGAGCTGGAAGAGCAGACTACGGATCCGGACTCGGTTACCGATACTAATAGTGTACAACA  
 GGTCGCTCAAGATGGATCGCTATGGTCTGATCGGCAGTCCCGCTACTGCCTGAGAACAGTCT  
 GTGCATGGCCTCAGACAGCACAGCACGGCGATATGCCCGTTCCACAATGACGAAGAATCTGA  
 TGCGAATCTACCAGATAGTATGGAGAATGCACTGTCTGCTGGCTGACAGAGCAATAATTGTC  
 CATACTCCGACCAGATCAGCTACCTGCCGCCAAGCAGCGGGCGGAATGGGGCCCCAAGTGG  
 TCAAACAGGATGTGCATCCGGGTGTGCCGGCTAGATCGCGTATCTACCTCATTACGCGGGCGC  
 GCCCTGAGTGCAGGAAAGAGGACAAAGCCGACGCCGAGCCCTGCATCTGGCGATCGTAGCTTT  
 TGCGTCGCAATGGACGCAGCATGCGCAGAGGGGGGCTGGGCTAAATGTTCTGCGACATAG  
 CCGCCGATGAGAGGTCCATCCGGAGGAACGCCTGGAATGAAGCACGCCATGCCTTGCAGCAC

V81263WO

ACGACAGGGATTCCATCATTCCGGGTTATATTTGCGAATATCATCTTTTCTCTCACGCAGAGTG  
 TGCTGGATGATGATGAGCAGCACGGTATGGGTGCACGTCTAGACAAGCTACTCGAAAATGAC  
 GGTGCGCCCGTGTTCCTGGAAACCGCGAACCGTCAGCTTTATACATTCCGACATAAGTTTGCA  
 CGAATGCAACGCCGCGGTAAGGCTTTCAACAGGCTCCCGGGAGGATCTGTGCGATCGACATTC  
 GCCGGTATTTTCGAGACACCGACGCCGTCGTCTGAAAGCCACAGCTTGACCCGGTTGTGGCC  
 AGTGAGGAGCATCGCAGTACATTAAGCCTTATGTTCTGGCTAGGGATCATGTTTCGATACACTA  
 AGCGCTGCAATGTACCAGCGACCACTCGTGGTGTGATGAGGATAGCCAGATATCATCGGC  
 ATCTCCACCAAGGCGCGGCTGAAACGCCGATCAACCTAGACTGCTGGGAGCCCCCGAGAC  
 AGGTCCCGAGCAATCAAGAAAAGAGCGACGTATGGGGCGACCTTTCCTCCGACCTCGGAC  
 TCTCTCCAGATCACGAATCCCACACAAAATCTCTCAGCCAGCGGCTCGATGGCCCTGCACC  
 TACGAACAGGCCGCGCGCTCTCTCTCTGCAACGCCCGTCAAAGTCTCTCTACCGCCG  
 GTCACGCAGCTCCAAACCCTCCTCTATCGCGGCCAGCCCTGCCCGCCTGAAGCGGCCATC  
 CAGAGAACGCTCTACGTTTATAATCACTGGACAGCGAAGTACCAACCATTTATGCAGGACTGC  
 GTTGCTAACCACGAGCTCCTCCCTTCGCGCATCCAGTCTTGGTACGTCATTCTAGACGGTCACT  
 GGCATCTAGCCGCGATGTTGCTAGCGGACGTTTTGGAGAGCATCGACCGCGATTCTGACTCTG  
 ATATCAACCACATCGACCTTGTAACAAAGCTAAGGCTCGATAATGCACTAGCAGTTAGTGCC  
 TTGCGCGCTCTTCACTCCGAGGCCAGGAGCTGGACCCGGGCAAAGCATCTCCGATGTATCGCC  
 ATTTCCATGATTCTCTGACCGAGGTGGCATTCTGGTAGAACCGTGGACCGTCGTTCTTATTCA  
 CTCGTTTGCCAAAGCTGCGTATATCTTGTGACTGTTTAGATCTGGACGGCCAAGGAAATGC  
 ACTAGCGGGGTACCTGCAGCTGCGGCAAATTGCAACTACTGCATTCCGGGCGCTGCAATTTCT  
 GGGCAGGAAGTCGGATATGGCGGCGCTGTTGCGAAGGATTTAGAGAGAGGTTTGAATGGGA  
 AAGTTGACAGCTTTTTGTA

**Figure 8 K**  
**SEQ ID NO: 23**  
**Cpn21AS**

CACACGTGCCAGATTATGCTCAGGCCGTTTACGGAAAAAATTTCCACAATTGGGATACAAGTT  
 GCAGATTACAAAGATATAACATAACTAAGAAAGTATAGCCATCACATCTGAAGCTCTGAGGG  
 CAATGTAGTTGGAACCATCTTTGCCCTTGAAGTCGTTACCAGCATACTTGGAGTAAAGTACTG  
 TGCTTCCGGTTGACTGGTAGAGGCGTAATTTTACCTTCTCGTCTAGGGAACCCGGTCCAAC  
 TGCTATCACCGTGCCAATAGAAGGCTTCTCTTTGGTAGTCTCGGTTAACAACAACCCTCCAGCT  
 GTTTTCTCCTCCGCTCAGCAACCTTAATAAAGACTCGGTCATTCAAAGGTTTGAGATCTTTGA  
 TGCTCTGTCTCAAGAATGCCAACAATATCATCTTCTTGGAGATAAGATGCTTACATCATT  
 GAACTCCACCTCAGTTCTGCGTATTTGGAGTAGATAATTTGTGCTCCAGTAGGGACAGTGAT  
 ATCAATTTTGTCTTCCAATAGTTCTTCTTACCCACGGCAACGACTTCACCTCCTTGAGGT  
 TTTGATTGAGCAGTGGATGGAAGTAAGATACCACCTAAAGTCTTCTCCTCTGCCTCCTTGATCT  
 TCACCAAACTCGATCTCCAATGGCTTAATTGAAGTATACTTAGGGGCAACAACAGAAGCA  
 GCTTTGACAACCAACGACGGAAGTGGCTCTGTCTAAGGGTCCCTGGTTTCAAAGATGAAAAC  
 TTGACACTCGAAGCTCTGAGACCATCCAGCGAGGCTAAGTCTCCTTGTGACATAGTCACTGGT  
 GACGCTGTAAGTTGAGTCGCCGCCATT

**Figure 8 L**  
**SEQ ID NO: 2**

AATGGCGGGACTCAACTTACAGCGTCACCAGTGACTATGTCAGCAAGGAGCTTAGCCTCGCT  
 GGATGGTCTCAGAGCTTCGAGTGTCAAGTTTTTCATCTTTGAAACCAGGGACCCTTAGACAGAG  
 CCAGTTCCGTCGTTTGGTTGTCAAAGCTGCTTCTGTTGTTGCCCTAAGTATACTTCAATTAAG  
 CCATTGGGAGATCGAGTTTGGTGAAGATCAAGGAGGCAGAGGAGAAGACTTTAGGTGGTAT  
 CTTACTTCCATCCACTGCTCAATCAAAACCTCAAGGAGGTGAAGTCGTTGCCGTGGGTGAAGG  
 AAGAACTATTGGGAAGAACAAAATTGATATCACTGTCCCTACTGGAGCACAAATTATCTACTC  
 CAAATACGCAGGAAGTGAAGTGGAGTTCAATGATGTGAAGCATCTTATCCTCAAGGAAGATG

V81263WO

ATATTGTTGGCATTCTTGAGACAGAGGACATCAAAGATCTCAAACCTTTGAATGACCGAGTCT  
TTATTAAGGTTGCTGAGGCGGAGGAGAAAACAGCTGGAGGGTGTGTTAACCAGACTACC  
AAAGAGAAGCCTTCTATTGGCACGGTGATAGCAGTTGGACCGGGTCCCTAGACGAGGAAGG  
TAAAATTACGCCTCTACCAGTATCAACCGGAAGCACAGTACTTTACTCCAAGTATGCTGGTAA  
CGACTTCAAGGGCAAAGATGGTTCCAACACTACATTGCCCTCAGAGCTTCAGATGTGATGGCTAT  
ACTTTCTTAGTTATGTTATATCTTTGTAATCTGCAACTTGTATCCCAATTGTGGAAATTTTTCC  
GTAAACGGCCTGAGCATAATCTGGCACGTGTG

**Figure 8M**  
**SEQ ID NO: 28**  
**pGreen0029-RBC**

ATTCAGGGCACCGGACAGGTTCGGTCTTGACAAAAAGAACCAGGGCGCCCCTGCGCTGACAGCC  
GGAACACGGCGGCATCAGAGCAGCCGATTGTCTGTTGTGCCAGTCATAGCCGAATAGCCTCT  
CCACCCAAGCGGCCGAGAACCTGCGTGCAATCCATCTTGTTCAATCATGCCTCGATCGAGTT  
GAGAGTGAATATGAGACTCTAATTGGATACCGAGGGGAATTTATGGAACGTCAGTGGAGCAT  
TTTTGACAAGAAATATTTGCTAGCTGATAGTGACCTTAGGCGACTTTTGAACGCGCAATAATG  
GTTTCTGACGTATGTGCTTAGCTCATTAACTCCAGAAACCCGCGGCTGAGTGGCTCCTTCAA  
CGTTGCGGTTCTGTCAGTTCCAAACGTAACGCTTGTCCCAGGTCATCGGCGGGGGTCATA  
ACGTGACTCCCTTAATTCTCATGTATCGATAACATTAACGTTTACAATTTGCGGCCATTGCGCA  
TTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTG  
GCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCAGTCACG  
ACGTTGTAAAACGACGGCCAGTGAATTGTAATACGACTCACTATAGGGCGAATTGGGTACCTC  
TGCAGATAAGCTTGTGGGAACGAGATAAGGGCGAAGTGCCTAGTAGCCTGCTATTTAAAAT  
ATATCCACAATTTATAATGTATTTGAAGATTAGTCAATTCGTCCAAAATTCAGGACTAAGTAT  
CTTGAATTTTTGTATCCTGAATTTTTGGGCTACTAATTTGGAACCTCAGGACTTAATGTCCTAAA  
TTTTTGAGCCGCTAATTTGAAATTCAGGACTAAGTGTTTTTGAAATTTTTGAACTGCTTATTCGAA  
ATGCAAGACTAAGTGACATGAATTTTTGAACTGCTAATTTAAAATTCAGGACATAAGATTTGA  
ATTTTCAAACATAATTTTTAACTTTAGGGCACGATGTCCTGAAGTTTGAATCTTGAGATCTAA  
ACTTCAAGATGCAGCGTCTTGAAGTTTGAAGTGAAGTGGCTAATCTTTAAATACTTGAAACTG  
TGGATACATTTTTAAATAATATATTTAAAAGCGGCTACCTGGTATCATCTTCACGAGAATTTTC  
CAAGTTAATTGTAAGGAAATAGTGGTGTGCATCAAGTTATGGACAATATAAGGAAGCAAA  
CAGTACTCTAGCTATCAAATTAGTTTCCACTTCAAACCATGAATATTAGGAAAAACAAGAAA  
CAAAACAATATACATAACAATACGGCTAAAGCCAAGGAAAAGGGACTCTAAAAAATTA  
ACCAACCTCAATCACACATTCATATCCTCTTCTACCCATCTAGGATGAGATAAGATTACTA  
GGTCTTACACGTGGCACCTCCATTGTGGTGAATAATGAAGAGTGGCTTAGCTCAAAATATAA  
TTTTCCAACCTTTTATGTGTGGATATTAAGTTTTGTGTAGTGAATCAAGAACCACATAATCCAA  
TGGTTAGCTTTTATCCAAGATGAGGGGGTGTGATTTTTGTCCGTCAGATATAGGAAATATGT  
AAAACCTTATCATTATATATAGGGTGGTGGGCAACTATGCAATGACCATATTGGAAGTTAAAG  
GAAAAGAGAGAAAGAGAAATCTTTCTGTCTAAGTGAATTAACCTTCTAGATACATGTCTCGAG  
CGGCCGCCAGTGTGATGGATATCGAATTCGCCCTTGGATCCTCACTAGTGGATCCGAGCTCAT  
CGATAAGCTTGGCGTCGATCGTTCAAACATTTGGCAATAAAGTTTTCTAAGATTGAATCCTGTT  
GCCGGTCTTGCATGATTATCATATAATTTCTGTTGAATTACGTTAAGCATGTAATAATTAACA  
TGTAATGCATGACGTTATTTATGAGATGGGTTTTATGATTAGAGTCCCAGCAATTATACATTTA  
ATACGCGATAGAAAACAAAATATAGCGCGCAAACACTAGGATAAATTATCGCGCGCGGTGTCAT  
CTATGTTACTAGATCGGGGAATTGATCCCCCTCGACAGCTTCCCATGGTCCCCGGGGAGGGC  
CCCCCTCGAGGTCGACGGTATCGATAAGCTTGATATCGAATTCCTGCAGCCCGGGGATCCA  
CTAGTTCTAGAGCGGCCGCCACCGCGGTGGAGCTCCAGCTTTTGTTCCTTTAGTGAGGGTTA  
ATCCGAGCTTGGCGTAATCATGGTCATAGCTGTTTCTGTGTGAAATTGTTATCCGCTCACAA  
TTCCACACAACATACGAGCCGGAAGHCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAG  
CTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTCCAGTCGGGAAACCTGTCGTGCCAG  
CTGCATTAATGAATCGGCAACGCGCGGGAGAGGGCGGTTTGCATTTGGGCGCTCTTCCGCT  
TCCTCGCTCACTGACTCGCTGCGCTCGGCTCGGCTCGGCTCGGCGAGCGGTATCAGCTACTCA  
AAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGAAGGCCTT  
GACAGGATATATTGGCGGGTAAACTAAGTCGCTGTATGTGTTTGTGAGATCTCATGTGAGC

V81263WO

AAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGC  
TCCGCCCCCTGACGAGCATCACAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACA  
GGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACC  
CTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCT  
CACGCTGTAGGTATCTCAGTTCGGTGTAGGTGCTTCGCTCCAAGCTGGGCTGTGTGCACGAAC  
CCCCGTTACGCCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAA  
GACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTA  
GGCGGTGCTACAGAGTTCCTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTT  
GGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAGAAGAGTTGGTAGCTCTTGATCCGGC  
AAACAACCACCGCTGGTAGCGGTGGTTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAA  
AAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGTCTGACGCTCAGTGAACGAAAAAC  
TCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTACCTAGATCCTTTTAAATT  
AAAAATGAAGTTTTAAATCAATCTAAAGTATATATGTGTAACATTGGTCTAGTGATTAGAAAA  
ACTCATCGAGCATCAAATGAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTG  
AAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGAT  
CCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTC  
AAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCA  
AAAGTTTATGCATTTCTTTCCAGACTTGTTCACAGGCCAGCCATTACGCTCGTCATCAAAATC  
ACTCGCATCAACCAACCCTTATTCATTTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATC  
GCTGTTAAAAGGACAATTACAACAGGAATCGAATGCAACCCGGCGCAGGAACACTGCCAGCG  
CATCAACAATATTTTACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCTGG  
GATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAA  
GAGGCATAAATTCGCTCAGCCAGTTTGTCTGACCATCTCATCTGTAACAACATTGGCAACGC  
TACCTTTGCCATGTTTCAGAAACAACCTCTGGCGCATCGGGCTTCCCATACAATCCGTAGATTGT  
CGCACCTGATTGCCCCGACATTATCGCGAGCCATTTATACCCATATAAATCAGCATCCATGTT  
GGAATTTAATCGCGGCCTTGAGCAAGACGTTTCCCCTTGAATATGGCTCATAACACCCCTTGT  
ATTACTGTTTATGTAAGCAGACAGTTTTATTGTTTCATGATGATATATTTTTATCTTGTGCAATGT  
AACATCAGAGATTTTGAGACACAACGTGGCTTTGTTGAATAAATCGAACTTTTGCTGAGTTGA  
AGGATCAGATCACGCATCTTCCCGACAACGACAGCCGTTCCGTGGCAAAGCAAAGTTCAA  
ATCACCAACTGGTCCACCTACAACAAAGCTCTCATCAACCCGTGGCTCCCTCACTTTCTGGCTG  
GATGATGGGGCGATTACAGGCGATCCCATCCAACAGCCCGCCGTCGAGCGGGCTTTTTATCC  
CCGGAAGCCTGTGGATAGAGGGTAGTTATCCACGTGAAACCGCTAATGCCCCGCAAAGCCTT  
GATTCACGGGGCTTTCCGGCCCCGCTCCAAAAACTATCCACGTGAAATCGCTAATCAGGGTACG  
TGAAATCGCTAATCGGAGTACGTGAAATCGCTAATAAGGTACGTGAAATCGCTAATCAAAA  
AGGCACGTGAGAACGCTAATAGCCCTTTCAGATCAACAGCTTGCAAACACCCCTCGCTCCGGC  
AAGTAGTTACAGCAAGTAGTATGTTCAATTAGCTTTTCAATTATGAATATATATATCAATTATT  
GGTCGCCCTTGGCTTGTGGACAATGCGCTACGCGCACCCGGCTCCGCCGTGGACAACCCGCAAG  
CGGTTGCCACCGTCGAGCGCCAGCGCCTTTGCCACAACCCGGCGGCCGCGCAACAGATC  
GTTTTATAAATTTTTTTTTTTGAAAAAGAAAAGCCCGAAAGGCGGCAACCTCTCGGGCTTCT  
GGATTTCCGATCCCCGGAATTAGAGATCTTGGCAGGATATATTGTGGTGTAACGTTATCAGCT  
TGCATGCCGGTCGATCTAGTAACATAGATGACACCCGCGCGGATAATTTATCCTAGTTTGGC  
GCTATATTTGTTTTCTATCGCGTATTAATGTATAATTGCGGGACTCTAATCAAAAAACCCAT  
CTCATAAATAACGTCATGCATTACATGTTAATTATTACATGCTTAACGTAATTCAACAGAAATT  
ATATGATAATCATCGCAAGACCGGCAACAGGATTCATCTTAAGAACTTTATTGCCAAATGT  
TTGAACGATCTGCTTACTCTAGCTAGAGTCCGAACCCAGAGTCCCCTCAGAAGAACTCGT  
CAAGAAGGCGATAGAAGGCGATGCGCTGCGAATCGGGAGCGGCGATACCGTAAAGCACGAG  
GAAGCGGTCAGCCATTGCGCCCAAGCTCTTCAGCAATATCACGGGTAGCCAACGCTATGTC  
CTGATAGCGGTCCGCCACACCCGCGCCACAGTCGATGAATCCAGAAAAGCGGCCATTTTC  
CACCATGATATTCGGCAAGCAGGCATCGCCCTGGGTACAGACGAGATCCTCGCCGTCGGGCAT  
CCGCGCCTTGAGCCTGGCGAACAGTTTCGGCTGGCGGAGCCCCCTGATGCTCTTCGTCCAGATC  
ATCCTGATCGACAAGACCGGCTTCCATCCGATACGTCCTCGCTCGATGCGATGTTTCGCTTG  
GTGGTCGAATGGGCAGGTAGCCGGATCAAGCGTATGCAGCCGCCGCAATTGCATCAGCCATGA  
TGGATACTTTCTCGGCAGGAGCAAGGTGAGATGACAGGAGATCCTGCCCCGGCACTTCGCCCA  
ATAGCAGCCAGTCCCTTCCCCTTCAGTGACAACGTCGAGCACAGCTGCGCAAGGAACGCC  
GTCGTGGCCAGCCACGATAGCCGCGCTGCCTCGTCTTGGAGTTC

V81263WO

Figure 8N  
SEQ ID NO :29  
pUC57-RBC

TATGGGGTACCTCTGCAGATAAGCTTGTGGGAACGAGATAAGGGCGAAGTGCCTAGTAGCC  
TGCTATTTAAAATATATCCACAATTTATAATGTATTTGAAGATTAGTCAATTCGTCCAAAATTC  
AGGACTAAGTATCTTGAATTTTTGTATCCTGAATTTTTGGGCTACTAATTTGGAACCTCAGGACT  
TAATGTCCTAAATTTTTGAGCCGCTAATTTGAAATTCAGGACTAAGTGTTTTGAATTTTTGAAC  
TGCTTATTCGAAATGCAAGACTAAGTGACATGAATTTTTGAACTGCTAATTTAAAATTCAGGA  
CATAAGATTTGAATTTTCAAACATAATTTTTTAACTTTAGGGCACGATGTCCTGAAGTTTGAAT  
CTTGAGATCTAACTTCAAGATGCAGCGTCTTGAAGTTTGAAGTGAAGTGGCTAATCTTTAAAT  
ACTTGTAACTGTGGATACATTTTTTAAATAATATATTTAAAAGCGGCTACCTGGTATCATCTTC  
ACGAGAATTTTTCCAAGTTAATTGTAAAGGAAATAGTGGTGTTCATCAAGTTATGGACAATAT  
AAGGAAGCAAACAGTACTCTAGCTATCAAATTAGTTTCCACTTCTAAACCATGAATATTAGGA  
AAAACAAGAAACAAAACAAATATACATAAACAATACGGCTAAAGCCAAGGAAAAGGGACTC  
TAAAAAATTAACCAACCTCAATCACACATTCATATCCTCTTCTACCCCATCTAGGATGAGA  
TAAGATTACTAGGTCTTACACGTGGCACCTCCATTGTGGTGAAGTAAATGAAGAGTGGCTTAGC  
TCAAATATAATTTTCAAACCTTTCATGTGTGGATATTAAGTTTTGTGTAGTGAATCAAGAACC  
ACATAATCCAATGGTTAGCTTATCCAAGATGAGGGGGTGTGATTTTTGTCCGTCAGATAT  
AGGAAATATGTAAAACCTTATCATTATATATAGGGTGGTGGGCAACTATGCAATGACCATATT  
GGAAGTTAAAGGAAAAGAGAGAAAGAGAAATCTTTCTGTCTAAGTGAATTAACCTTCTAGAT  
ACATGTCTCGAGCGGCCCGCCAGTGTGATGGATATCGAATTCGCCCTTGGATCCTCACTAGTGG  
ATCCGAGCTCATCGATAAGCTTGGCGTCGATCGTTCAAACATTTGGCAATAAAGTTTCTTAAG  
ATTGAATCCTGTTGCCGGTCTTGCATGATTATCATATAATTTCTGTTGAATTACGTTAAGCAT  
GTAATAATTAACATGTAATGCATGACGTTATTTATGAGATGGGTTTTTATGATTAGAGTCCCGC  
AATTATACATTTAATACGCGATAGAAAACAAAATATAGCGCGCAAACCTAGGATAAATTATCG  
CGCGCGGTGTCATCTATGTTACTAGATCGGGGAATTGATCCCCCTCGACAGCTTCCCATTGGT  
CCCCGGGAGGGCCCGCATGCAAGCTTGGCGTAATCATGGTCATAGCTGTTTCTGTGTGAA  
ATTGTTATCCGCTCACAATTCACACAACATACGAGCCGGAAGCATAAAGTGAAGCTGGG  
GTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTCCAGCTCGG  
GAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCCT  
ATTGGGCGCTCTTCCGCTTCCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCCGGCTGCGGCGAG  
CGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGA  
AAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGG  
CGTTTTTCCATAGGCTCCGCCCCCTGACGAGCATCACAAAATCGACGCTCAAGTCAGAGGT  
GGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCCT  
CTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTCTCCCTCGGGAAGCGTGGC  
GCTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCCGCTCCAAGCTGGGC  
TGTGTGCACGAACCCCCGTTACGCCCCGACCCTGCGCCTTATCCGGTAACTATCGTCTTGAGT  
CCAACCCGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGA  
GCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGA  
AGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGA AAAAGAGTTGGTAGC  
TCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTTGTTTGAAGCAGCAGATT  
ACGCGCAGAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAG  
TGGAACGAAAACCTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTACCTAG  
ATCCTTTTAAATTA AAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAACTTGGTCT  
GACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTTCGTTTATCCA  
TAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCA  
GTGCTGCAATGATACCGCGAGACCCACGCTCACCGCTCCAGATTTATCAGCAATAAACCAGC  
CAGCCGGAAGGGCCGAGCGCAGAAGTGGTCTGCAACTTTATCCGCCTCCACTCCAGTCTATTA  
ATTGTTGCCGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCCTAACGTTGTTGCCA  
TTGCTACAGGCATCGTGGTGTACGCTCGTCTTGGTATGGCTTCAATCAGCTCCGGTTCCCA  
ACGATCAAGGCGAGTTACATGATCCCCATGTTGTGCAAAAAGCGGTTAGTCCCTTCGGTCC  
TCCGATCGTTGTCAGAAGTAAGTTGGCCGAGTGTATCACTCATGGTTATGGCAGCACTGCA  
TAATCTCTTACTGTCATGCCATCCGTAAGATGCTTTTTCTGTGACTGGTGAGTACTCAACCAAG  
TCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCTGGCGTCAATACGGGATAAT

V81263WO

ACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAA  
ACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTG  
ATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGC  
CGCAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATA  
TTATTGAAGCATTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAA  
AATAAACAATAGGGGTCCGCGCACATTTCCCGAAAAGTGCCACCTGACGTCTAAGAAAC  
CATTATTATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGCCCTTTCGTCTCGCGCG  
TTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTGTCT  
GTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTGGCGGGTGTCT  
GGGGCTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCA

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CA2010/001853

A. CLASSIFICATION OF SUBJECT MATTER IPC: <i>C12N 15/82</i> (2006.01) , <i>A01H 1/04</i> (2006.01) , <i>A01H 5/00</i> (2006.01) , <i>C07K 14/415</i> (2006.01) , <i>C12N 15/29</i> (2006.01) , <i>C12Q 1/68</i> (2006.01) According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) C12N* (2006.01), A01H* (2006.01), C07K* (2006.01), C12Q* (2006.01)		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic database(s) consulted during the international search (name of database(s) and, where practicable, search terms used) Databases: Canadian Patent Database, TotalPatent, Pubmed, SCOPUS, GenBank Keywords: chaperonin, cpn21, cpn20, cpn10, variegation, variegated plants, antisense, RNAi, selection method		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HANANIA et al. Silencing of chaperonin 21, that was differentially expressed in inflorescence of seedless and seeded grapes, promoted seed abortion in tobacco and tomato fruits. Transgenic Research. August 2007 (08-2007). Vol. 16, No. 4, pages 515-525. ISSN:0962-8819	1-6, 9-11, 17-21
Y	*whole document*	7, 8
Y	HIROHASHI et al. cDNA sequence and overexpression of chloroplast chaperonin 21 from <i>Arabidopsis thaliana</i> . Biochimica et Biophysica Acta. 11 January 1999 (11-01-1999). Vol. 1429, No. 2, pages 512-515. ISSN:0167-4838	7, 8
	*figure 1*	
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents :	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent but published on or after the international filing date	"Y"	document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search 17 January 2011 (17-01-2011)	Date of mailing of the international search report 16 February 2011 (16-02-2011)	
Name and mailing address of the ISA/CA Canadian Intellectual Property Office Place du Portage I, C114 - 1st Floor, Box PCT 50 Victoria Street Gatineau, Quebec K1A 0C9 Facsimile No.: 001-819-953-2476	Authorized officer <b>Scott Gurd (819) 994-4157</b>	